In re: Appraisal of Jarden Corporation

• Court: Court of Chancery of Delaware
• Decided: July 19, 2019
• Docket: CA 12456-VCS
• Status: Published

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

: IN RE: APPRAISAL OF : CONSOLIDATED JARDEN CORPORATION : C.A. No. 12456-VCS :

MEMORANDUM OPINION

Date Submitted: May 1, 2019 Date Decided: July 19, 2019

Stuart M. Grant, Esquire, Cynthia M. Calder, Esquire, Kimberly A. Evans, Esquire, Kelly L. Tucker, Esquire and Vivek Upadhya, Esquire of Grant & Eisenhofer P.A., Wilmington, Delaware, Attorneys for Petitioners.

Srinivas M. Raju, Esquire, Brock E. Czeschin, Esquire, Robert L. Burns, Esquire, Sarah A. Clark, Esquire and Matthew W. Murphy, Esquire of Richards, Layton & Finger, P.A., Wilmington, Delaware and Walter W. Davis, Esquire, Michael J. McConnell, Esquire and Robert A. Watts, Esquire, of Jones Day, Atlanta, Georgia, Attorneys for Respondent Jarden Corporation.

SLIGHTS, Vice Chancellor This statutory appraisal action arises from a merger whereby Newell

Rubbermaid, Inc. (“Newell”) acquired Jarden Corporation (“Jarden” or the

“Company”) (the “Merger”) for cash and stock totaling $59.21 per share

(the “Merger Price”). Petitioners, Verition Partners Master Fund Ltd., Verition

Multi-Strategy Master Fund Ltd., Fir Tree Value Master Fund, LP and Fir Tree

Capital Opportunity Master Fund, LP (together “Petitioners”), were Jarden

stockholders on the Merger’s effective date and seek a judicial appraisal of the fair

value of their Jarden shares as of that date.

At the close of the trial, I observed, “[w]e are in the classic case where . . .

very-well credentialed experts are miles apart. . . . There’s some explaining that is

required here to understand how it is that two very well-credentialed, I think, well-

intended experts view this company so fundamentally differently.”1 This

observation was prompted by the all-too-frequently encountered disparity in the

experts’ opinions regarding Jarden’s fair value. Jarden’s expert, Dr. Glenn Hubbard,

applying a discounted cash flow (“DCF”) analysis, opines that Jarden’s fair value as

of the Merger was $48.01 per share. Petitioners’ expert, Dr. Mark Zmijewski,

applying a comparable companies analysis, contends that Jarden’s fair value as of

1 Trial Tr. 1315:21–1316:5.

1 the Merger was $71.35 per share. To put the disparity in context, Dr. Zmijewski’s

valuation implies that the market mispriced Jarden by over $5 billion.

In a statutory appraisal action, the trial court’s function is to appraise the

“fair value” of the dissenting stockholder’s “shares of stock” by “tak[ing] into

account all relevant factors.”2 The statute does not define “fair value” but our courts

understand the term to mean the petitioner’s “pro rata share of the appraised

company’s value as a going concern.”3 This definition of fair value “is a

jurisprudential, rather than purely economic, construct.”4 Even so, the remarkably

broad “all relevant factors” mandate necessarily leads the court deep into the weeds

of economics and corporate finance. These are places law-trained judges should not

go without the guidance of experts trained in these disciplines. In other words,

corporate finance is not law. The appraisal exercise is, at bottom, a fact-finding

exercise, and our courts must appreciate that, by functional imperative, the evidence,

including expert evidence, in one appraisal case will be different from the evidence

2 8 Del. C. § 262(h). 3 DFC Global Corp. v. Muirfield Value P’rs, L.P., 172 A.3d 346, 367 (Del. 2017). DFC explained that the statutory definition of fair value has been distilled further to require the court “to value the company on its stand-alone value.” Id. at 368. 4 Id. at 367 (citing Cavalier Oil Corp. v. Hartnett, 564 A.2d 1137 (Del. 1989)). As the Court further explained, “the definition of fair value used in appraisal cases is a jurisprudential concept that has certain nuances that neither an economist nor market participant would usually consider when either valuing a minority block of shares or a public company as a whole.” Id.

2 presented in any other appraisal case. Different evidence, of course, can lead to

different decision paths and different outcomes. After all, the appraisal exercise

prescribed by the governing statute contemplates a trial—a good, old-fashioned

trial—where the parties carry burdens of proof, present their evidence in hopes of

meeting that burden and subject their adversary’s evidence to the “crucible of cross-

examination” in keeping with the traditions of our adversarial process of civil

justice.5

Our Supreme Court has had several opportunities recently to provide direction

with regard to certain frames of reference this court should consider while

5 Gilbert v. M.P.M. Enters., Inc., 1998 WL 229439, at *3 (Del. Ch. Apr. 24, 1998) (noting that while certain approaches to a DCF valuation might be endorsed in other cases, the experts endorsing those approaches had not been “subject to the crucible of cross- examination” in the appraisal trial conducted by the court and the court would not consider their testimony from other cases). See also Merion Capital L.P. v. Lender Processing Servs., Inc., 2016 WL 7324170, at *16 (Del. Ch. Dec. 16, 2016) (noting that the “relevant factors” informing the fair value determination will “vary from case to case depending on the nature of the [acquired] company”); DFC, 172 A.3d at 388 (observing: “[i]n some cases, it may be that a single valuation metric is the most reliable evidence of fair value and that giving weight to another factor will do nothing but distort that best estimate. In other cases, it may be necessary to consider two or more factors.”); D.R.E. 702 (recognizing that lay fact-finders may rely upon expert testimony when the expert’s “scientific, technical or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue”). In this regard, it is worth noting that submitting the fair value determination to a “court-appointed ‘appraiser’” was “essentially required practice under the appraisal statute before 1976.” Lawrence A. Hammermesh & Michael L. Wachter, Finding the Right Balance in Appraisal Litigation: Deal Price, Deal Process, and Synergies, 73 Bus. Law 961, 976 (2018). Now that expert “appraisers” have been “eliminated as a statutory requirement,” it is for the court to decide fair value based on its assessment of the factual evidence presented at trial, including expert evidence, using traditional fact-finding methods. Id.

3 performing the statutory appraisal function.6 I will not recount those holdings here

as they are well known. Suffice it to say, as I approached my deliberation of the

evidence in this case, my “takeaway” from the Supreme Court’s recent direction

reduced to this: “What is necessary in any particular [appraisal] case [] is for the

Court of Chancery to explain its [fair value calculus] in a manner that is grounded

in the record before it.”7 That is what this court endeavors to do after every trial and

what I have endeavored to do here.8

6 See DFC, 172 A.3d 346; Dell, Inc. v. Magnetar Global Event Driven Master Fund Ltd., 177 A.3d 1 (Del. 2017); Verition P’rs Master Fund Ltd. v. Aruba Networks, Inc., 2019 WL 1614026 (Del. Apr. 16, 2019). 7 DFC, 172 A.3d at 388. 8 In this regard, I reiterate with renewed appreciation then-Chancellor Chandler’s astute observation in the Technicolor, Inc. appraisal saga:

[V]aluation decisions are impossible to make with anything approaching complete confidence. Valuing an entity is a difficult intellectual exercise, especially when business and financial experts are able to organize data in support of wildly divergent valuations for the same entity. For a judge who is not expert in corporate finance, one can do little more than try to detect gross distortions in the experts’ opinions. This effort should, therefore, not be understood, as a matter of intellectual honesty, as resulting in the fair value of a corporation on a given date. The value of a corporation is not a point on a line, but a range of reasonable values, and the judge’s task is to assign one particular value within this range as the most reasonable value in light of all the relevant evidence and based on the considerations of fairness.

Cede & Co. v. Technicolor, Inc., 2003 WL 23700218, at *2 (Del. Ch. Dec. 31, 2003), aff’d in part, rev’d in part on other grounds, 875 A.2d 602 (Del. 2005), withdrawn from bound volume, opinion amended and superseded, 884 A.2d 26 (Del. 2005).

4 The parties have reveled in the statutory mandate that the court consider

“all relevant factors.” Indeed, they have joined issue on nearly every possible

indicator of fair value imaginable, including market indicators (unaffected market

price, deal price less synergies, Jarden stock offerings shortly before the Merger)

and traditional valuation methodologies (comparable companies and DCF

analyses).9 The result: an unfortunately long opinion, made so by a sense that I

needed to traverse every road the parties waived me down right to the bitter end,

even if that road did not lead to the desired fair value destination. Appraisal litigation

can be unwieldy. This is one of those cases. Apologies in advance to those who

read on.

I begin my fair value analysis where I believe I must—with the market

evidence.10 As explained below, I have found Jarden’s unaffected market price of

$48.31 per share is a reliable indicator of its fair value at the time of the Merger.

This finding is supported by credible, unrebutted expert testimony from

Dr. Hubbard, including an event study that analyzed the market’s response to

9 Respondent’s expert undertook a precedent transactions analysis as well but the parties did not engage on this valuation approach at trial, so I will not address it here. See JX 1816 at ¶11. 10 DFC, 172 A.3d at 369–70 (observing that “[m]arket prices are typically viewed [as] superior to other valuation techniques because, unlike, e.g., a single person’s [DCF] model, the market price should distill the collective judgment of the many based on all the publicly available information about a given company and the value of its shares.”).

5 earnings and other material announcements. Dr. Hubbard’s expert analysis of the

Unaffected Market Price is corroborated by credible evidence, including that Jarden

had no controlling stockholder, its public float was 93.9%, it was well covered by

numerous professional stock analysts, its stock was heavily traded and it enjoyed a

narrow bid-ask spread. As important, there was no credible evidence that material

information bearing on Jarden’s fair value was withheld from the market as of the

Merger. This market evidence was persuasive and I have given it substantial weight

in my fair value determination.

As noted, the Merger consideration, or “deal price,” was $59.21 per share.

Respondent proffers this evidence as a reliable indicator fair value, particularly when

synergies are “backed out” as required by our law.11 Petitioners respond that the sale

process leading to the Merger was highly flawed because Jarden’s lead negotiator

was willing to sell Jarden on the cheap and the Jarden board of directors

(the “Board”) failed to test the market before agreeing to sell the Company to

Newell. After considering the evidence, I agree with Petitioners that the sale process

left much to be desired. Jarden’s lead negotiator acted with little to no oversight by

the Board and, in doing so, got way out in front of the Board and Jarden’s financial

11 See ACP Master, Ltd. v. Sprint Corp., 2017 WL 3421142, at *31 (Del. Ch. July 21, 2017) (collecting cases and noting that if the court were to rely upon “deal price, it would have to determine the value of synergies and back them out.”).

6 advisors in suggesting to Newell a price range the Board would accept to sell the

Company before negotiations began in earnest. There was no pre-signing or post-

signing market check. Moreover, the contemporaneous evidence regarding deal

synergies was conflicting and the parties’ experts acknowledged that valuing the

synergies and assessing which party took that value in the Merger was especially

difficult in this case. For these reasons, I have placed little weight on the deal price

less synergies beyond considering that evidence as a “reality check” on my final fair

value determination.

As additional market evidence of Jarden’s fair value, Respondent points to

Jarden’s decision to finance a sizeable acquisition just prior to the Merger (in the

midst of negotiations) with an equity offering valued at $49.00 per share. When the

market reacted poorly to the acquisition, Jarden announced that it would buy back

up to $50 million in Jarden shares at prices up to $49.00 per share as a signal of

confidence to the market. This contemporaneous evidence of Jarden management’s

internal valuation of the Company, performed to facilitate Jarden’s acquisition

strategy in furtherance of its standalone operations, is relevant market evidence of

fair value. While far from dispositive, Jarden’s internal efforts to value itself as a

going concern for business, not litigation, purposes provides a useful input.

In keeping with their theme that the market evidence is not reliable, Petitioners

have focused on “traditional valuation methodologies” to carry their burden of

7 proving Jarden’s fair value as of the Merger. Their valuation expert opines that a

comparable company/market multiples analysis provides the best evidence of fair

value, and that methodology supports his conclusion that Jarden’s fair value at the

Merger was $71.35 per share. The credibility, or not, of this methodology depends

in large measure on the quality of the comparables. And then the appraiser must

select an appropriate multiple. After considering the evidence, I am satisfied that

Petitioners’ comparable companies analysis is not credible because Jarden had no

reliable comparables. Consequently, I give no weight to the results derived from

this valuation approach.

Not surprisingly, both parties proffered expert evidence regarding Jarden’s

fair value based on DCF and, not surprisingly, the experts’ DCF analyses yielded

results that were solar systems apart. After carefully reviewing the evidence,

including the valuation treatises submitted as evidence in support of the experts’

conclusions, I am satisfied that both experts utilized inputs in their DCF models that

were not justified and that skewed the results.12 Accordingly, I have utilized the

12 To the extent the parties sought to rely upon valuation texts or articles addressing valuation methodologies, they were directed to submit these sources as evidence in the case. Unlike a law review article cited by a party in support of a legal proposition, a text or scholarly article addressing economic or valuation principles contains factual matter, the admissibility of which must be tested under Delaware’s Uniform Rules of Evidence. In my view, it is not proper for parties to an appraisal case, or any other case for that matter, to refer to, or expect the court sua sponte to refer to, a scholarly work addressing a matter that has been the subject of expert testimony without first having the work received as evidence in the case or at least tested under evidentiary standards. Nor is it proper, in my view, for parties to an appraisal case to cite to decisions of this court, or our Supreme Court, for the 8 most credible components of both expert’s analyses to conduct my own DCF

valuation, in my best effort to obey our appraisal statute’s “command that the Court

of Chancery undertake an ‘independent’ assessment of fair value” when performing

its mandated appraisal function.13 As explained below, my DCF analysis reveals a

valuation of $48.13 per share.

After considering all relevant factors, I have appraised Jarden’s fair value as

of the Merger at $48.31 per share. This value, derived from the unaffected market

price, is consistent with Jarden’s DCF value and the less reliable, but still relevant,

deal price less synergies value.

I. FACTUAL BACKGROUND

I recite the facts as I find them by a preponderance of the evidence after a

four-day trial beginning in June 2018. That evidence consisted of testimony from

twenty-eight witnesses (twenty-five fact witnesses, some presented live and some

proposition that a particular valuation methodology should be applied to value the target company. While legal authority may support the contention that a valuation methodology has been accepted by Delaware courts as generally reliable, I see no value in referring to the factual conclusions of another court in another case while appraising the fair value of another company when attempting to fulfill the statutory mandate that I determine the fair value of this Company. 13 Dell, 177 A.3d at 21 (quoting Golden Telecom, Inc. v. Global GT LP, 11 A.3d 214, 218 (Del. 2010) (emphasis in original)); see also Gholl v. eMachines, Inc., 2004 WL 2847865, at *5 (Del. Ch. Nov. 24, 2004) (noting that both parties bear a burden of proof in a statutory appraisal trial and holding that, “[i]f neither party satisfies its burden . . . the court must then use its own independent business judgment to determine fair value.”).

9 by deposition, and three live expert witnesses) along with more than 2,000 exhibits.

To the extent I have relied upon evidence to which an objection was raised but not

resolved at trial, I will explain the bases for my decision to admit the evidence at the

time I first discuss it.

A. Parties and Relevant Non-Parties

Prior to its acquisition by Newell on April 15, 2016 (the “Merger Date”),

Jarden was a consumer products company that held a diversified portfolio of over

120 quality brands.14 This portfolio included well-known goods like Ball jars,

Coleman sporting goods, Crock-Pot appliances and Yankee Candle candles.15

Jarden was incorporated in Delaware with headquarters in Boca Raton, Florida, and

corporate offices in Norwalk, Connecticut and Miami, Florida.16 Prior to the

Merger, Jarden traded on the New York Stock Exchange.17 Following the Merger,

the combined company was re-named Newell Brands, Inc. (“Newell Brands”).18

14 Stip. Joint Pre-Trial Order (“PTO”) ¶¶1, 6, 36. 15 PTO ¶41. Trial Tr. 49:20–50:10 (Lillie). Because consumable household staples primarily comprised Jarden’s product offerings, Jarden’s growth correlated to Gross Domestic Product (“GDP”) growth. JX 860 at 1 (“As we suspected [Jarden] is a GDP growth business”). 16 PTO ¶36. 17 Id. ¶39. 18 Id. ¶1.

10 Petitioners are Verition Partners Master Fund Ltd., Verition Multi-Strategy

Master Fund Ltd., Fir Tree Value Master Fund, LP and Fir Tree Capital Opportunity

Master Fund, LP.19 Petitioners acquired their Jarden shares after the announcement

of the Merger and were stockholders as of the Merger Date. They collectively hold

2,435,971 shares of Jarden common stock.

B. The Company

Jarden traces its origins to Alltrista Corporation, a company that was spun off

in 1993 from Ball Corporation’s canning business.20 In 2000, Martin Franklin and

Ian Ashken acquired Alltrista after having initiated a stockholder campaign to unseat

Alltrista’s board and senior management.21 By 2001, Franklin and Ashken served

as Alltrista’s Chief Executive Officer and Chief Financial Officer, respectively, and

renamed the company Jarden.22 In August 2003, James Lillie joined the Jarden team

as Chief Operating Officer.23 Their shared goal was to create the “best consumer

products company in the world.”24

19 Id. ¶¶14–35. 20 JX 1780 (Franklin Dep.) at 5:14–18. 21 JX 1778 (Ashken Dep.) at 77:11–17. 22 JX 1778 (Ashken Dep.) at 9:3–5; JX 1780 (Franklin Dep.) at 5:20–25. 23 PTO ¶62. 24 JX 1777 (Lillie Dep.) at 195:17–23.

11 Franklin served as CEO and Chairman of the Board until 2011,25 when Jarden

reorganized its management structure. The Company created the “Office of the

Chairman,” comprising Franklin as Executive Chairman, Ashken as Vice Chairman

and CFO,26 and Lillie as CEO.27 As a result of this reorganization, Franklin

surrendered direct control of Jarden’s day-to-day operations, but remained chiefly in

charge of capital distribution and M&A activity.28 Lillie and Ashken took over the

day-to-day operation of the Company.29 Ashken also maintained a dominant role in

Jarden’s financial planning and acquisitions.30

As a holding company,31 Jarden maintained a unique, decentralized structure.

Its various businesses functioned autonomously, allowing them to pursue outside

opportunities and synergies.32 The respective business unit heads exercised full

control over the development of their individual strategic plans.33 Even so, the

25 PTO ¶54. 26 JX 1778 (Ashken Dep.) at 8:24–11:5. 27 Trial Tr. 368:3–19 (Franklin). 28 Trial Tr. 367:15–22, 467:20–22 (Franklin). 29 JX 1778 (Ashken Dep.) at 11:9–10, 15:20–22. 30 Id. at 10:20–11:10. 31 PTO ¶38. 32 JX 1777 (Lillie Dep.) at 11:5–12:24, 49:6–50:13. 33 JX 502 at 5; JX 1804 (Polk Dep.) at 17:15–21.

12 businesses stayed in constant communication with Jarden senior management

regarding operations.34

C. Jarden Experiences Strong Growth from 2001–2015

Jarden pursued a two-pronged growth strategy, focusing on internal growth

and growth via acquisitions.35 In this regard, management set a goal of 3 to 5%

annual internal revenue growth,36 10 to 15% earnings per share (“EPS”) growth, 3 to

5% organic top-line growth, 7 to 10% EBITDA growth and 20 to 50 basis points of

gross margin growth.37 These targets produced laudable results. From 2010 through

2015, Jarden saw average organic yearly revenue growth of 4.8%, the top of its

targeted range.38 In fact, Jarden was regarded as “best in class by any measure in

terms of shareholder returns over 15 years, 10 years, 5 years, 3 years, 1 year.”39

Jarden’s margins experienced continued expansion and it met or exceeded its

34 Id. 35 JX 502 at 6. 36 Id. at 21. 37 JX 1192 at 11; JX 1777 (Lillie Dep.) at 11:5–14; JX 1775 (Sansone Dep.) at 101:5–20, 146:21–147:3. 38 JX 786 at 17. 39 Trial Tr. 423:1–9 (Franklin).

13 guidance in all but one quarter of its existence.40 By 2015, Jarden generated over

$1.2 billion in segment earnings and revenues of almost $9 billion.41 This reflected

an increase in revenue of 4.8% year over year in fiscal year 2015.42

Given its impressive results, it is not surprising that Jarden’s stock performed

well and traded efficiently. In 2012, Jarden joined the “S&P 400.”43 By the end of

2015, Jarden’s market capitalization topped $10.2 billion, placing it among the top

20% of all US publicly traded firms.44 More than twenty professional financial

analysts followed Jarden, reporting regularly on the Company’s business operations

and forecasts.45 In addition to its high average trading volume, Jarden’s “bid-ask

spread” was just 0.02% and its public float was approximately 94% of its outstanding

stock.46 Jarden’s stock trading price historically responded to the announcement of

value-relevant information as one would expect in a semi-strong efficient market.47

40 Trial Tr. 451:14–18, 451:19–21(Franklin); Trial Tr. 81:10–11 (Lillie) (“Q. That was one quarter miss in 13 years? A. Yes.”); JX 1779 (Tarchetti Dep.) at 265:16–266:7. 41 Trial Tr. 53:12–24 (Lillie); JX 1459 (“Consistent with its guidance, the Company expects that net sales for 2015 will be approximately $8.6 billion”). 42 JX 1519 at 47. 43 See JX 1816 at ¶47. The S&P 400 refers to the Standard & Poor’s MidCap 400 index. 44 Id. 45 Id. at ¶¶46–48 and Figure 11; JX 1439. 46 JX 1816 at ¶¶45–48. 47 Id. at ¶¶48–50; see also Trial Tr. 1019:24–1020:23 (Hubbard).

14 M&A drove Jarden’s growth.48 With Franklin at the helm, Jarden acquired

over 40 companies and brands, its stock grew over 5,000% and its sales progressed

from approximately $305 million in 2001 to over $8.6 billion in 2015.49 Franklin

and his team were not only well-known “deal-makers” in the public markets,50 they

were among “the best performers in the sector.”51

Under Franklin’s leadership, Jarden management constructed a well-

conceived convention for singling-out and completing acquisitions.52 Jarden

avoided acquisitions that would insert it in spaces where major pure-play

competitors, like Proctor & Gamble, operated.53 Jarden, instead, concentrated on

acquiring top brands in niche markets.54 This strategy developed secure trenches

48 Trial Tr. 370:17–18 (Franklin) (“We were building a business, both organically and by acquisition.”); JX 578 at 33. 49 JX 1519 at 40, 44; JX 30 at 36; JX 502 at 19; JX 1459. 50 JX 1519 at 40. 51 Trial Tr. 125:12–22 (Gross); JX 502 at 25; JX 1773 (Talwar Dep.) at 21:19–22:3, 27:6– 10. 52 The strategy included targeting: (i) category-leading positions in niche consumer markets; (ii) with recurring revenue and margin growth channels; (iii) robust cash flow characteristics, including substantial EBITDA multiples; (iv) a successful management team; and (v) strong transaction valuations, with value-generating presynergies. JX 502 at 25. 53 JX 1778 (Ashken Dep.) at 24:25–25:21; JX 1773 (Talwar Dep.) at 28:4–13. 54 Id.

15 that presented barriers to others who might look to compete with Jarden’s niche

product lines.55 It also enabled Jarden globally to expand its brands.56

D. Jarden Shifts Its Strategic Focus

Jarden’s businesses sold their products across a vast spread of distribution

channels, including business-to-business, direct-to-consumer (“DTC”), e-commerce

retailers, and club, department store, drug, grocery and sporting goods retailers.57

In 2014, Jarden committed to expanding its DTC operations by promoting then-

Vice President of International Development, Leo Trautwein, to Vice President of

Direct to Consumer and Revenue Development. Trautwein, along with Jarden

management, developed a DTC Council that comprised of representatives from

Jarden and each of its individual business units.58 The DTC Council aimed to detect

55 JX 1777 (Lillie Dep.) at 133:2–21; JX 1773 (Talwar Dep.) at 27:11–24. 56 JX 502 at 11.

[We] . . . looked at everything. Again, it goes back to being professional opportunists, in terms of building a business. You’ve got to––you know, we were a fairly unusual group. We started from a $200 million business 15 years prior, to becoming a 10-plus billion dollar business 15 years later. It wasn’t done from sitting behind a desk. We were building a business, both organically and by acquisition.

Trial Tr. 370:11–18 (Franklin). 57 PTO ¶40. 58 JX 763 at 25.

16 DTC best practices and put in place DTC initiatives.59 It set meaningful benchmarks

to enhance DTC sales.60 In their July 2015 Board presentation, Jarden management

expected online sales to represent 13% of Jarden’s total sales by 2019, equating to

15.9% of total EBITDA.61 The DTC initiative, on the other hand, was expected to

yield a 55–60% return on investment.62 As it turned out, from 2012 through 2016,

Jarden’s DTC e-commerce sales (i.e., not including brick and mortar DTC sales)

experienced a more than 270% increase in five years—expanding from roughly

$237 million to $643 million.63

E. Jarden Makes Two Major Acquisitions Just Prior to the Merger

Jarden completed two of the largest acquisitions in its history in 2015. In July

2015, Jarden acquired the Waddington Group, Inc. for approximately $1.35 billion.64

Waddington manufactures plastic consumables for the $14 billion U.S. food sector

59 JX 514 at 10. 60 JX 1393. 61 JX 763 at 22. 62 Id. at 17. 63 JX 1795 at 21. 64 PTO ¶110.

17 market.65 The acquisition was projected to yield revenue of $840 million in 2016

with an approximately 20% EBITDA margin.66

In November 2015, Jarden acquired the parent company of Jostens, Inc. for

$1.5 billion.67 Jostens was a market leader in manufacturing and marketing

yearbooks, rings, caps and gowns, diplomas, regalia and varsity jackets, mainly

selling to schools, universities and professional sports leagues.68 Jarden predicted

the Jostens acquisition would not only offer Jarden “unique access to the difficult-

to-enter academic market,”69 but also would allow Jarden to grow a number of its

existing distribution channels and develop new ones, intensifying Jarden’s DTC

impact.70 Jostens provided superior market positions, steady financial performance,

strong margins and attractive cash flow to Jarden’s portfolio.71 Indeed, Jostens’

65 JX 527 at 23, 26. 66 Id. at 23; JX 606 at 3–4. 67 PTO ¶113. 68 JX 726 at 15. 69 Id. 70 Trial Tr. 455:3–9 (Franklin) (“Q. And in 2015, you were spending real money on direct- to-consumer and expanding your distribution channels. Correct? A. Well, we bought a business that expanded our distribution capabilities. We bought Jostens for the same kind of reason. It gave us a different access into schools.”). 71 JX 726 at 11; JX 823 at 3–4.

18 gross margins were anticipated to better Jarden’s overall margins and, in fact, the

transaction was instantly accretive.72

Overall, Jarden anticipated that these two acquisitions would push Jarden’s

total annual revenues over the $10 billion threshold. At the same time, however,

they simultaneously would increase Jarden’s debt to a point where Jarden would be

unable to make another substantial acquisition for at least another year.73

F. Franklin Considers a Sale of Jarden

Jarden was not Franklin’s only business interest. In 2013, Franklin founded

Platform Specialty Products Corporation (“Platform”), a specialty chemicals

production company, with financial backing from Bill Ackman.74 In 2014, Franklin

founded Nomad Foods Ltd. (“Nomad”), a frozen foods company headquartered in

the U.K.75 Franklin also ran a “family investment vehicle” called Mariposa

Capital.76 Mariposa entities often acquired orphan brands, like its acquisition of

72 JX 726 at 12. 73 JX 1816 at ¶¶46–48, Figure 11; JX 1439. 74 PTO ¶234. As of the Merger Date, Ashken was a director of Platform. Id. ¶61; JX 576 at 2. 75 PTO ¶235. As of the Merger Date, Lillie was a director of Nomad. Id. ¶63. 76 JX 1780 (Franklin Dep.) at 359:15–16; PTO ¶97. Lillie and Ashken were also investors in Mariposa. Trial Tr. 527:11–13 (Franklin).

19 Royal Oak in 2016.77 In 2017, after the Merger, Franklin created a special purpose

acquisition vehicle, J2 Acquisition Limited (“J2”), that raised more than $1 billion

in order to buy consumer-focused brands.78 Franklin also looked forward to

pursuing business ventures with his sons, as his father did with him.79

In early July 2015, during a meeting between Franklin and Roland Phillips of

Centerview Partners relating to Nomad, Phillips mentioned that Newell’s CEO,

Michael Polk, wanted to meet Franklin.80 As discussed below, Newell had

previously retained Centerview to assist with Newell’s search for transformative

M&A opportunities.81 Understanding that Polk would likely want to talk about a

Newell/Jarden transaction, Franklin told Phillips he would take the meeting, he

77 PTO ¶282. But for the Merger, Franklin would have pursued the Royal Oak transaction for Jarden. Trial Tr. 559:4–560:5 (Franklin). Jarden’s lead independent director, Michael Gross, also participated in the Royal Oak acquisition. Id.; JX 1807 (Gross Dep.) at 14:22– 15:10. Gross and Franklin have been close personal friends for 30 years. JX 1807 (Gross Dep.) at 15:14–18. 78 PTO ¶249; JX 1807 (Gross Dep.) at 93:7–8. Ashken and Lillie were also investors in J2. JX 1770. 79 JX 765; JX 1804 (Polk Dep.) at 71:20–72:12; JX 1779 (Tarchetti Dep.) at 164:14–165:3. 80 JX 533; JX 490; PTO ¶125; Trial Tr. 584:12–585:24 (Polk). Phillips previously worked opposite Franklin in a transaction with Nomad. Trial Tr. 585:14–18 (Polk); Trial Tr. 373:6–18 (Franklin). 81 Trial Tr. 576:5–13 (Polk); JX 490; JX 524; PTO ¶123.

20 “would gladly take equity, [and he] ha[d] no issue with someone else running the

combined business.”82

Later that month, Franklin met with Bill Ackman, his Platform partner, and

expressed his willingness to sell Jarden so he could devote more energy to Platform

and Nomad.83 Ackman emailed Warren Buffett the following day and indicated that

Franklin would entertain a negotiated sale of Jarden to Berkshire Hathaway.84

Franklin was not authorized by the Board to entertain discussions regarding a

sale of Jarden nor did he disclose to the Board his discussions with Phillips or

Ackman.85

G. Newell and Franklin Meet

Like Jarden, Newell was a major consumer products company with a vast

portfolio of products sold under brands like Sharpie, Paper Mate, Elmer’s,

Rubbermaid, Lenox, Graco and Baby Jogger.86 In 2011, Newell implemented a

82 JX 533; PTO ¶125. 83 JX 576 at 2. 84 Id. 85 JX 1807 (Gross Dep.) at 28:9–19; JX 1788 (L’Esperance Dep.) at 121:10–122:3; JX 1786 (Wood Dep.) at 157:25–158:14. 86 PTO ¶79. Newell was a member of the NYSE and the S&P 500. PTO ¶84. It was followed by at least 16 financial analysts and, like Jarden, its stock exhibited the attributes of a narrow “bid-ask spread,” a high average trading volume and a large public float. JX 1816 at ¶57, Figure 15.

21 strategic roadmap known as the “Growth Game Plan” under the direction of its new

CEO, Polk.87 This plan incorporated an initiative known as “Project Renewal” to

streamline the Company’s business structure and decrease costs.88

For many years, Newell operated as a traditional holding company, much as

Jarden did, owning several portfolio businesses that essentially functioned as

independent companies.89 In 2010, Newell retooled by implementing an integrated

operating company model as contemplated by Project Renewal.90 Newell

“delayered the structure of the company, . . . releas[ing] a whole bunch of money”

that was invested back into Newell’s brands.91 As a result, Newell doubled its brand

expenditures, creating fast-tracked growth and amplified margins for its business.92

By the fall of 2014, Newell realized that the “investment firepower” Project Renewal

generated “was going to wane” by late 2018.93 It needed a new growth plan.

87 Trial Tr. 566:21–567:8 (Polk). 88 Trial Tr. 567:9–569:3 (Polk); see also Trial Tr. 721:22–722:5 (Torres). 89 PTO ¶80. Trial Tr. 566:11–20 (Polk). 90 Trial Tr. 566:11–20 (Polk). 91 Trial Tr. 567:20–569:3 (Polk). 92 Trial Tr. 571:2–7 (Polk). 93 Trial Tr. 571:20–572:2 (Polk).

22 In late 2014, Newell initiated a strategy of pursuing “transformational M&A”

opportunities that would generate larger scale and market share in its central

businesses, in addition to new prospects for growth.94 This new strategy prompted

Newell to engage Centerview to produce a list of possible targets for Newell and to

arrange “get-to-know-you meetings” as requested.95 While Jarden was included on

Centerview’s list, it was the target “least familiar” to Newell since it “had been built

[steadily] through acquisitions from 2001 onward” and was, therefore, in Newell’s

eyes, a “relatively new company.”96 Polk had reservations about Jarden because it

was seen as a “company of diversified niche categories,” when Polk was “looking

for scaled brands and big, global categories.”97 Even so, Polk asked Centerview to

arrange the “get-to-know-you meeting” with Franklin.98 As noted, Franklin agreed

to take the meeting.99

94 Trial Tr. 572:6–574:19 (Polk). 95 Trial Tr. 576:12–582:1 (Polk). See JX 655; JX 860. 96 Trial Tr. 581:10–17 (Polk). 97 Trial Tr. 581:18–582:1 (Polk). 98 Trial Tr. 584:12–24 (Polk); Tr. 373:19–24 (Franklin).

Trial Tr. 375:5–14 (Franklin). As Franklin explained, “[i]f a CEO wants to meet with 99

me, I’ll always want to meet with him.” Trial Tr. 376:17–20 (Franklin).

23 Franklin and Polk’s first meeting took place at the Barclays’ investor “Back-

to-School” conference on September 9, 2015 (the “Back-to-School Meeting”).100

The conversation exposed their different perspectives regarding the roles they played

at their respective companies—Franklin defined his role at Jarden as creating value

and “[t]hat’s it,” while Polk defined his role at Newell as building stronger brands

and a stronger company.101 In other words, Franklin focused on M&A, while Polk

concentrated on organic growth.102 Near the meeting’s end, Franklin directed the

conversation to where he believed Polk wanted it to go by confirming that his team

was open to “strategically connecting” with Newell.103 The meeting closed with

both Franklin and Polk agreeing to continue the conversation about a potential

deal.104

Polk reported back to the Newell board that Franklin “cut straight to the chase

about being willing to sell his company and offered a deeper discussion over the next

few weeks.”105 At this point, however, Franklin still had not informed Jarden’s

100 JX 902; PTO ¶¶127, 129. 101 Trial Tr. 588:3–13 (Polk). 102 Trial Tr. 586:14–21 (Polk). 103 Trial Tr. 376:13–20 (Franklin); Tr. 588:22–589:7 (Polk). 104 JX 902 at 2. 105 Id.

24 Board that he was entertaining Newell’s overture.106 Indeed, it was not until several

days after the Back-to-School meeting that Franklin made individual calls to

members of the Board to let them know about his discussions with Polk.107

For his part, Polk warmed quickly to the idea of acquiring Jarden, believing

that Jarden would provide scale and immediate cost synergies once Newell

consolidated Jarden’s operations per Project Renewal.108 As Polk explained,

“we believed we had the potential, based on what we could see through the public

data, to apply the playbook we’d just run on Newell Rubbermaid to a broader set of

categories that looked very similar to the categories that we were managing as part

of [Newell].”109

On October 5, 2015, Franklin and Polk met again, this time on Franklin’s

yacht in Miami, along with Ashken, Lillie and Mark Tarchetti, Newell’s then-Chief

106 JX 1788 (L’Esperance Dep.) at 54:13–22; JX 1786 (Wood Dep.) at 25:2–7, 26:10–19. The Board met on September 28, 2015, but the minutes do not reflect any discussion of a potential transaction with Newell or Franklin’s September 9th meeting with Polk. See JX 691; PTO ¶131. 107 Trial Tr. 378:24–380:18, 480:16–17 (Franklin); JX 1788 (L’Esperance Dep.) at 57:2– 23, 58:22–59:3 (Franklin called board members to advise them on meeting); JX 1807 (Gross Dep.) at 26:24–27:12 (same); JX 1786 (Wood Dep.) at 28:20–29:8, 33:20–34:4 (same). 108 Trial Tr. 566:9–20 (Polk). 109 Trial Tr. 598:10–16 (Polk); JX 1779 (Tarchetti Dep.) at 29:18–30:9, 32:10–33:9 (explaining Jarden “was by far the most likely [acquisition] candidate to reapply the Newell Rubbermaid business model” of consolidation, which “could release a large amount of value”).

25 Development Officer (the “Boat Meeting”).110 While Franklin informally provided

some advance notice of the Boat Meeting to certain members of the Board, he did

not obtain Board approval to meet with Newell and certainly did not have Board

approval to discuss the financial parameters of a deal.111 But that is precisely what

he did.

Franklin advised Newell’s team that Newell’s offer for Jarden would have to

“start with a six” and would have to include a significant cash component if Newell’s

goal was to gain control of the combined company.112 According to Franklin, he

arrived at this number based, in part, on his understanding of Jarden’s value as

determined in connection with the Jostens acquisition which was underway as of the

110 JX 685 at 2; JX 902 at 2; PTO ¶132. Trial Tr. 383:23–384:8 (Franklin). Following the Merger, Tarchetti became the President of the combined entity. JX 1779 (Tarchetti Dep.) at 14:17–21. 111 JX 1788 (L’Esperance Dep.) at 58:9–21; JX 1786 (Wood Dep.) at 31:12–25; PTO ¶133. I note that Franklin’s testimony that he did not intend to negotiate definitive deal parameters during the Boat Meeting was credible. Trial Tr. 486:11–16 (Franklin). It appears, instead, that Franklin intended to lay out certain expectations and then “tell[] [the] Newell [team that] if they had different expectations, they shouldn’t bother spending time, effort, and money.” Trial Tr. 489:14–17 (Franklin). As Franklin explained, “I didn’t want to go down the path of having any real substantive conversations unless they understood that we were looking for a real premium.” Trial Tr. 469:2–22 (Franklin); see also Trial Tr. 384:21–385:2 (Franklin); JX 1778 (Ashken Dep.) at 64:4–9 (explaining “we sort of made it very clear that Jarden wasn’t for sale; but if we got an extraordinary offer our job was to create value for our shareholders, so we would always listen to whatever Mike had to say”). 112 JX 1794 (Christian Dep.) at 159:9–160:14; JX 1780 (Franklin Dep.) at 72:2–3; JX 1804 (Polk Dep.) at 85:24–86:7; JX 1779 (Tarchetti Dep.) at 305:24–306:10; PTO ¶134.

26 Boat Meeting.113 He also wanted to state a number he believed Newell had the

“ability to pay,”114 and he assumed a price of $70.00 or higher was “laughable.”115

At the time of the Boat Meeting, Jarden’s stock was trading in the high $40s.116

Therefore, by this metric, a price “starting with a six,” by any measure, would be a

premium for Jarden’s stockholders.117 According to Franklin, even if $60 per share

undervalued Jarden,118 Franklin believed Jarden stockholders would reap additional

value by sharing in the upside of the Merger with stock in the combined company.119

On the other side of the table, Polk expressed Newell’s hope that a merger

would open substantial synergies given the Newell team’s demonstrated ability to

113 JX 2502; JX 1778 (Ashken Dep.) at 64:17–65:4, 97:14–98:2; JX 1785 (LeConey Dep.) at 27:10–21; Trial Tr. 369:22–370:2, 471:11–472:16 (Franklin). While Jarden had asked Barclays to prepare some preliminary combination models and to do some “rough math” prior to the Boat Meeting (Trial Tr. 472:7–8 (Franklin); JX 688), Jarden had no formal analysis of its standalone value, nor had it retained a financial advisor when Franklin set the range for a transaction at $60–$69 per share. JX 1789 (Welsh Dep.) at 135:14–136:3; Trial Tr. 470:18–471:8 (Franklin). 114 JX 1780 (Franklin Dep.) at 95:15–19. See also Trial Tr. 473:24–475:1 (Franklin) (explaining his sense of Newell’s financial limits). 115 Trial Tr. 391:24–392:10 (Franklin). 116 Trial Tr. 385:10–14 (Franklin). 117 Trial Tr. 385:24–386:4 (Franklin); Trial Tr. 666:6–7 (Polk) (“And I interpreted that to be between 60 and 69, which is a very wide range.”); see also JX 1778 (Ashken Dep.) at 65:21–23 (referring to a price in the $60s as “a very, very, very, very full price”). 118 Trial Tr. 474:14–475:1 (Franklin); JX 1780 (Franklin Dep.) at 103:3–13. 119 Trial Tr. 475:18–476:22 (Franklin).

27 consolidate business functions and utilize the resulting cost savings to produce

growth.120 Jarden’s team had a more modest outlook on possible synergies in the

early stages of the discussions, but became progressively more “excited” by the

opportunity to unlock significant transaction synergies as the negotiations

advanced.121

Although he had not sought Board approval to meet with Newell, Franklin

briefed the Board on the Boat Meeting within a matter of days, including his

admonition to Newell that an offer would need to “start with a six.”122 The Board

was supportive and encouraged Franklin and his team to continue the discussions

with Newell within Franklin’s outlined parameters.123

Jarden did not formally engage Barclays until November 2015. Even so,

Franklin contacted Welsh, his personal Barclays banker, on October 16, 2015, after

the Boat Meeting.124 Franklin told Welsh he already signaled to Newell that Jarden

120 Trial Tr. 598:3–16 (Polk) (explaining that “the logic for the deal” was the expectation of synergies by recreating the success of Project Renewal); see also JX 674 at 2 (Polk noting that “there are tons of synergies because they have not done what we have done with Renewal (they are a holding company)”) (emphasis in original). 121 Trial Tr. 387:13–388:23 (Franklin); see also Trial Tr. 664:3–665:8 (Polk). 122 Trial Tr. 391:24–392:10 (Franklin). 123 JX 1788 (L’Esperance Dep.) at 60:5–13 (discussing Franklin’s view that any offer “needed to start with a 6 handle” and explaining that “[g]iven where the stock was trading, that made a lot of sense”); see also JX 1786 (Wood Dep.) at 49:3–11. 124 Trial Tr. 548:22–549:4 (Franklin); JX 1789 (Welsh Dep.) at 135:14–136:3.

28 would agree to sell at $60 per share and instructed him to start developing an analysis

supporting a transaction in the range of $60–$69 per share.125

H. The Ebb and Flow of the Negotiations

On October 9, 2015, Newell distributed a press release revealing that Tarchetti

and another executive would leave Newell at the end of the year.126 Franklin was

“very upset” Polk had not informed him that “his chief lieutenant” was on his way

out of Newell.127 Franklin was so upset, in fact, that he entertained the idea of

“stopping the conversations at that point” because he “didn’t want to look stupid in

front of [the Jarden] board . . . [by] having a conversation with someone that wasn’t

serious.”128 Within days of the announcement, Franklin and Polk had a “tough

conversation” where Polk explained that Tarchetti would stay with Newell if the

parties agreed to a deal.129 After this, Franklin “got over it” and negotiations

continued.130

125 JX 769; JX 785; JX 915; JX 977; JX 1073; JX 1203; JX 1862; Trial Tr. 550:16–20 (Franklin); JX 1789 (Welsh Dep.) at 137:22–138:18. 126 Trial Tr. 392:8–15 (Franklin); see also JX 1778 (Ashken Dep.) at 62:23–63:2. 127 Trial Tr. 392:16–393:6 (Franklin). 128 Id. 129 Trial Tr. 393:7–394:2 (Franklin). 130 Id.

29 As the parties were discussing a Jarden/Newell combination, Jarden was

closing the Jostens deal. On October 14, 2015, Jarden announced it would acquire

Jostens and finance the acquisition through an equity offering priced at $49.00 per

share and additional debt.131 The next day, Jarden presented five-year projections to

potential financing sources that reflected net sales growth of 3.1% (the “Lender

Presentation”).132

The market reacted negatively to the Jostens acquisition.133 Jarden’s stock

price dropped approximately 12% over the following two weeks and analysts’

reduced their Jarden price targets accordingly.134 The Board determined that Jarden

needed to project confidence to the market. Accordingly, in early November 2015,

it approved a stock buy-back up to $50 million at prices capped at $49.00 per

share.135 Jarden ultimately repurchased 276,417 shares on November 2, 2015, at an

131 JX 2502 at 2, 10. 132 JX 775. 133 JX 871 at 1; JX 1779 (Tarchetti Dep.) at 259:14–261:13. 134 On October 13, 2015, the day prior to the Jostens announcement, Jarden’s stock price was $50.69. Jarden’s stock price fell to $44.80 by the end of October 2015. PTO Ex. A; see also JX 1816 at ¶¶66–68. 135 Trial Tr. 404:1–9 (Franklin). Franklin testified, “we were buyers up to [$]49, which we considered full value at the time.” Trial Tr. 404:16–18 (Franklin).

30 average price of $45.96 per share, and repurchased an additional 775,685 shares on

November 3, 2015, at an average price of $48.05 per share.136

On October 15, 2015, Franklin caused Jarden to enter into a mutual

confidentiality and standstill agreement with Newell, and the parties began

preliminary due diligence.137 True to form, Franklin did not seek Board

authorization to begin diligence on Jarden’s behalf.138 The next day, also without

the Board’s authorization, Franklin and Polk spoke on the phone to continue

negotiations on the cash and stock components of a deal, and Franklin introduced

the concept of Jarden taking seats on the combined company’s board.139

On October 22, 2015, Franklin, Ashken and Lillie met with Newell

representatives at Jarden’s offices in Norwalk, Connecticut (the “Norwalk Meeting”)

and shared non-public information, including a set of three-year financial

projections.140 The three-year projections, apparently created in connection with the

negotiations, incorporated financials for both the Waddington and Jostens

136 JX 900 at 2. 137 JX 1565 at 85; PTO ¶135. Trial Tr. 394:23–395:4 (Franklin). 138 JX 1780 (Franklin Dep.) at 136:12–15; JX 1565 at 85. See Trial Tr. 492:5–10 (Franklin) (explaining Jarden’s Board learned of the confidentiality agreement). 139 PTO ¶136. 140 JX 786 at 110; PTO ¶138; Trial Tr. 396:17–397:2 (Franklin); Trial Tr. 602:24–603:15 (Polk).

31 acquisitions,141 and forecast 5% revenue growth, i.e., growth at the high end of

Jarden’s historic guidance range of 3% to 5%.142

Entering into negotiations with Newell, Jarden had set the market standard for

average annual revenue growth within the 3% to 5% range.143 These growth figures

were meant to reflect Jarden’s “organic growth” range, but they included revenue

from “tuck-in” acquisitions, where a Jarden portfolio company would acquire a

target.144 Other public companies operating as holding companies typically do not

include tuck-in acquisitions when projecting “organic growth.”145 Nevertheless,

even when tuck-in acquisitions are excluded, Jarden generally performed in line with

its target growth range.146

At trial, Lillie justified giving Newell projections at the very top of the

Company’s 3%–5% guidance range by explaining that 5% was a “round

141 JX 786 at 110; JX 1777 (Lillie Dep.) at 131:7–12, 148:6–149:5. 142 JX 786 at 111; see also Trial Tr. 827:19–828:11 (Waldron). 143 JX 1777 (Lillie Dep.) at 24:16–25:8. 144 Tuck-in acquisitions usually amounted to less than 1% of Jarden’s yearly revenue. See, e.g., JX 380 at 11; JX 1778 (Ashken Dep.) at 20:6–16; JX 432 at 5; JX 380 at 3, 11. 145 Trial Tr. 929:9–930:9 (Zenner). 146 JX 1816 at ¶30; JX 1831, Ex. 5A. Jarden achieved “organic growth” of 4% (including tuck-in acquisitions) and adjusted organic growth of 3.2% (excluding all acquisitions), from 2011 to 2015. Id.

32 number[].”147 He went on to explain that, while the projections given to Newell were

not “wildly optimistic,” Jarden internally projected growth “in the fours.”148 Polk

took notice of Jarden’s “really aggressive” projections.149 He and his team

determined that it was best to stick with the 3.1% growth projections as stated in the

Lender Presentation when evaluating the transaction.150

In November 2015, Jarden’s financial advisor, Barclays, asked Jarden

management for projections extended to 2020.151 In response, Lillie told Barclays

to “extrapolate out” the three-year forecast at a continuing growth rate of 5%

(the “November Projections”).152 Barclays used these five-year projections in its

analyses of the potential transaction and in its fairness opinion.153

147 Trial Tr. 106:13–107:3 (Lillie). 148 Trial Tr. 106:1–9 (Lillie); JX 1777 (Lillie Dep.) at 252:15–253:6. 149 Trial Tr. 604:3–12 (Polk) (explaining Newell did not use Jarden’s projections because “I didn’t believe 6 percent and 5 percent compounded. Those were really aggressive growth rates in the environment.”); see also id. 604:22–605:21 (Polk) (explaining that Newell utilized more realistic projections when analyzing Jarden’s value). 150 JX 1252 at 12; JX 1247 at 29. 151 JX 927 at 1. 152 Id. 153 JX 1045 at 31; JX 1205 at 44. With only minor adjustments for 2015 year-end actuals, the November Projections were also included in the Company’s proxy statement regarding the Merger.

33 In addition to negotiating price terms during the Norwalk Meeting, Newell

and Franklin began to discuss specifics regarding change-in-control payments that

would be due to Franklin, Ashken and Lillie in the event of a merger.154 And, again,

Franklin did not seek Board approval before undertaking these discussions.155

Following the Norwalk Meeting, Franklin, Ashken, Lillie and John Welsh of

Barclays on behalf of Jarden, and Polk and Tarchetti on behalf of Newell, met for

dinner.156 Franklin believed whether the transaction would be consummated

depended on whether Tarchetti stayed at Newell.157 Accordingly, he asked Tarchetti

to share his thoughts on the potential transaction.158 Tarchetti declined to respond,

explaining he believed Newell still lacked adequate information to evaluate the

transaction.159 Franklin was not happy.

154 JX 791 (Tarchetti told a colleague that “Martin change of control” was on a list of discussion points Franklin brought to the meeting on October 22); JX 1807 (Gross Dep.) at 33:20–35:4. 155 JX 1807 (Gross Dep.) at 38:12–16, 67:13–25; JX 1788 (L’Esperance Dep.) at 89:6–8; JX 1786 (Wood Dep.) at 67:12–15, 68:11–13. 156 Trial Tr. 397:8–10, 399:6–10 (Franklin); see also JX 1789 (Welsh Dep.) at 154:4–10. 157 Trial Tr. 397:15–398:4 (Franklin) (“I thought it was a little odd that, you know, a potential $20 billion transaction would all hinge on the whims of the guy who is not the CEO, who is not even on the board . . . .”). 158 Id. 159 Trial Tr. 398:5–20 (Franklin); JX 1779 (Tarchetti Dep.) at 201:6–202:7.

34 After this “difficult dinner” among the negotiators, Franklin told Ashken and

Lillie, “I’m done. I don’t want to deal with this.”160 Likewise, Polk said he thought

about “pull[ing] the plug” on the negotiations.161 After a “conciliatory” call between

Lillie and Tarchetti, however, the parties decided not to “let a bad dinner get in the

way of looking at whether this makes sense[,]” and negotiations continued.162

The Board held its first formal meeting to discuss a potential Newell

transaction on October 28, 2015.163 There was no discussion of a pre-signing market

check.164 Instead, the Board focused its attention on Newell and directed that

negotiations continue.165

In the meantime, Newell retained both Goldman Sachs (“Goldman”) and

Bain & Company (“Bain”) as additional financial advisors to assist in evaluating a

possible acquisition of Jarden.166 Tasked with performing a thorough evaluation of

160 Trial Tr. 398:16–20 (Franklin). 161 Trial Tr. 615:5–14 (Polk); see also JX 799 at 2. 162 JX 1779 (Tarchetti Dep.) at 221:24–222:9; Trial Tr. 398:21–399:5 (Franklin). 163 JX 815; PTO ¶140; JX 1807 (Gross Dep.) at 35:9–36:17; JX 1786 (Wood Dep.) at 58:9– 14. 164 JX 1786 (Wood Dep.) at 94:22–95:6; JX 1807 (Gross Dep.) at 46:17–20; JX 1785 (LeConey Dep.) at 87:2–13; JX 1789 (Welsh Dep.) at 162:20–163:9. 165 JX 815. 166 JX 1779 (Tarchetti Dep.) at 246:17–247:7; Trial Tr. 725:7–14 (Torres).

35 Jarden’s product categories, Bain’s initial assessment was that Jarden’s portfolio

demonstrated strong performance across many promising product segments, 167 but

its historic organic growth rate, once “tuck-in” acquisitions were separated, was at

most 3.5%.168 Early in the process, Centerview had projected that potential

synergies of $500 million to $900 million would result from a combination with

Jarden.169 By the end of October 2015, Bain was estimating that the combination

had the “potential to create $700M–$800M in cost synergies.”170 Bain’s assessment

encompassed “annualized savings” that would recur annually.171

Through due diligence, Newell discovered “almost every deal Jarden had

done, which were profound in number, had been left standalone with almost no cost

synergies or revenue synergies realized.”172 As a result of this holding company

167 Trial Tr. 734:12–14 (Torres). Bain continued to analyze Jarden’s category growth rates through closing. It eventually determined that Jarden’s categories “were relatively weak and were actually losing market share,” like the Coleman brand that lost distribution to dominant outlets such as WalMart. This prompted Bain to downgrade its category growth rate for Jarden to 2.5% as of closing. Trial Tr. 737:16–738:8 (Torres). When additional information became available post-closing, Bain further decreased Jarden’s category growth rate to 2.2%. Trial Tr. 739:2–8 (Torres). 168 Trial Tr. 753:1–7 (Torres). 169 Trial Tr. 600:16–601:7 (Polk); see also JX 1309 at 80. 170 JX 706 at 3; Trial Tr. 746:22–23 (Torres). 171 Trial Tr. 741:4–742:2 (Torres). 172 JX 1779 (Tarchetti Dep.) at 251:9–14; Trial Tr. 722:8–16 (Torres).

36 structure, Newell and its advisors believed that Jarden presented a substantial

opportunity to replicate Newell’s Project Renewal success by combining Jarden’s

businesses into Newell’s operating company structure.173

I. Newell Makes an Offer and Jarden Negotiates

On November 10–11, 2015, the Newell board met to discuss, among other

things, whether to make an offer to acquire Jarden.174 On the first day, Tarchetti

presented the results of the diligence efforts so far, in addition to management’s

perspective on the benefits of a merger with Jarden.175 On the second day, Bain and

Goldman presented their analysis of potential synergies.176 Bain opined that the

potential Newell/Jarden “combination would enable ~$600M in cost savings

opportunities, with potential upside to ~$700M.”177 Goldman appraised cost

synergies based on comparable transactions ranging from 2.1% to 14.0% of revenue,

173 Trial Tr. 598:10–16, 686:17–687:13 (Polk) (the “logic for the deal” was to apply the Newell integration playbook to Jarden’s businesses); see also id. 699:6–9 (Polk) (“the costs associated with [Jarden’s] decentralized model, that’s where the synergies were”). 174 JX 957 at 1. 175 Id. at 1–2. 176 Id. at 3 (Bain “highlighted three key benefits of the deal: transformational scale; high cost synergies; and likely above average revenue synergies due to channel overlap and the ability to apply the Growth Game Plan to selected categories at [Jarden]”). 177 JX 973 at 42; Trial Tr. 767:2–24 (Torres).

37 with a median of 10.0%, translating to roughly $850 million of annual cost synergies

resulting from the acquisition.178

Despite Bain and Goldman’s synergies estimates, Newell and its advisors

structured their deal model on an estimate of $500 million in annual cost

synergies.179 With this estimate, Newell’s model priced Jarden at $57.00 to $61.00

per share.180 Within these parameters, the Newell board understood that if its

management team did not realize the $500 million synergies estimate, then Newell

shareholders would not receive any increase in EPS.181 After the advisors’

presentations, the Newell board authorized management to negotiate an acquisition

of Jarden at a price between $57.00 and $60.00 per share, with cash consideration

up to $21.00 per share.182

On November 12, 2015, Polk sent Franklin an offer whereby Newell would

acquire Jarden in a cash-and-stock transaction consisting of $20.00 cash plus a fixed

exchange ratio of 0.823 Newell shares for each share of Jarden common stock,

178 JX 943 at 11. 179 Trial Tr. 614:4–18, 678:12–16 (Polk). 180 Id. 181 Trial Tr. 678:12–16 (Polk) (“The deal architecture assumed $500 million of gross synergies. If we didn’t deliver $500 million of gross synergies, we would not have delivered the operating margin outcomes, and we would not have delivered accretive EPS.”). 182 Trial Tr. 616:12–23 (Polk); JX 957 at 9.

38 representing total per share consideration of $57.00.183 The offer reflected an 18%

premium over Jarden’s then-current share price ($48.19) and a 19% premium to

Jarden’s 30-day volume-weighted average share price ($47.89). Newell arrived at

the cash and stock mix to preserve Newell’s investment grade credit rating and

dividend policy.184 Polk’s offer letter made clear that Newell “expect[ed] that

Mr. Franklin would join the Newell Brands Board of Directors given the role he has

played in Jarden’s performance and strategy to date,” and allowed that Newell was

“open to adjusting the size of our board and taking on a limited number of

[additional] members from Jarden’s board.”185

The Board met that day to discuss Newell’s offer.186 Barclays made a

presentation regarding the adequacy of Newell’s $57.00 offer in which it provided a

preliminary valuation of Jarden based on Jarden’s historic market price as well as

comparable companies, precedent transactions and DCF analyses.187

While the $57.00 per share offer was higher than Jarden’s stock had ever

traded, the Board unanimously decided “it was not inclined to engage in discussions

183 JX 986; PTO ¶142. 184 JX 986 at 2. 185 Id. 186 JX 976 at 1–2; PTO ¶143. 187 JX 977.

39 and possible negotiation with [Newell] on the economic terms set forth in the [offer]

[l]etter,” and authorized management to “seek to obtain a revised proposal with more

favorable proposed terms.”188 The Board “emphasized that the Company was not

for sale and that it would consider a potential business combination with [Newell]

only on terms that appropriately valued the relative contribution (including revenue

and EBITDA) of each standalone company to the pro forma combined company.”189

The Board authorized Franklin to continue negotiations with Newell, but did

not authorize him to make a counteroffer because, as director Robert Wood testified,

doing so would “tie their hands.”190 Franklin, however, recalled, “the board basically

authorized [him] to go back and have further discussions and . . . push the envelope

to try to come back to them with an enhanced offer from Newell.”191

During the November 12 Board meeting, Franklin suggested that the Board

formally engage Barclays as the lead banker for the Company and UBS Group AG

as “co-investment banker.”192 Jarden thought a transaction of this magnitude

188 JX 976 at 2–3; Trial Tr. 405:12–16 (Franklin). 189 JX 976 at 2; PTO ¶145. 190 JX 1786 (Wood Dep.) at 91:22–25; see also JX 1807 (Gross Dep.) at 48:3–8 (“Q. Did Jarden to your knowledge ever make a counteroffer to Newell? A. Not that I’m aware of. Q. Did the Board ever discuss parameters of the counteroffer? A. Not that I’m aware of.”). 191 Trial Tr. 406:2–5 (Franklin). 192 JX 976 at 3.

40 justified having two banks on board to guide the Company through the process.193

Barclays, in particular, had a longstanding, fruitful relationship with Franklin and it

knew Jarden well.194 Accordingly, Franklin believed Barclays was positioned to

provide Jarden with “genuine good advice” on the potential merger.195 And he

believed UBS would serve as a well-informed source for “second opinions.”196 The

retention of UBS, however, did cause Jarden director Ros L’Esperance to recuse

Trial Tr. 562:4–5 (Franklin) (“The board wanted a second advisor.”); see also JX 1778 193

(Ashken Dep.) at 100:12–101:6. 194 Trial Tr. 407:2–15 (Franklin). Barclays earned about $180 million from all of Franklin’s businesses, including nearly $70 million from Platform alone in the four years between Platform’s founding and the Merger Date. JX 1805; Trial Tr. 546:11–17 (Franklin). Barclays’ history with Franklin and his businesses earned Franklin “Platinum client” status. JX 438; JX 1789 (Welsh Dep.) at 50:25–54:4. The Board made no inquiry regarding the thickness of Franklin’s relationship with Barclays and there is no indication that either Franklin or Barclays made any effort to disclose their past relationships to the Board. See JX 976; JX 1070. 195 Trial Tr. 407:16–408:3 (Franklin). 196 Trial Tr. 560:22–24 (Franklin). Franklin explained to the Board that UBS had done work for the Company in the past for free, and described the UBS engagement in connection with the Newell transaction as giving UBS a “kiss.” Trial Tr. 561:19–562:12 (Franklin) (“I described it at one point as giving them a kiss. It was a way of saying thanks for all the work that you’ve done that you didn’t get compensated for. We—you know, you’re on par with a couple of other firms to do this advisory work for us for the board, and we’re happy to have you do that work.”). Petitioners argue that this means UBS was paid for doing no work and that the payment diverted value from stockholders. This is not a fair characterization of UBS’s role. The record reflects that UBS prepared Board decks, led discussions at Board meetings and was generally available to the Board as a sounding board. Trial Tr. 560:22–24 (Franklin); JX 1785 (LeConey Dep.) at 35:23–36:10. Whether UBS’s compensation was fully earned is beyond the scope of this appraisal proceeding.

41 herself from all deliberations and votes of the Board, as she led UBS’s Client

Corporate Solutions Group.197

On November 16, 2015, Jarden and Newell, along with their financial

advisors, met to continue negotiations over the potential transaction.198 In advance

of the meeting with Newell, the Jarden management team scheduled an evening

Board dinner anticipating there would be new developments in the negotiations that

would require the Board’s prompt attention.199 In yet another demonstration of

Franklin getting ahead of his Board, Franklin announced to the Newell team at the

outset of the meeting that their $57.00 offer was too low and then made a

counteroffer of $63.00 per share––$21.00 in cash with the balance in stock of the

combined company.200 The Newell team balked. Not only did they decline the

197 Trial Tr. 408:4–15 (Franklin); JX 1807 (Gross Dep.) at 44:10–14; JX 976 at 3; PTO ¶146. See JX 1565 at 89 (“With respect to UBS, it was noted that Ms. Ros L’Esperance is the Head of Client Corporate Solutions of UBS, and as such she would be recused from all deliberations and votes of the Jarden board, if any, in respect of the possible business combination with Newell Rubbermaid.”). 198 Trial Tr. 408:24–409:8 (Franklin); JX 1001 at 1. 199 Trial Tr. 411:4–10 (Franklin). 200 Trial Tr. 409:1–8 (Franklin); Trial Tr. 618:24–619:3 (Polk); JX 1789 (Welsh Dep.) at 214:2–9; JX 1779 (Tarchetti Dep.) at 297:3–12, 300:8–16; JX 1807 (Gross Dep.) at 48:3–8; JX 1016 at 3; JX 1786 (Wood Dep.) at 91:15–92:2; PTO ¶148.

42 counteroffer on the spot, they also refused to raise their $57.00 offer.201 Discussions

turned “acrimonious” and the meeting abruptly adjourned.202

After the meeting, Ashken emailed the Board to advise that the parties were

at impasse and there was no need for the scheduled Board dinner.203 According to

Ashken, “[a]s far as we were concerned the deal was dead.”204

J. Newell Increases Its Offer

On November 21, 2015, Newell submitted a revised offer to acquire Jarden

for $21.00 in cash plus a floating exchange ratio between 0.85 to 0.92 Newell shares

for each Jarden share to be determined based on Newell’s trailing 10-day unaffected

volume weighted average price (“VWAP”) at the time of signing, with a target price

of $60.00 per share.205 This revised proposal was a 30% premium over Jarden’s

201 Trial Tr. 410:2–7 (Franklin). 202 JX 1778 (Ashken Dep.) at 116:22–119:20 (“[A]s we explained to them, we were not sellers. If you want to buy it, buy it. But don’t waste our time. And it was a pretty acrimonious meeting. And it didn’t make any difference to us whether we bought or sold.”); see also Trial Tr. 410:8–24 (Franklin). 203 JX 1778 (Ashken Dep.) at 116:13–21. 204 JX 1778 (Ashken Dep.) at 119:6–9. Franklin similarly explained: “I went back to the board and said, This deal is dead. We tried to get a better offer out of them, and they refused.” Trial Tr. 504:23–505:1 (Franklin). 205 JX 1069; JX 1066 at 2; JX 1149; PTO ¶153; JX 1064 at 2; see also Trial Tr. 619:18– 620:5 (Polk) ($21.00 was “the limit to what we could afford” in cash consideration). According to Franklin, Newell “blinked” and agreed to increase its offer. Trial Tr. 412:19– 413:2 (Franklin).

43 then-current stock price ($46.33) and a 27% premium over Jarden’s 30-day VWAP

($47.43). Newell reiterated that it expected the potential merger to produce annual

cost synergies of approximately $500 million.206 It also renewed its offer for

Franklin, Ashken, Lillie and a new independent director to join the board of the

combined company.207

The Board convened the following day to discuss the $60.00 per share offer.

After discussions with its financial advisers, the Board determined that the offer

would be accepted and that Newell would be granted exclusivity during a period of

confirmatory due diligence.208 Outside director Robert Wood testified that the Board

viewed the revised offer “much more favorably,”209 and explained that while the

Board thought Jarden’s forecast of 5% growth over the next three years was

achievable, “the [B]oard’s level of concern [regarding future growth] was higher”

206 JX 1064 at 3; see also JX 1779 (Tarchetti Dep.) at 307:4–8 (“So by this stage, we’d obviously recommended to the board that we should try to consummate the transaction because we believed the synergies would create a lot of value for both parties.”). 207 JX 1064 at 3. 208 JX 1070 at 2; PTO ¶¶155, 157. Franklin went over the terms of the revised offer, discussing the increased proposed cash consideration from $20.00 to $21.00 per share and the formula for determining the exchange ratio. JX 1070 at 1. Barclays also presented its analysis of the updated offer, including a revised valuation analysis of Jarden as a standalone company. JX 1079 at 27–28. 209 JX 1786 (Wood Dep.) at 112:5–6.

44 following recent acquisitions.210 Specifically, the Board had come to appreciate that

Jarden could not sustain historic growth without pursuing “bigger and bigger

acquisitions,” a strategy the Company had found was increasingly difficult to

execute.211 As a result, Wood and the other directors believed the $60.00 offer

provided more value for shareholders than Jarden could deliver as a standalone

company.212

Franklin believed the $60.00 offer represented a 13.5x EBITDA multiple,

“a high multiple, by any standard, for our business . . . [and] the highest multiple, by

far, our company would have ever traded or been valued.”213 By way of comparison,

just a few weeks before Newell delivered its revised offer, Jarden had acquired

Jostens for $1.5 billion, representing a 7.5x EBITDA multiple.214 The Board also

concluded that Jarden stockholders stood to benefit from any synergies on top of the

210 Id. at 55:7–15. 211 Id. at 55:10–56:9. 212 Id. at 49:3–11. See also JX 1778 (Ashken Dep.) at 68:19–23, 69:23–70:4 (“When we looked at it and we thought, you know, if we can realize something that begins with a 6 for our shareholders is that more than we could expect if we continue to run the operations and did all the stuff? And we felt the answer was yes.”). 213 Trial Tr. 415:2–11 (Franklin). 214 Trial Tr. 415:19–23 (Franklin).

45 $500 million estimate baked into the purchase price, by remaining invested in the

combined company following the Merger.215

As noted, the Board agreed to mutual exclusivity.216 This, of course, disabled

any market check prior to consummation of the Merger.217 The Board thought

“Newell was the best and most likely acquirer of our business” and there were no

other “companies that had the same fit in terms of synergies and ability to pay as

Newell.”218 From the Board’s perspective, Jarden was a “very diverse business”

operating in siloed industries that were not of interest to other large consumer

product companies.219 Accordingly, the Board and management understood that

215 Trial Tr. 684:13–685:22 (Polk) (explaining that $500 million in synergies was assumed in the deal model, but “if there’s future value to be created, more synergies, more growth, then any equity owner benefits from that”); see also Trial Tr. 415:2–15 (Franklin). Franklin described the $60.00 offer as “a full and fair price by any measure.” Trial Tr. 444:5–10 (Franklin). 216 JX 1070 at 2–3; PTO ¶¶155, 157. During the exclusivity period, Franklin and Ashken continued to negotiate the terms of the Merger Agreement, but also negotiated for Franklin, Ashken, and Lillie to continue with the combined company as paid consultants through Mariposa. See JX 906; JX 1061; JX 1074. 217 JX 1786 (Wood Dep.) at 102:6–8 (explaining the Board’s view that “it would not be value enhancing and perhaps very distracting to management to run an auction”). Respondent acknowledges that the Board never considered authorizing its bankers to reach out to other potential strategic buyers or financial sponsors. Id. at 94:22–95:6. 218 Id. at 100:13–23. 219 Trial Tr. 419:21–420:5 (Franklin); see also Trial Tr. 918:10–921:11 (Zenner) (explaining that other large consumer product companies had targeted businesses and were probably not interested in a diversified company like Jarden). Until Newell surfaced, no potential acquirer had expressed interest in Jarden during its entire 15-year history. Trial Tr. 425:10–13 (Franklin).

46 Jarden would likely continue standalone unless a unique opportunity for a business

combination came along.220 Newell provided that opportunity.

K. Jarden and Newell Finalize Deal Documents

Over November 29 and 30, 2015, Jarden and Newell convened at Jarden’s

Norwalk, Connecticut offices, where the Newell team continued its diligence and

presented its strategic plan for the combined company.221 Both Newell and Jarden

knew from the outset that a deal could only be done if a substantial portion of the

consideration was Newell stock.222 Because Newell understood this and appreciated

the magnitude and significance of Jarden’s assets to the combined company, Newell

committed that certain Jarden directors would be offered a seat on the Newell board

post-closing.223 Newell specifically wanted Franklin to sit on the combined board

to provide a positive signal to the market of his confidence in the future of the

combined company.224

220 JX 1786 (Wood Dep.) at 129:2–130:14; JX 1778 (Ashken Dep.) at 65:5–10. 221 JX 1565 at 90; JX 1116 at 194–242. 222 Trial Tr. 475:2–7 (Franklin); Trial Tr. 617:5–18 (Polk). 223 Trial Tr. 621:9–13 (Polk). 224 Trial Tr. 620:17–20 (Polk); Trial Tr. 406:24–407:1 (Franklin) (“[I]t would almost look odd if I didn’t agree to serve as a director in the go-forward company.”); JX 1779 (Tarchetti Dep.) at 120:3–16, 124:6–18 (discussing Franklin’s role as the “face of Jarden” and the importance of having Franklin on the board of the combined entity, which would serve as an endorsement of the Merger); JX 1803 (Cowhig Dep.) at 153:24–154:3.

47 The parties understood that Newell’s management team would lead the

combined company since capturing synergies through the implementation of Project

Renewal was the “logic for the deal.”225 Franklin, Ashken and Lillie each were

subject to two-year non-competition covenants in event they were terminated

following a change of control.226 Newell wanted to draw out these non-competition

covenants to four years.227 It also wanted to have access to Franklin, Ashken and

Lillie as consultants post-closing if needed.228 Accordingly, Newell, Franklin,

Ashken and Lillie negotiated an “Advisory Services Agreement” that extended their

non-competes but also provided for Mariposa (on behalf of the three executives) to

be paid an annual consulting fee of $4 million for three years ($12 million in total).229

The Advisory Services Agreement provided that Mariposa “shall, upon the request

of [Newell], devote up to an average of 120 hours per fiscal quarter” to Newell, and

225 Trial Tr. 686:17–687:13 (Polk) (“We wanted as part of––the deal terms, to get control of the company. Because there was no way that, without our leadership of the change agenda, those synergies were going to be realized.”); JX 1778 (Ashken Dep.) at 153:15– 19. 226 JX 1778 (Ashken Dep.) at 163:13–14. 227 Id. at 163:14–19 (explaining Newell was “very keen to have [the noncompete period] be four years” because Newell “had had a bad experience” before with competition from a past executive); see also JX 1807 (Gross Dep.) at 58:16–59:9 (noting Newell was “requiring that the management team extend their non-compete agreements from two to four years,” which was a “big ask” since management was in the prime of their careers). 228 Trial Tr. 526:18–20 (Franklin); JX 1779 (Tarchetti Dep.) at 347:15–349:7. 229 JX 1233 at 2–3.

48 that Franklin and Ashken waived “any and all fees and compensation” they would

have ordinarily received as directors of Newell during the term of the agreement.230

L. The Leak

On December 7, 2015, The Wall Street Journal reported that Newell and

Jarden were discussing a potential business combination, though the article did not

reveal the specifics of who would be buying whom or the transaction

consideration.231 In reaction to this news, Newell’s shares traded up 7.4%, closing

at $48.16 and Jarden’s shares traded up 3.7%, closing at $50.09.232

Following the leak, and resulting impact on the companies’ stock prices, the

parties agreed that it no longer made sense to calculate the final exchange ratio based

upon the 10-day trailing VWAP as of the day of signing.233 Ashken contacted

Tarchetti to re-negotiate and the parties ultimately settled on a fixed ratio of 0.862,234

230 Id. 231 JX 1150 at 1–2; JX 1148; PTO ¶164. According to one witness, Newell’s counsel leaked news of the Merger to a reporter. JX 1779 (Tarchetti Dep.) at 322:23–323:9. 232 PTO, Exs. A, B. 233 Trial Tr. 424:1–5 (Franklin); Trial Tr. 658:16–659:2 (Polk) (explaining that after the leak, Newell “had to” negotiate a fixed exchange rate because “we would have had exposure, potentially, if the stock had run one way or the other”); JX 1779 (Tarchetti Dep.) at 325:17–23 (fixing the exchange ratio was “in the interest of both parties because the stock prices were very volatile, and it was against the spirit of the agreement to not reflect the fact that there had been a leak”); JX 1778 (Ashken Dep.) at 136:12–17 (same). 234 JX 1195 at 1.

49 resulting in total merger consideration at that time of $60.03 based upon Newell’s

closing stock price on December 11, 2015.235

The 10-day trailing VWAP through the last unaffected day prior to the leak,

was $44.60.236 If Jarden held firm to the original agreement, on top of the $21.00 in

cash, Jarden stockholders would have received 0.874 shares of Newell stock for

every share of Jarden stock they owned.237 In other words, Jarden stockholders

would have received $120 million more in consideration if not for the renegotiation.

M. Jarden and Newell Stockholders Approve the Merger

On December 10, 2015, the Board met to discuss the status of negotiations

and to assess whether the transaction continued to make sense. Lillie opened the

meeting by presenting the 2015 estimated financial results that demonstrated 4.4%

growth in organic net sales over 2014.238 Barclays also presented a summary of the

transaction’s proposed terms and an analysis of Jarden’s standalone value.239 The

meeting minutes emphasize that “the Company has not been and is not currently for

sale and that remaining independent (as a standalone entity) is the sole alternative to

235 JX 1241 at 5; Trial Tr. 507:1–19 (Franklin). 236 JX 1218 at 2. Had Jarden negotiated for a 0.90 exchange ratio, Jarden stockholders would have received $380 million in additional equity. Id. 237 Id. 238 JX 1207 at 3. 239 JX 1205.

50 the proposed business combination with Newell, which offers unique revenue and

cost synergies and long-term value accretion opportunities for the Company’s

stockholders.”240

Jarden’s negotiating team had been discussing change of control payments

with Newell for several weeks but raised the subject with the Board for the first time

at the December 10 meeting.241 Ashken recommended to the Board that he, Franklin

and Lillie receive their 2017 and 2018 Restricted Stock Awards (“RSAs”) should

the transaction with Newell be approved.242 The RSAs would not have been due

under the existing employment agreements but Franklin’s team instructed Barclays

to include the RSAs in the shares outstanding calculation used for its valuation

analyses of the transaction and they had already presented that share calculation to

Newell.243 John Capps, Jarden’s General Counsel, advised the Board that Jarden

was legally obligated to grant the RSAs even though the agreements themselves

240 JX 1202 at 1. 241 Id. 242 Id. 243 JX 906 at rows 15–17; JX 1057; JX 1072 at 1–2.

51 were, at best, ambiguous on the point.244 Ultimately, the Board’s Compensation

Committee recommended that the Board award the 2017 and 2018 RSAs.245

The Board met next on December 13, 2015. Barclays presented the revised

proposed deal terms and its revised valuation of Jarden as a standalone company.246

Barclays also orally presented its opinion that the proposed merger was fair from a

financial point of view to Jarden and its stockholders.247 After hearing from Barclays

and reviewing the final deal terms, the Board approved the Merger.248 The Board

also approved the separation agreements and amendments to the employment

agreements with Franklin, Ashken and Lillie.249 The final Merger Agreement

244 JX 1786 (Wood Dep.) at 158:15–159:5. In addition to his work as Jarden’s General Counsel, Capps has served as General Counsel for Platform since 2016. S&P Global Market Intelligence, Platform Specialty Products (ESI:NYSE) (2019). Capps was also to be a beneficiary of any grant of 2017 and 2018 RSAs. JX 1565 at 146–147. 245 JX 1231 at 18. There is no evidence the Compensation Committee ever looked at the employment agreements. JX 1231 at 16; JX 1807 (Gross Dep.) at 66:12–22, 81:15–82:2 (“I don’t even know if I’ve seen it before.”). 246 JX 1232; JX 1231 at 2. 247 JX 1231 at 2; see JX 1255. Barclays delivered its written fairness opinion the following day. JX 1255. 248 JX 1231 at 4. The Jarden board reiterated “its belief that the combined company’s long- term value, prospects and benefits from the merger would exceed the value that could be realized by Jarden’s stockholders were Jarden to continue operating on a stand-alone (independent) basis.” Id. at 3. 249 Id. at 4, 9. The amended employment agreements for Franklin, Ashken and Lillie extended the term of their non-competes upon termination from two years to four years. JX 1326 at 15. They also confirmed the acceleration of certain RSAs in connection with the transaction. JX 1326 at 15; see also Trial Tr. 638:11–16 (Polk) (explaining that the negotiations concerning the RSAs were between the Jarden executives and the Jarden 52 provided that Jarden stockholders would receive 0.862 shares of Newell stock plus

$21.00 in cash for each Jarden share, representing a value as of signing of $60.03.250

The Newell board also met on December 13 to consider the final transaction

terms and to receive Goldman and Centerview’s final presentations.251 In their

analyses, both Goldman and Centerview used five-year projections for Jarden,

assuming 3.1% revenue growth during FY18–20, consistent with the Lender

Presentation and below the 5% revenue growth forecast in the November

Projections.252 Goldman maintained its estimate of $500 million in annual cost

synergies.253 Centerview estimated $500–$700 million in synergies.254 After the

board). Franklin, Ashken and Lillie had three-year “evergreen” employment agreements. Under those agreements, they each were guaranteed their 2017 and 2018 RSAs, which the Board agreed to grant prior to the Merger. JX 1778 (Ashken Dep.) at 142:23–143:4, 146:4–7; Trial Tr. 517:9–19 (Franklin). Using Newell’s stock price as of the Merger Date to determine the exchange ratio cash equivalent, Franklin received a total of $71.04 per share in Merger-related consideration, Ashken received a total of $76.11 per share and Lillie received an equivalent of $81.69 per share. JX 1818 at ¶40. 250 JX 1231 at 2. The final Merger consideration represented a premium of 24.3% over the unaffected market price of $48.31 on December 4, 2015 (the last day of trading before the leak) and a premium of 24% over the VWAP of $48.35 for the 30-day period prior to December 11, 2015. Id. 251 JX 1251 at 1–2. 252 JX 1252 at 12; JX 1247 at 29; see also JX 775 at 5. Newell also used numbers in line with the Lender Presentation projections in its internal modeling and in the presentation made to rating agencies on December 7, 2015. JX 1154 at 41. 253 JX 1230 at 10. 254 JX 1228 at 7. Bain’s report in advance of the meeting estimated total annual synergies ranging from $585 million to $1 billion, comprised of $500–$700 million in cost synergies and $85–$320 million in revenue synergies. JX 1139 at 50. Bain was “very comfortable” 53 presentations by its advisors, the Newell board approved the terms of the final

Merger Agreement and the parties announced the Merger.255

N. The Market Reacts

The Merger announcement, released on December 14, 2015, stated “[Newell]

anticipates incremental annualized cost synergies of approximately $500 million

over four years.”256 In response to the announcement, Jarden’s stock price closed at

$54.09, roughly 12% above the unaffected trading price of $48.31 from December 4,

2015.257 The delta between Jarden’s stock price and the implied Merger Price

(i.e., the merger arbitrage spread) slowly narrowed following the announcement and

ultimately converged in the days leading up to the closing.258

Newell’s stock price rose 7.4% on December 7, 2015, when financial media

outlets first reported the parties were negotiating.259 When the final terms of the

transaction were made public on December 14, 2015, however, Newell’s stock price

Newell would meet at least the low end of its estimate range. Trial Tr. 773:14–22, 774:17– 775:6 (Torres). 255 PTO ¶¶179, 181. 256 JX 1269 at 3. 257 PTO, Ex. A. 258 JX 1816 at ¶53. Jarden’s stock price never closed above the implied Merger price prior to closing. Id. at ¶54. 259 Id. at ¶58.

54 declined by 6.9% to $42.15.260 After accounting for market fluctuations, Newell’s

stock price after the announcement of the Merger terms reflected, at best, a neutral

market response.261

On February 26, 2016, Jarden reported its 2015 year-end results, including a

considerable loss in operating income and net income as compared to the prior two

years.262 A few days later, on February 29, 2016, Lillie shared weak results for the

first quarter of 2016 with the Board.263 Lillie also shared the final 2016 budget,

which was adjusted downward to reflect year-end revenue of $9.79 billion

(as compared to the $10.15 billion in the November Projections).264

During March and April 2016, before the Merger closed, Jarden management

prepared updated multi-year projections for the period 2016 to 2020 (the “April

260 Id. at ¶59. 261 Id. at ¶¶59–60. 262 JX 1519 at 68. Net income fell by nearly 40% as compared to 2014 year-end. Id. Jarden also adjusted its guidance downward twice during 2015. JX 454 at 4, 17, 41. And, in November 2015, Lillie advised investors that Q4 2015 organic growth would be in the 2– 4% range, not the 3–5% range as earlier reported. JX 1034 at 1. 263 JX 1514 at 1–2; see also Trial Tr. 622:15–17 (Polk) (noting that Jarden fell below its goals for Q1 2016). 264 Id.; Trial Tr. 440:22–441:1 (Franklin); see also JX 1510; Trial Tr. 823:13–19, 856:1–6 (Waldron). The 2016 budget assumed Jarden would remain a standalone company. Trial Tr. 830:16–21 (Waldron).

55 Projections”).265 The original version of the April Projections reflected a “bottoms

up build” from the business units and forecast a 4.4% compound annual revenue

growth rate.266 This was well below the 5.0% forecast in the November

Projections.267

Jarden and Newell stockholders voted to approve the Merger on April 15,

2016.268 As of the closing, the mix of cash and Newell shares valued Jarden at

$59.21 per share.269

265 JX 1562 (revised multi-year plan projecting $9.816 billion in total revenue); see also Trial Tr. 833:5–834:11 (Waldron). Newell asked for a copy of Jarden’s updated multi-year plan in mid-March 2016, which Jarden provided. Trial Tr. 833:5–834:11 (Waldron). Newell later asked Jarden to reevaluate the operating cash flow assumptions in the plan. After doing this, Jarden circulated a revised version on April 1, 2016. Trial Tr. 832:24– 838:3 (Waldron). See also JX 1563; JX 1597; JX 1598. While this revision included minor adjustments, the annual revenue and EBITDA projections remained the same as those estimated in the unrevised plan. Id. 266 Trial Tr. 834:12–835:11 (Waldron). 267 JX 1598; JX 1565; see also JX 1826 at ¶88, Figure 16. Newell incorporated the revised multi-year plan into its own multi-year forecast. Newell’s forecast, however, assumed growth at 3.5%. JX 1691 at 95; Trial Tr. 626:4–627:15 (Polk). 268 PTO ¶183. Over 97% of voting Jarden stockholders approved the Merger (representing 83% of the outstanding shares). JX 1663 at 7. 269 JX 1816 at ¶10. The per share decrease in consideration from $60.03 to $59.21 reflects the change in Newell’s stock price from signing to closing.

56 O. Post-Closing

By January 2016, Bain shortened the time Newell would realize $500 million

in recurring annual cost synergies from four years to three.270 By May 2016, Bain

raised its projection of potential cost savings to a range of $900 million to

$1 billion.271 In February 2017, Newell announced it would meet the initial estimate

of $500 million in annual cost synergies by Q3 2018, and doubled the size of its total

cost synergy target from $500 million to $1 billion, to be reached by 2021.272 Newell

also announced its intention to divest several businesses—both historical Jarden and

Newell—and to exit certain product lines.273 In early 2018, Newell announced it

would sell businesses accounting for almost 50% of its customer base and

approximately one-third of its revenue.274

The Jarden/Newell integration did not go smoothly.275 Newell Brands

(the combined company) faced an uphill battle with the divestitures of highly-

270 Trial Tr. 780:14–781:2 (Torres); see also JX 1373 at 11. 271 Trial Tr. 781:18–782:20 (Torres); JX 1691 at 7. 272 Trial Tr. 783:4–784:7 (Torres). 273 JX 1666; JX 2015; Trial Tr. 447:16–18 (Franklin); Trial Tr. 796:22–797:11, 798:20– 799:11, 800:20–801:24, 802:18–804:3 (Torres). 274 JX 1801; JX 1802; Trial Tr. 802:18–803:4 (Torres). Franklin strongly objected to this strategy. JX 1808; JX 1809; JX 1825; JX 1807 (Gross Dep.) at 16:9–14. 275 JX 1803 (Cowhig Dep.) at 191:13–20.

57 profitable and valuable businesses.276 In early 2018, Franklin resigned from the

Newell Brands board in spectacular fashion, publicly proclaiming that Polk was

“ruining the company” and calling for Polk’s ouster.277 Ashken, L’Esperance and

long-time Newell director, Dominico De Sole, left the Newell Brands board soon

after.278

After leaving, Franklin, Ashken and Lillie united with Starboard Value LP, an

activist hedge fund, to advance a slate of directors to challenge the Newell Brands

board.279 Carl Icahn entered the mix and ultimately was successful in placing his

slate of five directors on the Newell Brands board, thereby effectively ending the

Franklin/Starboard-led challenge.280 In the fallout of the proxy contest, Tarchetti,

President of Newell Brands, resigned.281

276 Newell Brands announced an agreement to sell Waddington in April 2018 for $2.3 billion, almost $1 billion more than the price Jarden paid less than three years prior. Trial Tr. 450:18–451:2 (Franklin) (“Q. Okay. Waddington, you bought for 1.35 million [sic] in July of 2015. Correct? A. Correct. Q. And Newell sold that business this year for 2.3 billion. Right? A. Correct. Q. They made almost a billion on that. Right? A. Yes.”). 277 Trial Tr. 447:2–11 (Franklin); JX 1808; JX 1809; JX 1823; JX 1834. 278 JX 1803 (Cowhig Dep.) at 184:17–188:12; JX 1809. 279 Trial Tr. 447:12–15 (Franklin); JX 1809. 280 JX 1822. 281 Newell Brands, Inc., Form 8-K at 3 (dated May 17, 2018).

58 P. Procedural Posture

Between June 14, 2016 and August 12, 2016, four petitions for appraisal were

filed in connection with the Merger.282 By order of the Court dated October 3, 2016,

the four appraisal actions were consolidated.283 On July 5, 2017, Merion Capital LP,

Merion Capital II LP and Merion Capital ERISA LP were dismissed from the

consolidated action after reaching settlement agreements with Jarden.284 On July 7,

2017, Dunham Monthly Distribution Fund, WCM Alternatives: Event-Driven Fund,

Westchester Merger Arbitrage Strategy sleeve of the JNL Multi-Manager

Alternative Fund, JNL/Westchester Capital Even Driven Fund, WCM Master Trust,

The Merger Fund, The Merger Fund VL and SCA JP Morgan Westchester were also

dismissed, again after reaching settlement agreements with Jarden.285

The Court held a four-day trial in June 2018. Three experts testified. For

Petitioners, Dr. Mark Zmijewski evaluated the standalone value of Jarden on the

Merger Date by conducting a market multiples analysis and a DCF analysis,

ultimately relying on his multiples (comparable company) analysis for his fair value

conclusion. He opined that Jarden’s fair value on the Merger Date was $71.35 per

282 PTO ¶11. 283 D.I. 13. 284 D.I. 35. 285 D.I. 37.

59 share. Dr. Zmijewski holds the Charles T. Horngren Professorship at the University

of Chicago Booth School of Business.

For Respondent, Dr. Glenn Hubbard evaluated the standalone value of Jarden

on the Merger Date by analyzing market evidence, including Jarden’s unaffected

market price and the Merger Price less synergies, and traditional valuation

methodologies, including comparable companies and DCF. Based on his DCF

analysis, which he correlated to the market evidence, Dr. Hubbard opined that

Jarden’s fair value on the Merger Date was $48.01 per share. Dr. Hubbard holds the

Russell L. Carson Professorship in Finance and Economics in the Graduate School

of Business of Columbia University, where he is also the Dean.286

Respondent also presented the testimony of Dr. Marc Zenner, a retired

investment banker. Dr. Zenner testified that the projected synergies estimates

reported in the joint proxy statement issued by Jarden and Newell in connection with

the Merger were conservative and that the synergies were taken by Jarden

stockholders. He also opined that the Board’s decision not to hold an auction for

Jarden was reasonable because Jarden’s size and diverse product portfolio made it

unlikely that a merger partner more suitable than Newell would have emerged.

286 The expert reports were submitted under seal. At the close of this case, the Court will unseal the reports. Perhaps the legal and business academies will find interesting, and worthy of study and classroom discussion, how two such well-credentialed experts in their fields reached such wildly divergent conclusions regarding the fair value of the same company as of the same date.

60 Following post-trial briefing and argument, the Court wrote to the parties, as

previewed at the conclusion of post-trial oral argument, to advise that it would

postpone the issuance of its post-trial opinion in this case until our Supreme Court

issued its decision in Aruba.287 The parties submitted brief (and unsolicited) letters

regarding Aruba on April 30 and May 1, 2019, at which time the matter was

submitted for decision.

II. ANALYSIS

Delaware’s appraisal statute, 8 Del. C. § 262(h) provides, in part:

Through [the appraisal] proceeding, the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger or consolidation, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors.288

“Section 262(h) unambiguously calls upon the Court of Chancery to perform

an independent evaluation of ‘fair value’ at the time of a transaction . . . [and] vests

the Chancellor and Vice Chancellors with significant discretion to consider

‘all relevant factors’ and determine the going concern value of the underlying

company.”289 “By instructing the court to ‘take into account all relevant factors’ in

287 D.I. 154. 288 8 Del. C. § 262(h). 289 DFC, 172 A.3d at 364 (quoting 8 Del. C. § 262(h)).

61 determining fair value, the statute requires the Court of Chancery to give fair

consideration to ‘proof of value by any techniques or methods which are generally

considered acceptable in the financial community and otherwise admissible in

court.’”290 Since “‘[e]very company is different; [and] every merger is different,’

the appraisal endeavor is ‘by design, a flexible process.’”291

I have carefully considered all relevant factors. I have weighed those factors

according to the credible evidence in the record and applied “accepted financial

principles” as derived from that evidence.292 To follow is my independent evaluation

of Jarden’s fair value as informed by my findings of fact.

A. Merger Price Less Synergies

Respondent has proffered the Merger Price less synergies as a reliable

indicator of fair value, and for good reason. Our Supreme Court has stated, “a buyer

in possession of material nonpublic information about the seller is in a strong

position (and is uniquely incentivized) to properly value the seller when agreeing to

buy the company at a particular deal price, and that view of value should be given

considerable weight by the Court of Chancery absent deficiencies in the deal

290 Dell, 177 A.3d at 21 (quoting Weinberger v. UOP, 457 A.2d 701, 713 (Del. 1983)). 291 Id. 292 Id. at 22.

62 process.”293 This court has heeded the Supreme Court’s guidance and regularly rests

its appraisal analysis on the premise that when a transaction price represents an

unhindered, informed and competitive market valuation, that price “is at least first

among equals of valuation methodologies in deciding fair value.”294

In PetSmart, I observed, “[a]fter years of striving for it, Vince Lombardi

finally arrived at the understanding that perfection in human endeavors is not

attainable.”295 “Even in the best case, a process to facilitate the sale of a company,

constructed as it must be by the humans who manage the company and their human

advisors, will not be perfect.”296 With that said, I am mindful of our Supreme Court’s

guidance in Dell, where the Court observed that certain factors, including “fair play,

293 Aruba, 2019 WL 1614026, at *6. 294 In re Appraisal of AOL Inc., 2018 WL 1037450, at *1 (Del. Ch. Feb. 23, 2018). See also In re Appraisal of PetSmart, Inc., 2017 WL 2303599, at *27 (Del. Ch. May 26, 2017) (collecting cases). 295 In re Appraisal of PetSmart, Inc., 2017 WL 2303599, at *27 (citing Chuck Carlson, Game of My Life: 25 Stories of Packer Football (Sports Pub. 2004) (quoting Coach Lombardi as opening his first Packers team meeting in 1959, after twenty years of coaching, by saying: “Gentleman, we are going to relentlessly chase perfection, knowing full well we will not catch it, because nothing is perfect.”)).

Id. (citing Merlin P’rs LP v. AutoInfo, Inc., 2015 WL 2069417, at *14 (Del. Ch. Apr. 30, 296

2015) (observing that no “real-world sales process” will live up to “a perfect, theoretical model”)).

63 low barriers to entry, [and] outreach to all logical buyers,” are reflective of the kind

of “robust sale process” that will discover a company’s fair value.297

The “sale process” for Jarden, if one can call it that, raises concerns. To be

sure, there was no need for a full-blown auction of Jarden. In this regard,

Dr. Zenner’s testimony, corroborated by other evidence, was credible.298 Moreover,

there were signs of arms-length, provocative negotiating between Jarden and

Newell.299 This is not surprising given that Jarden’s negotiators owned millions of

Jarden’s shares and had every incentive to negotiate a good deal.300 But the evidence

297 Dell, Inc., 177 A.3d at 35. 298 Dr. Zenner testified that auctions are less effective as companies increase in scale and complexity. Trial Tr. 915:3–14, 916:17–917:17 (Zenner). For sale transactions over $5.4 billion, as here, only one in five are the product of an auction. Id.; JX 1817, App’x C-5. See also JX 1827 at ¶¶53–54 (explaining that the most logical strategic partners were too small to buy the Company); JX 1786 (Wood Dep.) at 101:18–102:11 (Jarden routinely “looked at likely people we could have business combinations with or that we could acquire . . . [and] didn’t think there was anybody out there who would come in and make a preemptive offer to buy the company”); Trial Tr. 921:12–923:16 (Zenner); JX 1817 at ¶95 (explaining that financial sponsors were not interested in Jarden because its leverage was too high); Trial Tr. 419:6–8 (Franklin) (“In 15 years of building the company, I haven’t had one company come and sort of make an offer to buy Jarden.”); JX 1789 (Welsh Dep.) at 143:5–10 (“The combination with Newell was viewed to be a highly strategic combination that couldn’t necessarily be replicated with other counterparties. . . .”); JX 1785 (LeConey Dep.) at 88:3–4 (“UBS was not aware of any other buyers that were interested in acquiring all of Jarden.”). 299 Trial Tr. 504:23–505:1 (Franklin) (“I went back to the board and said, This deal is dead. We tried to get a better offer out of them, and they refused.”); JX 1778 (Ashken Dep.) at 119:6–9; see also JX 1807 (Gross Dep.) at 41:3–15. 300 JX 1816 at ¶169, Figure 23.

64 revealed a troubling theme. Franklin immediately took charge and, consistent with

a stereotypical “cut to the chase” CEO mentality,301 he laid Jarden’s cards on the

table before the negotiations began in earnest and before the Board and its financial

advisors had a chance to formulate a plan. Petitioners are right to complain that

Franklin’s approach may well have set an artificial ceiling on what Newell was

willing to pay.

Franklin did not inform the Board he was meeting with Polk at the Back-to-

School Meeting or the Boat Meeting, and he certainly did not receive authority from

the Board to suggest a price (“beginning with a 6”) at which the Board might agree

301 I appreciate Franklin was no longer CEO when he negotiated with Newell. With regard to M&A, however, his role as Executive Chairman was tantamount to that of a typical CEO. Trial Tr. 367:15–22, 467:20–22 (Franklin).

65 to sell the Company.302 Franklin made counteroffers unauthorized by the Board.303

He negotiated his change-in-control compensation with no authorization from

(or knowledge of) the Board.304 And he recommended Barclays as the lead financial

302 JX 1788 (L’Esperance Dep.) at 54:13–22, 58:9–21, 121:10–122:3; JX 1786 (Wood Dep.) at 25:2–7, 26:10–19, 31:12–25, 32:2–17, 157:25–158:14. Franklin’s revelation at the Boat Meeting that he would like to exit from Jarden in order to have more time to pursue business ventures with his sons also made an impression on Polk and, when coupled with his direction regarding an acceptable offer price, likely communicated to Newell that he was eager, maybe overly eager, to do a deal. See JX 765 (Tarchetti reporting that Franklin revealed “his desire for an exit, which as the company figurehead is difficult. He says he would like to inve[st] in business with his sons having taken some money off the table (assuming he has about 0.5bn if this happened”)); Trial Tr. 71:20–72:12 (Polk); Trial Tr. 164:14–165:3 (Tarchetti). There is other evidence in the record that Franklin was perceived as an anxious seller. See JX 576 (Bill Ackman’s July 2015 email to Warren Buffett, copying Franklin, attempting to interest Buffett in acquiring Jarden); JX 533; JX 1786 (Wood Dep.) at 157:25–158:14; JX 860 (Centerview set up the first meeting between Franklin and Polk, marketing Jarden to Newell as a “willing seller.”); JX 902 at 2 (Polk stating that Franklin “cut straight to the chase” about his willingness to sell Jarden). 303 JX 1807 (Gross Dep.) at 38:12–16, 48:3–8, 67:13–25; JX 1786 (Wood Dep.) at 72:9– 18, 91:15–92:2; JX 1788 (L’Esperance Dep.) at 89:6–8. 304 JX 1049. The Board justified the compensation awards after the fact. JX 1212 at 15; JX 1565 at 146. Moreover, as Franklin and Ashken were telling Newell they were entitled to the 2017 and 2018 RSAs, Jarden’s Compensation Committee had not discussed the possibility of awarding those grants. JX 1145; JX 1202. The Board was told by in-house counsel Capps—who was also receiving 2017 and 2018 RSAs—that Jarden was contractually obligated to make these awards even though the agreements at issue were not clear on the point. JX 1629 at 5; JX 1786 (Wood Dep.) at 158:15–159:5. There are other troubling facts relating to the change-in-control payments, including that Franklin arranged for his long-time legal counsel to advise the Board with respect to the payments and the payments ultimately resulted in the lead negotiators for Jarden receiving substantially more in Merger consideration than Jarden’s other stockholders. See JX 1145; JX 1234; JX 1235; JX 1236; Trial Tr. 534:18–536:11–18 (Franklin); JX 1780 (Franklin Dep.) at 362:20–22. Respondent argues the RSAs that made up most of the Merger consideration differential Franklin and the other Jarden managers received were owed to them “in the regular course absent a sale.” Resp’t Jarden Corp.’s Opening Post-Trial Br. (“ROB”) at 57. The Merger agreement, however, terminated the employment contracts under which the RSAs were granted. See JX 1235. Franklin and the other Jarden managers claimed they were 66 advisor for the deal without fully disclosing his prior substantial relationship with

the bank, just as he nudged the Board to hire UBS as a second banker as a “kiss” in

gratitude for its prior uncompensated work for the Company.305

As factfinder, these flaws in the sale process, coupled with the fact that there

was no effort to test the Merger Price through any post-signing market check, raise

legitimate questions regarding the usefulness of the Merger Price as an indicator of

fair value.306 As explained below, the difficulty in assessing the extent to which

Newell ceded synergies to Jarden in the Merger makes the Merger Price less

synergies an even less reliable indicator of fair value.

In Merion Capital LP v. BMC Software Inc., the court set forth a useful

framework to approach the appraisal statute’s mandate that the court appraise “the

fair value of the shares exclusive of any element of value arising from the

contractually owed the 2017 and 2018 RSAs under their employment agreements before the separation agreements even existed. JX 906 at rows 15–17; JX 1057; JX 1072; JX 1786 (Wood Dep.) at 158:15–159:5. The Board then justified the disconnect by explaining the 2017 and 2018 RSAs served as consideration for the commitment to add two more years to the non-compete covenants. JX 1565 at 146. Of course, when the dust settled, the separation agreements extended the term of the non-compete covenants by only one year. JX 1234; JX 1235; JX 1236. 305 JX 1805; Trial Tr. 546:11–17 (Franklin); JX 438; JX 1789 (Welsh Dep.) at 50:25–54:4; JX 1780 (Franklin Dep.) at 269:6–19. 306 By so finding, I do not intend to suggest that Franklin or any Jarden fiduciary breached any fiduciary duty. That inquiry is beyond the scope of this appraisal proceeding. See In re Unocal Expl. Corp. S’holders Litig., 793 A.2d 329, 340 (Del. Ch. 2000) (noting that a breach of fiduciary finding is beyond the scope of statutory appraisal).

67 accomplishment or expectation of the merger or consolidation.”307 BMC

recommends a “two-step analysis[:]” “first, were synergies realized from the deal;

and if so, were they captured by the sellers in the deal price?”308

There is no dispute here that synergies were realized in the Merger, as one

would expect when two strategic partners combine.309 Indeed, the synergies created

the “logic for the deal” from Newell’s perspective.310 The first announcement of the

Merger stated, “[Newell] anticipates incremental annualized cost synergies of

approximately $500 million over four years.”311 This remained the case through the

release of the joint proxy statement.312 Internally, Newell believed the $500 million

estimate was conservative.313 Nevertheless, the experts have focused on the

expected synergies as disclosed in the joint proxy statement ($500 million), and they

307 Merion Capital LP v. BMC Software Inc., 2015 WL 6164771 (Del. Ch. Oct. 21, 2015). 308 Id. at *17. 309 JX 1817 at ¶¶32–33, 41–43. 310 Trial Tr. 686:17–687:13 (Polk) (“We wanted as part of––the deal terms, to get control of the company. Because there was no way that, without our leadership of the change agenda, those synergies were going to be realized.”); JX 1778 (Ashken Dep.) at 153:15– 19. 311 JX 1269 at 3. 312 JX 1565 at 85. 313 JX 1228 at 7. Bain had estimated synergies ranging from $585 million to $1 billion, comprised of $500–$700 million in cost synergies and $85–$320 million in revenue synergies. JX 1139 at 50.

68 have assumed that estimate is accurate.314 In the absence of any real expert analysis

of the issue, I have no basis in the evidence to depart from that assumption.

As for whether Jarden captured the synergies in the Merger, the evidence is

less clear. There is evidence in the trial record that would suggest Newell believed

it was not paying any of the synergies at the $59.21 per share Merger Price.315

During negotiations, Polk told his board that if Newell could “get the deal done

between $60 and $65 [per share], we are basically getting the synergies with no value

ascribed to them.”316 After the Merger, Polk further suggested that the premium over

market price that Newell paid in the Merger was not for synergies but instead was

for control of the combined company.317 Polk explained, “Jarden shareholders get a

premium versus their current stock price for [Jarden]. The Newell shareholders get

ownership of [Jarden], and after the synergies are delivered, the future value creation

314 JX 1817 at ¶40; JX 1816 at ¶183;

315 JX 1100 at 18; JX 1804 (Polk Dep.) at 100:2–5, 101:15–16. 316 JX 1100 at 18. 317 Trial Tr. 649:5–8 (Polk); JX 2022 (“The premium is designed to get Newell management control.”); JX 1804 (Polk Dep.) at 100:2–5, 101:15–16 (When asked “how did you come to the conclusion that a modest premium to their current market valuation would give Newell control,” Polk responded “I knew that it was a quid pro quo” and “[i]f we were going to pay a premium for the asset, we need management control.”). Of course, Polk clarified that control was necessary to achieve the synergies since Newell was not satisfied that Jarden management would take the steps needed to create synergies. See Trial Tr. 686:17–22 (Polk).

69 that comes through the new combination.”318 Even Franklin questioned whether the

premium to market price that Newell paid was for control of the combined entity.319

On the other hand, Jarden points out that there is evidence Newell was keenly

aware of synergies and that it was incorporating synergies into its value thesis for

the Merger.320 Dr. Hubbard supported Jarden’s view of the evidence that Jarden

stockholders realized the value of the synergies by conducting two separate analyses.

First, he performed a “discounted value of cash flows” analysis, in which the

expected future cash flows from the synergies (net of the costs to achieve them) were

discounted to their value as of the Merger Date, to conclude that the synergies had a

value of $4.2 billion, or $17.43 per Jarden share. This happens to line up nicely with

the delta between the unaffected market price ($48.31) and the Merger Price

($59.21), indicating that the delta, or premium, represented expected synergies.321

He then prepared a market-based analysis of the expected synergy value in which he

observed that the rise in stock price of both companies after the leak of merger

318 JX 1804 (Polk Dep.) at 115:4–9. 319 Trial Tr. 476:3–5 (Franklin). 320 Trial Tr. 598:10–21, 599:14–600:6, 614:4–18, 678:12–6 (Polk); JX 1803 (Cowhig Dep.) at 62:20–63:2; JX 1779 (Tarchetti Dep.) at 29:6–30:9; JX 674 at 2 (September 2015 Polk email, emphasizing the “tons of synergies” to be realized by employing the Project Renewal strategy) (emphasis in original); Trial Tr. 725:7–14, 742:3– 743:19 (Torres); JX 973 at 36; JX 1139 at 50, 56; JX 1565 at 67. 321 JX 1816 at ¶¶181–83; JX 1831 at ¶4, Figure 25; Trial Tr. 1087:23–1091:9 (Hubbard).

70 negotiations revealed that the market appreciated the presence of significant

synergies. The fact that Newell’s stock price fell when Jarden’s rose after

announcement of the Merger indicates the market appreciated that the anticipated

synergies would accrue to the Jarden stockholders.322

Jarden bears the burden of demonstrating “what, if any, portion of

[the synergies] value was included in the price-per-share . . . .”323 The evidence on

this point stands in equipoise. It is difficult to square Polk’s contemporaneous

assessment of where the synergies would land with Newell’s internal valuation

exercises and Dr. Hubbard’s straightforward analysis of the issue. Given the state

of the evidence, I give little weight to the Merger Price less synergies evidence when

assessing fair value.324 Not because I believe the Merger created no synergies. And

322 JX 1816 at ¶188 (“These results indicate that the market expected nearly all of the synergy value to accrue to Jarden shareholders, consistent with academic research finding that most of the benefits of mergers accrue to target-firm shareholders.”); Trial Tr. 1090:18–20 (Hubbard). 323 BMC Software, 2015 WL 6164771, at *17. 324 To be clear, and as explained below, I am satisfied from the evidence that the Merger Price exceeded fair value. It is less clear, however, what exactly justified the premium Newell was willing to pay for Jarden. This is partially a product of the complications in valuing synergies where the merger consideration includes stock, versus a strictly cash-for- stock merger.

In such a transaction, shareholders of both constituent corporations remain shareholders in the continuing combined enterprise. Thus, both groups–– acquirer shareholders and target shareholders––are able to participate pro rata in gains arising out of the merger. Therefore, a premium to the target’s shareholders cannot be justified, as in a cash acquisition, on the premise that 71 not because I believe that Jarden stockholders probably did not receive the value of

the synergies that were created by the deal. I place less weight on this market-based

valuation approach in this case because the sales process was not well-conceived or

well-executed and the expert analysis of the transaction synergies raised more

questions than it answered.

B. Unaffected Market Price

Jarden has proffered its unaffected stock trading price, $48.31 per share

(the “Unaffected Market Price”), as strong evidence of the Company’s fair value.325

According to Jarden, “[t]his value impounded the collective judgments of thousands

of stockholders, as well as the more than twenty professional analysts that followed

Jarden.”326 Jarden supports its position that the Unaffected Market Price is indicative

it is the only way to permit those shareholders to share in the gains arising from the merger.

Lawrence A. Hamermesh, Premiums in Stock-for-Stock Mergers and Some Consequences in the Law of Director Fiduciary Duties, 152 U. Pa. L. Rev. 881, 884 (2003). 325 As noted, news of the potential merger between Jarden and Newell leaked to the public on Monday, December 7, 2015. See JX 1150 at 1–2; JX 1148; PTO ¶164; JX 1164; Liz Hoffman, Dana Mattioli & Dana Cimilluca, Newell Rubbermaid, Jarden in Merger Talks, The Wall Street Journal (2015), https://www.wsj.com/articles/newell-rubbermaid- jarden-in-merger-talks-1449521419 (last visited July 19, 2019). The last day Jarden stock was traded without being affected by news of the merger negotiations was Friday, December 4, 2015. JX 1231 at 2. On that day, Jarden stock closed at $48.31 per share. JX 1816 at ¶47. 326 ROB at 2.

72 of fair value with detailed analysis from Dr. Hubbard.327 Petitioners elected not to

counter that evidence with expert evidence of their own. 328 Instead, they attacked

Dr. Hubbard’s opinion as lacking in doctrinal and factual foundation. For reasons

explained below, I find Dr. Hubbard’s analysis of the reliability of Jarden’s

Unaffected Market Price as an indicator of fair value both credible and persuasive.

1. The Market for Jarden’s Stock Was Efficient

In an efficient stock market, “a company’s market price quickly reflects

publicly available information.”329 In this environment, the company’s trading price

“balances investors’ willingness to buy and sell the shares in light of [available]

information, and thus represents their consensus view as to the value of the equity

in the company.”330 Efficient markets aggregate all available information and

quickly digest new information, which is then reflected by proportionate changes in

327 Trial Tr. 1267:17–1268:5 (Hubbard) (“I’ve seen nothing in the record that would suggest to me the unaffected stock price is not the right anchor [for fair value].”). 328 Trial Tr. 323:15–326:14 (Zmijewski). See also Trial Tr. 1021:2–9 (Hubbard) (“Does Dr. Zmijewski in his reports dispute that either Newell or Jarden traded in an efficient market? A. Not in his reports, no. Q. And did you hear that in his testimony? A. I did not. I was present, and I didn’t hear that.”). 329 JX 1816 at ¶45. See also JX 2032, Jonathan Berk & Peter DeMarzo, Corporate Finance 301 (Pearson Education Limited, 4th ed. 2017) (“Berk & DeMarzo, Corporate Finance”); JX 2515, Aswath Damodaran, Investment Valuation: Tools and Techniques for Determining the Value of Any Asset 4 (Wiley, 3d ed. 2012) (Damodaran, Investment Valuation); JX 2516, Tim Koller et al., McKinsey & Co., Valuation: Measuring and Managing the Value of Companies 37–38 (Wiley, 6th ed. 2015) (“Koller, Valuation”). 330 JX 1816 at ¶45.

73 market price.331 When the market is efficient, the trading price of a company’s stock

can be a proxy for fair value.332

As Dr. Hubbard explained, several factors support the conclusion that

Jarden’s stock traded in a semi-strong efficient market.333 The stock was traded on

the New York Stock Exchange (“NYSE”) and Jarden became a member of the S&P

400 index in 2012.334 In 2015, Jarden’s shares traded with a daily and weekly

average trading volume in the top 25% of the S&P 500.335 High trading volume

contributes to the efficiency of the market.336 Jarden’s market capitalization of

331 JX 2032, Berk & DeMarzo, Corporate Finance at 302. 332 JX 1816 at ¶45; Trial Tr. 323:15–324:4 (Zmijewski) (acknowledging that one “can look to stock price to corroborate a fair value conclusion”); Trial Tr. 1017:11–14 (Hubbard) (“For the unaffected stock price to be relevant, Your Honor, to your consideration, you need to believe that it’s an unbiased indicator of the value of the firm. That’s an efficient market.”). 333 Dr. Hubbard stated,

[t]here are tests for whether a market is efficient, tests that economists suggest, but tests that have been widely used in courts. So I used a number of factors that capture the scope of the firm, whether analysts follow it, transactions cost, liquidity, and so on. I do those tests for both Jarden and Newell and conclude that both trade in an efficient market, semi-strong form.

Trial Tr. 1017:11–14 (Hubbard). 334 Resp’t Jarden Corp.’s Pre-Trial Br. at 6. 335 JX 1816 at ¶44, Figure 10. 336 JX 242, Robert W. Holthausen & Mark E. Zmijewski, Corporate Valuation: Theory, Evidence & Practice 301–03 (Cambridge Business Publishers, 1st ed. 2014) (“Holthausen & Zmijewski, Corporate Valuation”).

74 approximately $10.2 billion placed it in the top 20% of all publicly traded firms.337

High market capitalization leads to greater “interest in the security being analyzed,”

which, in turn, “increases the likelihood that new information will be quickly

incorporated into the stock price.”338

Jarden had no controlling shareholder.339 In fact, Jarden had a 94% public

float.340 A high public float is another factor indicating an efficient market for

Jarden’s stock because the more holders of a security that are not insiders with access

to non-public information, the more likely the market will demand that information

be released for public consumption.341 Jarden stock exhibited a “bid-ask spread” of

only 0.02%.342 A narrow bid-ask spread indicates minimal information asymmetry

between insiders and the public markets and, as a result, higher market efficiency.343

Approximately twenty professional market analysts covered and disseminated

337 JX 1345, Duff & Phelps LLC, 2016 Valuation Handbook: Guide to Cost of Capital (Chapter 3) 9 (John Wiley, 2016) (“Duff & Phelps, Valuation Handbook”). 338 JX 1816 at ¶46. 339 Id. at ¶48. 340 Id. 341 JX 2032, Berk & DeMarzo, Corporate Finance at 73. 342 JX 1816 at ¶¶47–48. 343 Id. at ¶47.

75 reports on Jarden in the year prior to the Merger Date.344 Jarden exhibited no serial

correlation, meaning there were no patterns detached from events or news from the

Company that would enable the market to divine future price movements based

purely on past performance.345 Additionally, Jarden’s Unaffected Market Price

aligned with options market pricing, suggesting there were no arbitrage

opportunities for Jarden stock.346

Dr. Hubbard summarized the factors allowing him to conclude that Jarden’s

stock traded in a semi-strong efficient market in a helpful chart:

344 Id. at ¶48. 345 Id. 346 Id.; JX 2032, Berk & DeMarzo, Corporate Finance at 73 (“The term efficient market is also sometimes used to describe a market that, along with other properties, is without arbitrage opportunities.”) (emphasis in original).

76 For context, and to illustrate that Jarden’s stock price historically reacted

appropriately to material information, Dr. Hubbard performed an event study to trace

how, in the two years prior to the Merger, Jarden’s stock price responded quickly

and appropriately to earnings announcements and other performance guidance, even

when the news was unanticipated.347 In each instance, Dr. Hubbard traced the public

disclosure of material information, the reaction of analysts to the information and

the commensurate adjustment, up or down depending upon whether the news was

positive or negative, in the trading price of the stock.348

347 JX 1816 at ¶49; JX 2514 at 8–11; Trial Tr. 1019:2–16 (Hubbard). 348 Id.

77 The evidence shows that Jarden’s stock reached a pre-Merger peak of $56.25

on July 20, 2015, and then declined gradually over the next few months in response

to poor earnings reports.349 The decline was marked by low quarterly growth and it

prompted Jarden to lower its guidance for the second and third quarters of 2015.350

Jarden’s stock price recovered somewhat in the fourth quarter and closed at $48.31

on December 4, 2015 (i.e., the Unaffected Market Price).351 After The Wall Street

Journal article reported on the merger negotiations the following Monday, Jarden’s

stock price rose and continued to rise to $54.09 on December 14, 2015, the day

Jarden and Newell officially announced the Merger.352 The steady climb continued

following the announcement and then plateaued before the calendar year ended.353

Jarden’s stock price oscillated between $59.00 and $50.00 until early March 2016.354

In March, as the negotiations finalized and the Merger Date neared, Jarden’s share

349 JX 1816 at ¶51. 350 Id. 351 Id. 352 Id. at ¶52. 353 Id. at ¶¶52–53. 354 Id.

78 price approached but never exceeded the Merger Price of $59.21.355 As Dr. Hubbard

explained:

The fact that Jarden’s stock price never closed above the Merger Price is a strong indicator that fair value is no greater than the Merger Price. If investors believed that the Company was worth materially more, then one would expect to see the market price exceeding the Merger Price in anticipation of a topping bid. In more than five percent of M&A deals since 2001, the merger arbitrage spread the day after the merger announcement was negative, implying that the market expected a topping bid.356

Newell’s stock also traded in an efficient market and the market’s reaction to

the announcement of the Merger with respect to Newell’s trading price provides

further evidence that the Unaffected Market Price is reflective of Jarden’s fair

value.357 Newell’s stock price jumped after the leak of negotiations when the terms

of the deal were unknown.358 The market reacted differently, however, when the

terms of the Merger were announced. Newell’s stock price dropped significantly

(6.9%). Dr. Hubbard explained the significance: “The initial positive reaction to

the deal rumors suggests that the market was hopeful that some value would

355 Id. at ¶54. 356 Id. 357 The Merger marks the rare instance where two public companies of comparable size, comparable capital structure and comparable stock trading patterns combine. As Dr. Hubbard explained, for most of the reasons one can conclude that Jarden traded in an efficient market, the same can be said for Newell. Id., Figure 15. 358 Id. at ¶58.

79 accrue to Newell, but after learning the terms of the deal and additional

information about synergies, the market reassessed and shifted the value from

Newell to Jarden.”359

After carefully reviewing the evidence, I am satisfied that Jarden’s

Unaffected Market Price is a powerful indicator of Jarden’s fair value on the

Merger Date. Petitioners’ attempts to undermine this evidence, as explained

below, were not persuasive.

2. Petitioners Did Not Persuasively Rebut Jarden’s Market Evidence

Petitioners mount three challenges to the reliability of Jarden’s Unaffected

Market Price: (a) as of the date fixed for the Unaffected Market Price (December 4,

2015), the market lacked material information concerning Jarden (i.e., information

asymmetry) that skewed the trading price; (b) the Unaffected Market Price must be

adjusted to account for a so-called “conglomerate discount” and a “minority

discount;” and (c) the Unaffected Market Price was stale by the time the Merger

closed on April 15, 2016.360 I address each in turn.

359 Id. at ¶60. See also id. at ¶62 (“According to the analysts covering Newell at the time, consumer recession fears, merger integration risks, and the high initial leverage resulting from the Merger were key factors affecting Newell’s stock price.”). 360 Jarden is justified in pointing out that while he raised the criticisms, Dr. Zmijewski did “not explicitly opine on whether or not any of these factors actually depressed Jarden’s [unaffected] market price relative to fair value.” JX 1826 at ¶98. See also JX 1828 at ¶90 (Dr. Zmijewski making observations regarding the Unaffected Market Price but not correlating them).

80 a. Information Asymmetry

According to Dr. Zmijewski, Jarden’s market-based evidence should be

disregarded because the market lacked material information as of the date fixed for

Jarden’s Unaffected Market Price.361 Dr. Zmijewski cited the decline in the federal

risk-free rate, the rise in Jarden’s share price and the divergence between Jarden

management and market analysts’ projections for Jarden’s future performance as

reasons the Unaffected Market Price was not a reliable indicator of fair value.362

Importantly, Dr. Zmijewski also observed that Jarden stockholders had no access to

the November Projections as of the date fixed for the Unaffected Market Price. The

evidence supports the factual predicates for these observations, but it does not

support a conclusion that the absent facts resulted in the kind of information

asymmetry that would render the Unaffected Market Price unreliable.

As for the decline in the federal risk-free rate, Dr. Zmijewski states that, “[a]ll

else equal, the decline in the risk-free rate results in an increase in Jarden’s Fair

Value,” and goes on to argue that because the federal risk-free rate declined from

December 2015 to April 2016, Jarden’s fair value must be higher than the Unaffected

Market Price.363 Interest rates on U.S. Treasury 20-year constant maturity bills

361 JX 1828 at ¶90; JX 1826 at ¶98. 362 Id. 363 JX 1818 at ¶30.

81 declined 19%, from 2.65% to 2.14%, between December 4, 2015 and April 15,

2016.364 Dr. Hubbard conceded that, if “all else” were, in fact, “equal,” as

Dr. Zmijewski posited, then Jarden’s fair value would increase as the risk-free rate

decreased.365 But then Dr. Hubbard exposed the flaw in Dr. Zmijewski’s elephant-

sized assumption that “all else” remained “equal.” Specifically, Dr. Hubbard

referred directly to market data showing that, as the interest rate on 20-Year Treasury

Bonds declined between December 2015 and April 2016, stock prices in general,

represented by the S&P 500 Market Index, did not increase in response.366 Contrary

to Dr. Zmijewski’s “all else equal” assumption, the evidence shows that the stock

market declined just as the risk-free rate declined.367 In other words, the correlation

that supports the supposed information asymmetry is no correlation at all.

Regarding the lack of consensus between Jarden management and third-party

analysts’ projections, Dr. Hubbard emphasized the qualitative difference between

unvarnished raw information tracking Jarden’s performance and well-reasoned

opinions about Jarden’s prospects.368 Jarden’s revenue projections for 2016, 2017,

364 Id. at ¶¶29–31. 365 JX 1826 at ¶¶99–100. 366 Id., Figure 17. 367 Id. 368 Id. at ¶¶101–04.

82 and 2018 were 1.0%, 1.7% and 2.6% higher, respectively, than financial analysts’

consensus forecast.369 Jarden’s EBITDA projections for 2016, 2017 and 2018 were

1.3%, 6.6% and 9.0% higher, respectively, than financial analysts’ consensus

forecasts. Jarden’s November Projections incorporated this data but were not

released to the public until March 2016, and thus would not have been incorporated

into the Unaffected Market Price.370 But is this evidence of information asymmetry?

Dr. Hubbard hypothesized the answer is no.371

To test his hypothesis, Dr. Hubbard turned to his event study. The November

Projections were disclosed in the joint proxy in March 2016. If the November

Projections revealed information not previously incorporated in Jarden’s stock price,

Hubbard reasoned, then both Jarden and Newell’s stock price should have

proportionately reflected that information. In other words, if the November

Projections justified more value (according to Dr. Zmijewski substantially more

value), then Newell’s stock price should have increased substantially to reflect that

Newell was acquiring Jarden at less than fair value.372 But, of course, that is not

369 JX 1818 at ¶31. 370 Id. 371 Trial Tr. 1022:21–1023:14 (Hubbard). 372 JX 1826 at ¶¶101–04.

83 what happened; Jarden’s stock price climbed while Newell’s stock price dropped.373

Moreover, Jarden’s April Projections lowered the Company’s financial guidance to

forecasts more in line with the analysts’ earlier projections.374 Dr. Hubbard

persuasively opined that the April Projection’s convergence with the analysts’

forecasts was a strong indication that the difference between the November

Projections (as disclosed in the joint proxy) and the analysts’ projections was not

attributable to unreasonable market pessimism, but instead showed that market

analysts had more accurately estimated Jarden’s 2016 outlook than Jarden’s

management (who may have been motivated by factors other than actual anticipated

results when making their forecasts).375

373 Id. at ¶¶103–04. I acknowledge, and understand, Petitioners’ “tethering” argument, but I reject it as not supported by the credible evidence. The argument is that the market was not efficient as of the Merger because, after the announcement of the Merger, “Jarden’s stock price was tethered to Newell and to the perception of the stockholders of both companies that there was a large risk that Jarden could not be successfully integrated.” Pet’rs’ Post-Trial Opening Br. at 60. Newell’s stockholders may have reacted to that risk, as reflected in the stock’s performance after the announcement, but there is no evidence that Jarden’s stockholders, or the market, associated that risk with Jarden. See Trial Tr. 1020:12–23 (Hubbard); JX 2514 at 9; JX 1816 at ¶¶184–90. 374 JX 1826, Figures 18, 19. 375 Id. That the November Projections did not really move the needle is not surprising. They were optimistic, to be sure, but their projected growth was consistent with prior forecasts, albeit at the top of the range. JX 927 at 1; Trial Tr. 106:1–107:3 (Lillie). They were also not out of line with the views of several of the many analysts that followed the Company. See, e.g., JX 1401; JX 1407; JX 1439.

84 The credible evidence reflects no information asymmetry. The market was

well informed and the Unaffected Market Price reflects all material information.

b. The Conglomerate and Minority Discounts

Dr. Zmijewski also criticizes Dr. Hubbard’s Unaffected Market Price analysis

because it does not account for Jarden’s massively diversified portfolio of operating

companies (the conglomerate discount) and does not adjust for embedded agency

costs (the minority discount).376 Here again, Dr. Zmijewski flags the issues but

makes no attempt to quantify their impact, if any.377

As for the conglomerate discount, the evidence does not support that this is

even “a thing,” meaning it is not clear that this notion is accepted within the academy

or among valuation professionals.378 With that said, there is evidence that Jarden’s

unique structure and diversified portfolio did pose valuation challenges. Newell’s

Tarchetti described Jarden as a “fast-changing company” that was difficult to

376 JX 1818 at ¶¶37–39. 377 JX 1826 at ¶¶108–12; JX 2505 (Zmijewski Dep.) 318:23–319:4, 320:8–11. Dr. Zmijewski’s opinion that the market had not assessed Jarden’s acquisitions of Jostens and Waddington, as best I can tell, is nothing more than speculation. The fact that the market reacted poorly to the Jostens acquisition does not mean it did not understand it. Nor is there credible evidence that the market did not know, or understand, that Jarden had leveraged up to do the Jostens and Waddington deals. 378 Trial Tr. 1029:3–9 (Hubbard) (“academics differ in opinions on whether there is or isn’t [a conglomerate discount]”); JX 1826 at ¶111 & n.176 (citing academic commentary rejecting the notion of a conglomerate discount).

85 appraise, in part, due to its complexity and tendency to grow and evolve at any point

in time.379 Even so, the Company’s high trading volume and the intense scrutiny

paid it by market analysts has convinced me that the market understood Jarden’s

holding company structure as an operative reality, considered the high overhead

costs associated with decentralized management and imputed those factors into

Jarden’s Unaffected Market Price.380

The minority discount, likewise, does not fit here. For a company without a

controlling stockholder, the premise is that the appraiser must consider the conflict

of interest between Company management and a diffuse stockholder base and

account for minority trading multiples.381 Setting aside that Petitioners have offered

no credible evidentiary basis to quantify any minority discount here, I see no basis

to even try given that the foundation for applying the discount has not been laid.

Jarden’s management was well known to stockholders and well known to the

market. But for the Merger, they were not going anywhere as the Company was not

for sale.382 As Dr. Hubbard explained, under these circumstances, Jarden’s agency

379 JX 1779 (Tarchetti Dep.) at 32–33. 380 JX 1826 at ¶¶108–10; Trial Tr. 1029:10-21 (Hubbard); Trial Tr. 335:9–21 (Zmijewski) (“Q. So the holding company structure of Jarden, whatever its affects may be, were the operative reality of Jarden. Correct? As of the merger date? A. That’s true.”). 381 JX 2505 (Zmijewski Dep.) at 319:22–320:16; JX 1818 at ¶¶37–39. 382 JX 1778 (Ashken Dep.) 117:10–17; Trial Tr. 378:14–17 (Franklin).

86 costs were embedded in its operative reality and reflected in its Unaffected Market

Price.383

c. Staleness of the Unaffected Market Price

Petitioners also argue that the Unaffected Market Price was stale as of the

Merger Date.384 I disagree. There is no evidence to suggest that Jarden gained value

from the date set for the Unaffected Market Price and the closing of the Merger, or

that the market was deprived of information that might have been perceived as

enhancing value. Indeed, following a period where Jarden had been especially

acquisitive, the Company was experiencing declines in operating income and net

income and management was giving the Board revised, more conservative

projections for 2016.385 The April Projections forecasted reduced revenue growth

and increased working capital investment for FY17–20.386 This is not a case where

the credible evidence reveals that the Unaffected Market Price was demonstrably

below Jarden’s fair value as of the Merger.

**********

383 JX 1826 at ¶¶106–07. See also JX 59, Lawrence A. Hamermesh & Michael L. Wachter, The Short and Puzzling Life of the “Implicit Minority Discount” in Delaware Appraisal Law, 156 U. Pa. L. Rev. 1, 2 (2007). 384 JX 1818 at ¶30. 385 JX 1519 at 68; JX 1514 at 2. 386 JX 1562; Trial Tr. 821:6–828:1, 830:7–835:11 (Waldron).

87 After carefully considering the evidence, I find that the Unaffected Market

Price is a reliable indicator of Jarden’s value as a going concern on the Merger Date.

I have given it substantial weight in my assessment of fair value.

C. The Other Market Evidence

As Jarden was negotiating with Newell, it was also pursuing an acquisition of

Jostens. To raise capital for that deal, Jarden initiated a share offering priced at

$49.00 per share.387 At the time, the stock was trading in the mid-$40s.388 When the

market reacted poorly to the Jostens acquisition, and the stock price fell, the Board

believed it needed to send a signal that the Company and its management were

optimistic about Jostens. So it authorized a $50 million stock buyback,389 and it set

the price cap again at $49.00 because, after internal assessments, it believed that

price reflected Jarden’s value.390 Ultimately, Jarden repurchased 276,417 shares on

November 2, 2015, at an average price of $45.96 per share, and another 775,685

shares on November 3, 2015, at an average price of $48.05 per share. 391 This

evidence is by no means dispositive. But it is persuasive evidence that, in the weeks

387 JX 2502. 388 JX 1780 (Franklin Dep.) 201:19–24. 389 Trial Tr. 404:1–9 (Franklin); JX 900. 390 JX 1780 (Franklin Dep.) 241:11–14. 391 JX 900 at 2.

88 leading up to the leak of the merger negotiations, uncluttered by transactional or

forensic incentives, both the Company and the market saw Jarden’s value well below

what Petitioners seek here.

D. Comparable Companies

Both parties’ experts performed comparable companies analyses to estimate

Jarden’s value relative to sets of proposed peer firms. Applying his comparable

companies analysis, Dr. Zmijewski concluded that Jarden’s fair value on the Merger

Date, based on Jarden’s 2016 forecasted EBITDA using the 90th, 75th and 50th

percentiles of his peer set, was $81.44, $70.49 and $66.30, respectively.392 Based

on Jarden’s 2017 forecasted EBITDA, the market multiples based-valuation using

the 90th, 75th and 50th percentiles of his peer set, revealed a per share value of

$77.39, $72.20 and $65.56, respectively.393 For his part, Dr. Hubbard disclaimed

the efficacy of a comparable companies valuation for Jarden, but then performed his

own comparable analysis for the sake of completeness, resulting in a value range of

$40.12 to $55.21 per share.394 Before addressing the experts’ divergent analyses and

conclusions, it is useful to review basic concepts, separated from forensics.

392 Id. at 65. 393 Id. It is not entirely clear to me that Dr. Zmijewski feels as strongly about his comparable companies valuation of Jarden as Petitioners do. See JX 1828 at ¶8 (“I do not consider revenue multiples to be reliable to value Jarden . . . .”). 394 JX 1816 at ¶200.

89 1. The Comparable Companies Methodology

As a threshold matter, before a comparable companies multiples analysis can

be undertaken with any measure of reliability, it is necessary to establish a suitable

peer group through appropriate empirical analysis.395 In fact, nearly every text in

the record states that the accuracy of a multiples-based valuation depends entirely

on the existence of comparable peers:

 Holthausen & Zmijewski (JX 242): “While selecting comparable companies might not appear to be too difficult, we often quickly conclude that not many, if any, companies are truly comparable to the company we are valuing for purposes of a market multiple valuation once we understand all the different dimensions of comparability and begin to analyze the potential comparable companies . . . simply selecting close competitors is not sufficient to ensure the companies are comparable, as we observe a substantial amount of variation in multiples within an industry.”396  Koller (JX 2516): “Selecting the right peer group is critical to coming up with a reasonable valuation using multiples.”397  Damodaran (JX 2515): “. . . finding similar and comparable firms is often a challenge, and frequently we have to accept firms that are different from the firm being valued on one dimension or the other. When this is the case, we have to either explicitly or implicitly control for differences across firms on growth, risk, and cash flow measures.”398

395 JX 242, Holthausen & Zmijewski, Corporate Valuation at 510, 527–30; Trial Tr. 1068:13–15 (Hubbard) (“If you use [a] comparables [analysis], you have to be sure they are really comparable or you are introducing error yourself.”). 396 JX 242, Holthausen & Zmijewski, Corporate Valuation at 527–29. 397 JX 2516, Koller, Valuation at 345. 398 JX 2515, Damodaran, Investment Valuation at 20.

90  Berk & DeMarzo (JX 2032): “Of course, firms are not identical. Thus, the usefulness of a valuation multiple will depend on the nature of the differences between firms and the sensitivity of the multiples to these differences.”399

McKinsey recommends beginning the peer group identification process with

the Standard Industrial Classification (“SIC”) or Global Industry Classification

Standard (“GICS”) codes.400 While these codes are a good starting point for

selecting a peer group, the industry-specific company lists they produce require

significant refinement to identify truly comparable firms. 401

To isolate a relevant peer group from a larger industry data set, the appraiser

must identify firms with similar risk profiles, costs of capital, return on invested

capital and growth.402 It is better to have a smaller number of peers that truly

compete in the same markets with similar products than including aspirational or

399 JX 2032, Berk & DeMarzo, Corporate Finance at 296. 400 JX 2516, Koller, Valuation at 345–46. 401 Id. at 346; JX 242, Holthausen & Zmijewski, Corporate Valuation at 528–29. 402 JX 2516, Koller, Valuation at 346. See also JX 2032, Berk & DeMarzo, Corporate Finance at 710; Damodaran, Investment Valuation at 462 (“A comparable firm is one with cash flows, growth potential, and growth risk similar to the firm being valued . . . . The implicit assumption being made here is that firms in the same sector have similar risk, growth, and cash flow profiles and therefore can be compared with much more legitimacy”).

91 nearly comparable companies.403 In order effectively to narrow down a list of

potential comparables according to growth and risk, the analysis must consider

whether the companies have similar “value drivers” as the target.404

As Dr. Zmijewski described in his text:

[A] company’s product lines, customer types, market segments, types of operation, and so forth are all important aspects to consider when we identify comparable companies. Even after all these are taken into consideration, two companies can be in the same industry yet not be comparable on all of the characteristics that are important for a market multiple valuation.405

In addition, the finance literature advises against relying on peers provided by

the target company’s management. This reasoning reflects common sense;

optimistic executives often provide “aspirational peers” rather than companies that

actually compete head-to-head with their firm.406

The importance of selecting a proper peer set in the performance of a proper

comparable companies analysis cannot be overstated. Because this threshold task is

so important, and yet so difficult, the valuation treatises generally view the

403 Id. Trial Tr. 1068:13–15 (Hubbard) (“I mean, it’s really just a restatement of garbage in, garbage out. If you don’t have genuine comparables, you’re not going to get much out of the approach.”) 404 JX 242, Holthausen & Zmijewski, Corporate Valuation at 529–30. 405 Id. at 529. 406 JX 2516, Koller, Valuation at 346.

92 comparable companies methodology as inferior to other methodologies: “a key

shortcoming of the comparables approach is that it does not take into account the

important differences among firms,” therefore “[u]sing a valuation multiple based

on comparables is best viewed as a ‘shortcut’ to the discounted cash flow methods

of valuation.”407

If, and only if, a proper peer set can be selected, the next step in the

comparable companies analysis is to select an appropriate multiple and then

determine where on the distribution of peers the target company falls.408 The

Enterprise Value to EBITDA multiples valuation (“EV/EBITDA”) is widely

accepted as the most reliable data set for a comparable companies analysis.409 In this

regard, it appears that the preference is to use forward-looking projections instead of

407 JX 2032, Berk & DeMarzo, Corporate Finance at 296–97 (emphasis supplied). See Trial Tr. 1068:13–15 (Hubbard) (“Given the difficulty of finding comparables for this company in particular, this is a methodology that I used for completeness and for the record for the Court, but it would not be a principal method I would advocate that the Court center on.”). See also JX 1826 at ¶17. 408 JX 1816 at ¶194; JX 2516, Koller, Valuation at 335 (“Empirical evidence shows that forward-looking multiples are indeed more accurate predictors of value than historical multiples are.”). 409 The EBITDA multiples valuation is generally considered more reliable than a revenue multiples approach because the EBITDA approach accounts for firms’ operating efficiency and is not affected by leverage differences between firms. JX 2032, Berk & DeMarzo, Corporate Finance at 710.

93 a firm’s historical earnings data.410 Forward-looking multiples are deemed more

consistent with the principles of valuation, especially in the context of estimating the

present value of a company as a going concern.411 Projections generally exhibit less

variation across peer companies compared to historical data, and although long-term

earnings projections are favored, one- and two-year forecasts are reliable when they

uniformly represent the firm’s long-term prospects.412

With these generally accepted features of a proper comparable companies

valuation in mind, I turn to the experts’ comparable companies valuation of Jarden.

410 Id. at 710, 714; JX 2516, Koller, Valuation at 334–36; JX 242, Holthausen & Zmijewski, Corporate Valuation at 532. 411 JX 2516, Koller, Valuation at 334; Trial Tr. 159:7–14 (Zmijewski) (“Well, value is derived from what’s going to happen or what you expect to happen in the future, so looking forward is always better than looks backward. . . . If historical information doesn’t predict the future, it’s not useful at all. It’s only the forward-looking information that’s useful.”). 412 Id. at 335–36.

94 2. The Experts Attempt But Fail to Select a Valid Peer Set

Both experts developed their peer set by drawing from the peer set developed

by Barclays in its valuation work for the Company with regard to the Merger. They

then made adjustments based on their own sense of comparability. For his part,

Dr. Zmijewski conceded that he “did not do any qualitative assessment of any

inherent differences between the Jarden business and the business of its peers

companies.”413 Giving such deference to the peer set selected by management,

without any meaningful, independent assessment of comparability, is not useful and,

frankly, not credible.414 Dr. Zmijewski made no mention of GICS or SIC codes in

413 Trial Tr. 294:16–20 (Zmijewski); JX 1818 at ¶55 (“I base my set of comparable companies on those companies identified by Jarden’s CEO, Mr. Lillie and the comparable companies used by Jarden’s financial advisor, Barclays.”); JX 1828 at ¶¶68–70. I note it is not clear that Dr. Zmijewski drew his peer set from the right Barclays list. The list endorsed by management was prepared by Barclays’ equity analyst team while Dr. Zmijewski drew his list from the one prepared by Barclays’ investment banking team. Trial Tr. 264:23–268:14 (Zmijewski). Moreover, I find Dr. Zmijewski’s narrow focus on the Barclays list as the sole basis for his comparable companies peculiar given the extent to which he is critical of the Barclays Fairness Opinion. See JX 1818 at ¶¶1–42; JX 1826 at ¶¶46–47. 414 JX 1826 at ¶17; JX 2516, Koller, Valuation at 346; JX 242, Holthausen & Zmijewski, Corporate Valuation at 511 (“The key issues in valuing companies using market multiples are choosing appropriate comparable companies that would be priced similar to the company being valued and the making adjustments to the financial numbers used so that distortions to the valuation do not arise from accounting differences or certain events that can affect the financial statements in ways that render the numbers less useful for a market multiple valuation.”). Dr. Zmijewski’s decision apparently to ignore Barclays’ qualification that its peer set would have to be adjusted to account for qualitative differences between Jarden and the peer set was never adequately explained. Trial Tr. 294:24–296:24 (Zmijewski); JX 1565 at 127–28; JX 1205 at 11, 17.

95 his report and there is no indication that he employed them, or any other objective

criteria, in his selection of a peer set.415

Failing to ground his peer set in any objective methodology is all the more

problematic given Dr. Zmijewski’s apparent willingness to adjust the

management/Barclays’ peer set when it suited him to yield a higher valuation for

Jarden. As stated in his report, Dr. Zmijewski excluded Kimberly-Clark Corporation

and Colgate-Palmolive Company, which were both included in the Barclays list,

because both companies maintain a significantly larger market capitalization than

Jarden and the other comparables.416 The notion that a company with a very large

market capitalization is not a true peer of a company with a relatively smaller market

capitalization has a certain lay appeal. But Dr. Zmijewski’s own text makes clear

that “there is no theoretical model we are aware of that includes size as a determinant

of market multiples.”417 It may well be that Kimberly-Clark and Colgate-Palmolive

are not “comparables” for Jarden, but the absence of any meaningful analysis or

415 JX 1816 at ¶¶194–96. 416 JX 1818 at ¶57. 417 JX 242, Holthausen & Zmijewski, Corporate Valuation at 525. Given his willingness to defer to peer sets prepared by others, it is surprising that Dr. Zmijewski failed to reconcile his exclusion of Kimberly-Clark and Colgate-Palmolive from his peer set with the fact that those companies were included in the peer sets developed by several of the analysts who followed Jarden. JX 1826 at ¶¶43–45.

96 explanation in Dr. Zmijewski’s report leaves the Court with no way to determine if

the exclusion was arbitrary or principled.418

Before addressing Dr. Hubbard’s peer set, it must be emphasized that

Dr. Hubbard does not sponsor the comparable companies methodology as the

appropriate means by which to assess Jarden’s fair value.419 His preferred

methodology is DCF.420 Nevertheless, Dr. Hubbard engaged with Dr. Zmijewski on

comparable companies and, not surprisingly, reached a very different conclusion

after doing so.

Dr. Hubbard assessed Jarden’s peers by using GICS codes.421 He then cited

to over a dozen industry analyst reports that corroborated his peer set, which

included companies that were larger and smaller than Jarden and companies that

418 Dr. Hubbard flagged Dr. Zmijewski’s size discrepancy in his rebuttal report. As Dr. Hubbard noted, although the market capitalization of Kimberly-Clark and Colgate- Palmolive were, respectively, 4.6 and 6.0 times larger relative to Jarden, three of Dr. Zmijewski’s selected peers were correspondingly smaller than Jarden. JX 1826 at ¶¶40–43. WD-40 Company, Energizer Holdings and Helen of Troy were 7.3, 3.9 and 3.7 times smaller than Jarden, respectively, yet each of these firms remained in Dr. Zmijewski’s peer set. Id. Dr. Zmijewski provided no credible justification for the disparate, asymmetrical treatment of large and small companies in his peer set. Id. See also Trial Tr. 935:6–936:17 (Zenner); JX 1827 at ¶¶45–47 (credibly addressing the fallacy created by Dr. Zmijewski’s inconsistent approach to exclusion and inclusion of comparables based on size). 419 JX 1826 at ¶¶15–17. 420 Trial Tr. 1103:21–24 (Hubbard). 421 JX 1816 at ¶195.

97 were not on the Barclays list.422 Once he completed his peer set, however,

Dr. Hubbard emphasized his view that Jarden’s unique and highly diversified

portfolio of businesses, its aggressively acquisitive growth strategy and its holding

company structure made the selection of a valid peer set for a comparable companies

analysis a fundamentally flawed exercise since Jarden “lack[ed] truly comparable

peers.”423

After carefully reviewing the evidence, I am convinced that Dr. Hubbard is

correct—Jarden had no comparable peers, at least not as developed in the credible

evidence presented at trial. Under these circumstances, the fact that Dr. Zmijewski

engaged in no real analysis when developing his peer set is not surprising.424

Having found that the first, and most important, element of a proper

comparable companies analysis is lacking in this record, I give the experts’

422 JX 1826 at ¶¶38–35. Dr. Hubbard’s peer set included firms with core business lines comparable to Jarden’s core business, namely housewares, household appliances, consumer durables, apparel and personal products industry actors. JX 1816 at ¶195. 423 JX 1826 at ¶17. 424 JX 1818 at ¶¶55–57. As noted, Dr. Zmijewski offered no empirical analysis of Jarden’s growth, risk, or value drivers as compared to any of the firms in his peer group. Id. But see JX 242, Holthausen & Zmijewski, Corporate Valuation at 529–30 (“. . . simply selecting close competitors is not sufficient to ensure the companies are comparable . . . . Once we identify competitors, we analyze both the company being valued and the competitors with respect to characteristics that determine the variation in market multiples—such as future growth prospects, risk future profitability, and future expected investment requirements.”).

98 comparable companies conclusions no weight in my fair value determination.425

Accordingly, I move next to the parties’ competing DCF valuations.

E. Discounted Cash Flow

As I approach the parties’ fantastically divergent conclusions following their

DCF analyses, I am mindful of our Supreme Court’s admonition that, tempting as it

is to select the entirety of one expert’s analysis over the other’s, my review of the

experts’ opinions must not be presumptively binary:

425 The party sponsoring a comparable companies valuation has the burden of proving that the target has validly assessed peers. See In re Appraisal of SWS Gp., Inc., 2017 WL 2334852, at *10 (Del. Ch. May 30, 2017). Petitioners have not met that burden. In reaching this conclusion, I am mindful that Jarden, itself, employed a comparable companies analysis, among other approaches, when it performed internal valuations. But Petitioners have not proffered those valuations as evidence of Jarden’s fair value. Instead, they have presented Dr. Zmijewski’s version of a comparable companies analysis, which differed substantially from the Company’s valuations. Accordingly, they had the burden of proving that the Zmijewski comparable companies valuation was a reliable indicator of fair value. For reasons I have explained, I have determined they have not carried that burden. In other words, the fact the Company employed comparable companies analyses in the past to value Jarden might be evidence that the methodology can work for Jarden, but the appraiser still has to apply the methodology in a principled way. That principled application of the methodology is what is lacking here. As a final note, for what it’s worth, I did find Dr. Zmijewski’s approach to selecting a proper multiple for Jarden to be more credible than Dr. Hubbard’s approach, particularly given that he focused his multiples analysis on Jarden’s 2016 and 2017 projected earnings, as prescribed in the valuation texts, while Dr. Hubbard based his multiples analysis on Jarden’s historical EBITDA and revenue data. Compare JX 1818 at ¶¶74–76 (Zmijewski) with JX 1816 at ¶¶194–200. See JX 2032, Berk & DeMarzo, Corporate Finance at 710, 714; JX 2516, Koller, Valuation at 334–36; JX 242, Holthausen & Zmijewski, Corporate Valuation at 532 (expressing preference for using forward-looking projections over a firm’s historical earnings data when determining a proper multiple). Of course, this observation is worth little given the lack of credible evidence that Dr. Zmijewski created a proper peer set.

99 The role of the Court of Chancery has evolved over time to the present requirement that the court independently determine the value of the shares that are the subject of the appraisal action. Even though today a Chancellor may be faced with wildly divergent values presented by the parties’ experts, the acceptance of one expert’s value, in toto, creates the risk that the favored expert will be accorded a status greater than that of the now eliminated [expert appraiser]. This is not to say that the selection of one expert to the total exclusion of another is, in itself, an arbitrary act. The testimony of a thoroughly discredited witness, expert or lay, is subject to rejection under the usual standards which govern receipt of such evidence. The nub of the present appeal is not merely that the Chancellor made an uncritical acceptance of the evidence of SAP’s appraiser but that he announced in advance that he intended to choose between absolutes.426

As I discuss below, in many important respects, the experts have utilized very

different inputs in their DCF models leading to a substantial delta between their

ultimate DCF valuations—Dr. Zmijewski’s DCF valuation produced a range of

$70.36 and $70.40 per share;427 Dr. Hubbard’s DCF valuation is $48.01 per share.428

The number and degree of their differences has necessitated the lengthy discussion

that follows. For reasons I explain, I have adopted some of both expert’s inputs to

426 Gonsalves v. Straight Arrow Publ’rs, Inc., 701 A.2d 357, 361 (Del. 1997). See also M.G. Bancorp., Inc. v. Le Beau, 737 A.2d 513, 525–26 (Del. 1999) (reiterating the Chancellor’s role “as an independent appraiser” and observing that “[i]n discharging its statutory mandate, the Court of Chancery has the discretion to select one of the parties’ valuation models as its general framework or to fashion its own”). 427 Dr. Zmijewski made two DCF calculations: an industry-specific DCF, which incorporated his comparable companies analyses (“Composite DCF”), and a Jarden- specific DCF (“Jarden-Specific DCF”). JX 1818 at ¶¶70–72. 428 JX 1816 at ¶149; JX 1831 at ¶3.

100 construct my own DCF model. Based on that model, my DCF valuation is $48.13

per share.

I begin by noting where the experts agree. First, they agree that DCF is a widely

used and industry-accepted means of calculating the value of a corporation as a going

concern. Dr. Hubbard likes DCF best to value Jarden, while Dr. Zmijewski uses his

DCF valuation to corroborate his comparable companies analysis.429 Both experts

used the Weighted Average Cost of Capital (“WACC”) method to determine the

appropriate discount rate. Both agreed that the November Projections were the

appropriate cash flow forecasts upon which their DCF models should be based. Both

largely agreed on the required net investment to drive growth through the year 2020,

which is the last year included in the November Projections. And both agreed that

the Capital Asset Pricing Model (“CAPM”) was appropriate to calculate Jarden’s

Cost of Equity. Because I see no basis in the evidence to depart from these

stipulations, I adopt them without further analysis.

The bulk of the experts’ disagreements relate to how Jarden will perform in

the terminal period beyond the November Projections’ explicit forecasts.430

I address and do my best to resolve each of the disagreements below.

429 Pet’rs’ Pre-Trial Br. at 33. 430 JX 2514 at 14. Indeed, as Jarden points out, “over 83% of value in each of [Dr.] Zmijewski’s DCFs is from the terminal period.” Resp’t Jarden Corp.’s Answering Post- Trial Br. at 60.

101 1. Jarden’s Future Cash Flows

As noted, both experts used the November Projections for their DCF

analyses.431 Even so, both made different adjustments to the projections to calculate

Jarden’s unlevered free cash flows.432 After reviewing the adjustments, I find that

their adjustments for EBITDA, depreciation and amortization, and Dr. Zmijewski’s

adjustment for projected taxes, are appropriate.433 These adjustments yield the

following for Jarden’s Net Operating Profits after taxes (“NOPAT”):434

FY2016-E FY2017-E FY2018-E FY2019-E FY2020-E

$869 million $967 million $1,062 million $1,146 million $1,235 million

Using Jarden’s NOPAT, I have calculated Jarden’s unlevered free cash flows

for each projection year by: (1) adding back depreciation; (2) deducting Jarden’s

year-over-year change in working capital; and (3) deducting Jarden’s capital

expenditures. These adjustments track those made by Dr. Hubbard (albeit at a 35%

431 JX 1565 at 143. 432 JX 1816 at ¶¶75–78, Ex. 9; JX 1818 at ¶51, Ex. VI-7A. 433 I adopt Dr. Zmijewski’s 35.0% marginal tax rate for Jarden because Dr. Hubbard made no effort to support his effective tax rate of 36.3%. JX 1816 at ¶¶96–97; JX 1828 at ¶¶9– 11. A 35% marginal tax rate comports with the tax rates applied by Barclays, Centerview, Goldman Sachs and Jarden management—all of which set Jarden’s marginal tax rate between 33% and 35%. JX 1828 at ¶¶9–10, 24. 434 JX 1816 at ¶¶75–78, Ex. 9; JX 1818 at ¶51, Ex. VI-7A.

102 marginal rate),435 and yield the following as Jarden’s unlevered free cash flow in

each of the projected years:

$572 million $701 million $783 million $853 million $927 million

2. Jarden’s Terminal Value

Jarden’s terminal value is the value of the Company beyond the discrete

projection period as defined in a discounted future earnings model (“Terminal

Value”).436 In the context of the experts’ DCF analyses for Jarden, Terminal Value

refers to Jarden’s estimated value taking into account all future cash flows at the end

of the November Projection’s explicit forecast period assuming a stable growth rate

in perpetuity.437

Dr. Zmijewski’s Terminal Value calculation and accompanying analysis

mostly relies on his comparable companies analysis,438 which I have found not

435 JX 1816 at ¶¶75–78, Ex. 9. I track Dr. Zmijewski’s free cash flows analysis with respect to the tax rate because I agree with him that Dr. Hubbard’s approach to estimating Jarden’s tax rate in the projected years is not adequately supported. JX 1828 at ¶¶9–11. 436 JX 2032, Berk & DeMarzo, Corporate Finance at 256. 437 Id. (“[W]e estimate the value of the remaining free cash flow beyond the forecast horizon by including a[] . . . one-time cash flow at the end of the forecast horizon . . . . [The terminal value] represents the market value (as of the last forecast period) of the free cash flow . . . at all future dates.”). 438 Trial Tr. 300:17–24 (Zmijewski) (“I paired the comparable companies risk assessment with a lower growth rate because the comparable companies . . . were expected to perform 103 reliable for reasons already stated. Dr. Hubbard used a formula developed by

McKinsey & Co. to calculate Jarden’s Terminal Value. The McKinsey formula

involves dividing the value of cash flow in the Terminal Period by the difference

between the Discount Rate (the rate at which future cash flows are discounted to

present) and Jarden’s Terminal Growth Rate.439 According to Dr. Hubbard, this

formula generally provides that “all else remaining equal,” a company’s terminal

value is larger when cash flow is high, and the discount rate is low or the growth rate

is high.440 The “all else remaining equal” caveat, Hubbard explains, assumes that

increased growth will be supported by increased investment which, in turn, reduces

cash flow.441 In other words, increasing investment in the Terminal Period will

proportionately reduce Jarden’s cash flow and thereby lower Jarden’s measurable

value in the Terminal Period. To calculate Jarden’s Terminal Value, it is necessary

to estimate its Terminal Growth Rate, Terminal Investment Rate and Discount Rate.

at a lower growth rate. And for the Jarden-specific risk assessment, I used the midpoint of the expected inflation and expected GDP growth.”) 439 JX 1816 at ¶¶84–85. 440 Id. 441 Id.

104 a. Terminal Growth Rate

“Of all the inputs into a discounted cash flow valuation model, none creates

as much angst as estimating the [terminal] growth rate. Part of the reason for it is

that small changes in the [terminal] growth rate can change the terminal value

significantly[.]”442 The terminal growth rate (“TGR”) describes Jarden’s long-term

growth in revenue, earnings and cash flow in the Terminal Period, which includes

the years starting in 2021 and onward. Since acquisitions are typically not

considered in organic growth rate calculations,443 a key question is whether Jarden’s

several tuck-in acquisitions should be included in the TGR.444

Both experts measure Jarden’s TGR based on estimates of U.S. nominal GDP

growth and long-term economic inflation. This method makes sense and is generally

442 JX 2515, Damodaran, Investment Valuation at 308. 443 Trial Tr. 930:2–9 (Zenner) (“So it’s a little bit like saying I baked gluten-free bread for you, but I added some wheat because the consistency is going to be better. So it’s kind of saying I’m providing organic growth, but I’m adding some tuck-in transactions.”). 444 For Jarden, “tuck-ins” were defined as an acquisition where the target company’s last twelve months (“LTM”) of revenue was less than 1.0% of Jarden’s LTM revenue. JX 1828 at ¶¶46–47.

105 accepted.445 The experts disagreed, however, as to what forecast sources provide the

most useful data.446

Dr. Zmijewski derived a 2.1% projected long-term inflation rate from four

estimates of U.S. economic outlooks and an expected nominal GDP growth rate of

4.3% from three projections of U.S. GDP growth.447 Based on these projections,

Dr. Zmijewski applied the midpoint of 3.2%, which he asserts is a reasonable long-

term growth rate for Jarden.448 Dr. Zmijewski’s TGR analysis included an

assessment of the Company’s acquisition-driven and organic growth, and the results

showed Jarden’s historic organic growth rate to be roughly 3.1%.449

As corroboration, Dr. Zmijewski emphasized that key players in the Merger

projected that Jarden would grow between 2.0% to 4.0% annually in perpetuity.450

445 JX 2515, Damodaran, Investment Valuation at 306–07 (“no firm can grow forever at a rate higher than the growth rate of the economy in which it operates”); JX 2516, Koller, Valuation at 122. 446 JX 1816 at ¶¶87–92; JX 1818 at ¶¶52–53. 447 JX 1818 at ¶¶52–53. 448 Id. at ¶¶53–54. 449 JX 1828 at ¶¶46–47. 450 JX 1818 at ¶¶52–54, Ex. VI-2. Polk estimated Jarden would grow at 3.0% (mirroring U.S. GDP growth), while Bain forecasted Jarden’s growth to be between 2.0% and 4.0%. Id.

106 For his Composite DCF calculation, Dr. Zmijewski used the 2.1% projected

U.S. inflationary growth rate as Jarden’s TGR.451 Dr. Zmijewski explained he used

U.S. inflation as Jarden’s TGR as a “conservative” measure because the Composite

DCF relies on calculations supplemented by comparable companies data, and

Jarden’s long-term growth was estimated to be much higher than any of the

companies in Dr. Zmijewski’s peer set.452 For his Jarden-Specific DCF analysis,

Dr. Zmijewski set Jarden’s TGR at 3.2%, which he suggested conforms to the other

Jarden-only measurements and calculations in that valuation.453

Dr. Hubbard’s report set Jarden’s TGR at 2.5% based on several inflation and

nominal GDP growth forecasts for the U.S. economy and the European Union’s

Eurozone.454 He noted that his TGR comports with the TGR utilized by Goldman

Sachs and Centerview in advising Newell, both of which used a TGR of 2.0% in

their valuations of Jarden.455 He also pointed to analyst reports by Deutsche Bank

and RBC Capital that estimated Jarden’s TGR at 1.5% and 2.5%, respectively. 456

451 Id. at ¶¶67–69. 452 Id. 453 Id. at ¶¶70–72. 454 JX 1816 at ¶¶86–92. 455 Id. at ¶¶89–90, Figure 20. 456 Id. at ¶¶89–92, Ex. 5A.

107 Finally, he noted that his TGR is consistent with Jarden’s historic organic growth,

which he determined to be 2.2% annually.457 With all these factors considered,

Dr. Hubbard concluded that his 2.5% TGR falls squarely between his estimated

range of inflation and nominal GDP and aligns well with Jarden’s historic organic

growth when fairly adjusted for “tuck-in” acquisitions.458

Dr. Zmijewski took issue with Dr. Hubbard’s adjustments for “tuck-ins”

because the adjustments result in double counting certain companies that did not fit

Jarden’s definition of a “tuck-in.”459 Dr. Hubbard conceded this error, revised his

analysis and found Jarden’s organic, non-acquisitive growth rate to be 3.2%

annually.460 Despite his upward revision to Jarden’s historic organic growth,

Dr. Hubbard did not change his 2.5% TGR estimate.461

Jarden’s “tuck-in” acquisitions, although relatively small in scale, are

acquisition-driven growth, not organic growth.462 Accordingly, Dr. Hubbard’s

457 JX 1826 at ¶¶32–34, Figure 6. Dr. Hubbard maintains that the Company’s 3.0% to 5.0% growth projections in the years following 2015 do not agree with its 2.2% historic organic growth because management incorrectly failed to account for “tuck-in” acquisitions. Id.; JX 1816 at ¶¶90–92. 458 JX 1816 at ¶¶90–92, Ex. 5A; JX 1826 at ¶¶32–34, Figure 6. 459 JX 1828 at ¶¶46–48. 460 Trial Tr. at 1116–18 (Hubbard); JX 1831 at ¶8. 461 JX 1831 at ¶8. 462 JX 1826 at ¶32 (“[I]n recent history, tuck-ins contributed approximately 1.8 percentage points to the “organic” growth reported by management, indicating that Jarden would need 108 attempt to account for “tuck-in” acquisitions when estimating Jarden’s TGR is well

taken. Dr. Hubbard’s reluctance, however, to acknowledge the impact of his organic

growth rate miscalculation on his estimate of Jarden’s TGR is not. 463 Moreover,

considering Dr. Hubbard’s revised 3.2% historic organic growth rate in light of his

economic research supporting long-run inflation in the range of 2.0% annually, and

nominal GDP growth in the range of 4.07% annually, with a midpoint of roughly

3.04%,464 Dr. Hubbard’s 2.5% TGR is not supported.

Dr. Zmijewski calculated Jarden’s historic organic growth rate to be 3.1%.465

His economic research supported U.S. long-run inflation at 2.1% annually and

nominal GDP growth at 4.3% annually.466 And his estimates are within one- or two-

tenths of a percentage point of Dr. Hubbard’s. The midpoint of each experts’

inflation and GDP estimates is approximately 3.1%, which aligns with

Dr. Hubbard’s 3.2% revised historic organic growth rate and Dr. Zmijewski’s 3.2%

midpoint TGR in his Jarden-Specific DCF.467 The literature recommends a

to continue tuck-in acquisitions in order to achieve the five percent growth in the Proxy Projections.”). 463 Trial Tr. at 1116–18 (Hubbard); JX 1831 at ¶8. 464 JX 1816 at ¶¶86–90. 465 JX 1828 at ¶¶46–48. 466 JX 1818 at ¶¶52–53. 467 I note that the literature cautions against relying on comparable companies when estimating terminal value because inconsistencies in projected growth rates between the 109 conservative approach to estimating long-term growth rates for a DCF valuation, in

recognition that many companies experience cyclical growth in relation to the

overall economy.468 Jarden was considered a GDP growth business.469

Based on these factors, and the credible evidence in the trial record, I apply a

3.1% TGR. In my view, this reflects the most credible aspects of the experts’

analyses and comports with the most persuasive view of Jarden’s historic growth.

b. Terminal Investment Rate

The experts’ disagreement over the terminal investment rate (“TIR”) accounts

for 87% of the disparity in their DCF valuations.470 In other words, of the $22.39

difference between Dr. Hubbard’s DCF per share value of $48.01 and

Dr. Zmijewski’s DCF per share value of $70.40, $19.56 is attributable to the

disagreement over Jarden’s TIR. After carefully considering the experts’ analyses

of TIR, and exposing what I believe to be flaws in both, I have determined that an

appropriate TIR for Jarden is 27.75%.

target company and those of the peer group can either overvalue or undervalue the target business. JX 242, Holthausen & Zmijewski, Corporate Valuation at 212. 468 Trial Tr. 215:20–216:17 (Zmijewski); JX 242, Holthausen & Zmijewski, Corporate Valuation at 216–17. 469 JX 1818 at ¶¶52–53. 470 JX 1816 at ¶¶149–150; JX 1818 at ¶¶70–72; JX 1831 at ¶3.

110 The disagreement between the experts boils down to whether Dr. Hubbard

improperly relied upon accounting theory when calculating TIR.471 Dr. Zmijewski’s

approach to Jarden’s TIR aligns, in concept, with the Bradley-Jarrell Plowback

Formula, which provides, in broad terms, that the rate of reinvestment must be

measured by what is realistically required to drive real growth.472 Real growth,

under the plowback paradigm, is measured by the delta between the company’s

growth rate and inflationary growth, which is driven by the greater economy and not

cash reinvestment.473 In other words, as Jarden’s growth slowed over time and

became steadier, the Company required less capital expenditure to drive real growth

because a greater percentage of its overall growth was driven by inflation and

broader economic factors. According to Dr. Zmijewski, because Jarden was a

steady-growth company that expected lower growth in the Terminal Period, it

required a much lower TIR, which he calculated at only 4.9%.474

471 Trial Tr. 195:18–20 (Zmijewski) (“He’s using accounting data as if it were economic concepts. That doesn’t work. And so that’s my major disagreement with him.”); Trial Tr. 197:14–17 (Zmijewski) (“These are all economic concepts. They’re not––you can’t sort of say here’s an accounting number and it matches this. These are economic concepts, not accounting concepts”). 472 JX 63; JX 242, Holthausen & Zmijewski, Corporate Valuation at 235–37. 473 Id.; JX 1828 at ¶¶37–38. 474 JX 1828 at ¶¶34–35, 45. Dr. Zmijewski never expressly sets his TIR at 4.9%, but implicitly determines that net investment in 2021 and onward will equal $60 million, or approximately 4.9% of operating profits. JX 1826 at ¶¶54–55, 62, 66–67, Figure 14. Dr. Zmijewski also assumed that depreciation will equal capital expenditures in the Terminal Period, and that Jarden’s cash investment required to drive terminal growth will 111 Dr. Hubbard calculated TIR by applying a formula from McKinsey & Co.475

The McKinsey formula posits that a company’s return on invested capital (“ROIC”)

should converge towards its WACC over time.476 The formula rests on the premise

that a company operating in a competitive industry will not “have both high and

rising forever returns on invested capital.”477 Applying the McKinsey formula,478

Dr. Hubbard used 2.5% as his TGR and 7.38% as his WACC/ROIC, yielding a TIR

of 33.9%.479

Dr. Zmijewski expressed four principal criticisms of Dr. Hubbard’s

application of the McKinsey formula.480 First, according to Dr. Zmijewski,

Dr. Hubbard incorrectly assumes that any new investment Jarden made starting in

grow coequally with Jarden’s other financial metrics. JX 1818, Ex. VI-6A (Dr. Zmijewski made some adjustments to the historical financial data such that normalized depreciation is equal to normalized capital expenditures of $308 million). 475 Trial Tr. 1045:21–1046:2 (Hubbard). 476 JX 1816 at ¶94. 477 Trial Tr. 1055:16–18 (Hubbard). 478 IR = g/RONIC, where g is the terminal growth rate and RONIC is the return on new invested capital. JX 1816 at ¶94; JX 2516, Koller, Valuation at 31; JX 2515, Damodaran, Investment Valuation at 312–14. 479 JX 1816 at ¶94. As discussed in more detail below, Dr. Hubbard calculates WACC as follows: Jarden’s capital structure weights 36.1% debt and 63.9% equity, coupled with a cost of debt (after tax) of 3.20% and a cost of equity of 9.74%, results in a WACC of 7.38%. JX 1816 at ¶128, Ex. 15. 480 Trial Tr. 196:9 (Zmijewski) (“Well, I have four issues.”).

112 2021 would not create any value.481 Second, Dr. Zmijewski believes Dr. Hubbard

improperly defined investments to include only working capital and capital

expenditures, which, according to Dr. Zmijewski, is the accounting definition of

investments (meaning “what you put on a balance sheet”) that does not account for

real world economics.482 In other words, Dr. Hubbard’s definition of investment

excludes research and development, advertising and human capital expenditures that

would create value for Jarden in years beyond 2021.483 Third, Dr. Hubbard’s

definition of net investment as investment above depreciation is, again, an

accounting definition that does not fit when calculating TIR.484 Fourth, Dr. Hubbard

improperly calculated WACC by “using accounting rates of return” instead of

“economic rates of return,” which do “not measure the same thing.”485

Dr. Hubbard’s testimony that, in competitive industries, the return on new

invested capital should equal the company’s WACC was credible, and it is supported

by the valuation treatises.486 Although I found credible Dr. Hubbard’s well-reasoned

481 Trial Tr. 196:11–16 (Zmijewski). 482 Trial Tr. 197:19–198:17 (Zmijewski). 483 Trial Tr. 198:7–15 (Zmijewski). 484 Trial Tr. 198:18–199:6 (Zmijewski). 485 Trial Tr. 199:7–11 (Zmijewski). 486 Trial Tr. 1046:11–1049:23 (Hubbard); JX 2516, Koller, Valuation at 102, 250–56; JX 2515, Damodaran, Investment Valuation at 291, 299–300.

113 premise that companies like Jarden cannot maintain growth without sufficient

investment to drive growth above inflation over time, his relatively high TIR raises

at least yellow flags. At first glance, the empirical analysis Dr. Hubbard undertook

to support his 33.9% TIR appears reasonable, particularly given Jarden’s historic

investment rates, which averaged roughly 26.9% of comparable growth over six

years.487 But why study six years here when Dr. Hubbard’s TGR estimation was

premised on five years of Jarden’s historic growth?488 By including the sixth year,

2010, in his calculation, Dr. Hubbard was able to reach a significantly higher number

for Jarden’s historical average growth. After excluding the 2010 investment rate of

64.3%, Jarden’s five-year average investment rate is 21.6%.

In view of Jarden’s five-year 21.6% average historic investment rate,

Dr. Zmijewski’s 4.6% TIR is too low; it unreasonably assumes rising ROIC for more

than 40 years into the Terminal Period, unreasonably assumes all new investment in

the Terminal Period will be comprised entirely of working capital, and is based on a

methodology that conflicts with the valuation goal of striking a balance between

investment and growth.489 The November Projection’s forecast of net investment in

487 JX 1816 at ¶¶93–95, Ex. 10A; JX 1826 at ¶¶54–61. 488 JX 1816, Exs. 5A–5D (compare Ex. 10A starting at FY10 with Exs. 5A, C, D starting at FY11). 489 Trial Tr. 1055:14–18 (Hubbard) (“I just don’t know of firms and industries that have both high and rising forever returns on invested capital.”); Trial Tr. 1051:12–16 (Hubbard) (“you can’t simply change your growth, particularly your real growth, which is what is 114 2021 at 9.8%, likewise, stands out as low relative to Jarden’s five-year average

investment rate. The midpoint of Dr. Hubbard’s 33.9% TIR and Jarden

management’s projected 9.8% TIR is roughly 21.8%. With a calculated TGR of

3.1%, which coincides with Jarden’s historic organic growth rate, the appropriate

TIR should reflect Jarden’s historic investment rate but account for a slight increase

to accommodate sustained growth in the Terminal Period. The credible evidence, in

my view, supports a TIR for Jarden of 27.75%.490

c. Jarden’s Weighted Average Cost of Capital/Discount Rate

As previously stated, both experts’ DCF models used Jarden’s WACC as the

input for the Discount Rate in the DCF formula.491 The Discount Rate converts

Jarden’s future cash flows from the November Projections to present value as of the

Merger Date.492 WACC reflects Jarden’s cost of equity and debt financing and the

being done in this experiment, and not have any additional investment”); JX 2514 at 21 (a graph depicting the dramatically outsized ROIC implicated by Dr. Zmijewski’s TIR); JX 2516, Koller, Valuation at 19; JX 2515, Damodaran, Investment Valuation at 302; JX 2032, Berk & DeMarzo, Corporate Finance at 711. 490 This sets the TIR at the midpoint between Dr. Hubbard’s TIR of 33.9% and Jarden’s historic average investment rate of 21.6%. It also assumes a ROIC for Jarden of 11.2%, which is reasonable given Jarden’s innovative and highly acquisitive growth strategy and a WACC of 6.94% (as discussed below). JX 1828 at ¶39. 491 Trial Tr. 1066:21–23 (Hubbard) (“Q. And if we could, did you estimate the weighted average cost of capital for purposes of your DCF analysis? A. I did. Both Professor Zmijewski and I tendered estimates of the weighted average cost of capital.”); JX 1816 at ¶¶98–129; JX 1818 at ¶¶65–66. 492 JX 1816 at ¶¶98–99.

115 relative weight of each in Jarden’s capital structure.493 Given that a DCF valuation

is meant to calculate Jarden’s value as a going concern, the components relied upon

to calculate WACC should represent Jarden’s prospective outlook.494 The experts

agreed on one of the relevant inputs to calculate Jarden’s WACC, the risk-free rate

of return. They differed, however, in their respective estimates of Jarden’s capital

structure, beta, equity risk premium, and whether a size premium was appropriate.495

I address each issue below.

The application of a discount rate to financial projections converts the target

company’s future income stream at its expected opportunity cost of capital to its

present value.496 A company’s WACC represents the cost (to the company) of

financing its business operations; it comprises the weighted average of the

company’s cost of debt and equity:497

493 Id.; JX 1818 at ¶¶46–49; Trial Tr. 190:1–3 (Zmijewski) (“[WACC] is a standard calculation. You calculate the equity costs of capital, the after-tax debt cost of capital. You weight those two.”). 494 Id.; JX 2516, Koller, Valuation at 295–97. 495 Trial Tr. 244:2–6 (Zmijewski) (“[W]e have the same risk-free rate. We have a different equity risk premium, a slightly different beta. He doesn’t use a size premium. I do. So we have some differences in our calculations here.”). 496 JX 1818 at ¶68; JX 1816 at ¶98; JX 2516, Koller, Valuation at 269. 497 JX 1818 at ¶49; JX 2516, Koller, Valuation at 269–72.

116 E D WACC = (requity × ) + (rdebt × × (1 - t)) V V where: requity = cost of equity capital E = market value of the company’s equity rdebt = cost of debt capital D = value of the company’s debt V=E+D = total value of the company’s equity and debt t = marginal tax rate

i. Jarden’s Capital Structure

A company’s capital structure indicates what percentage of its activities is

financed by debt and what percentage is financed by equity.498 Determining the

correct capital structure is essential to WACC because without a clear picture of a

company’s debt-to-equity ratio, the cost of financing future operations will be

improperly weighted.499

Both experts recognized the impact of the substantial amount of convertible

debt in Jarden’s capital structure.500 Jarden’s convertible debt conceptually existed

as both debt and equity components in its capital structure, and both experts valued

the debt and equity components of Jarden’s convertible notes separately.501

498 JX 1816 at ¶99; JX 2516, Koller, Valuation at 215–19. 499 See Trial Tr. 1070:2–6 (Hubbard). 500 JX 1816 at ¶¶100–03; JX 1818 at ¶63. 501 Id.

117 Dr. Zmijewski calculated Jarden’s capital structure based on Jarden’s median

capital structure ratios in the last four quarters before December 4, 2015.502

According to the previous year’s ratios, Dr. Zmijewski selected a Jarden

capitalization ratio of 69% combined equity and 31% debt.503

For his part, Dr. Hubbard examined Jarden’s capital structure ratio for the five

years prior to the Merger.504 He noted that Jarden maintained a debt level of roughly

50% from the last quarter of 2010 through 2011, but beginning in 2012, Jarden’s

debt to equity ratio began shifting due to Jarden’s increased acquisition activity. 505

As Jarden stepped up acquisitions between 2012 and 2015, its total debt nearly

doubled but its equity value expanded in even greater proportions.506 By the third

quarter of 2015, Jarden’s market capitalization nearly tripled and its capital structure

had shifted from nearly a 50:50 ratio to 37.5% debt and 62.5% equity.507 Following

502 JX 1818 at ¶64. 503 Id. 504 JX 1816 at ¶98. 505 Id. at ¶¶100–04, Figure 21. 506 Id. 507 Id.

118 the Yankee Candle acquisition in 2013, Jarden’s goal was to de-lever itself to three

times its bank leverage-to-EBITDA ratio.508

Dr. Hubbard observed that, in order to capture Jarden’s value as a going

concern, the capital structure ratio used in the WACC analysis should reflect

Jarden’s long-run target capital structure.509 He concluded that, because Jarden was

on a trajectory of lower debt leading up to the Merger, and its long-term goal was to

achieve an even lower debt-to-equity ratio, Jarden’s average debt in the one-year

period before the Merger was the best estimate of Jarden’s target capital structure

for WACC.510 Based on that judgment, Dr. Hubbard calculated a capital structure

equal to Jarden’s one-year average ratios of 36.1% debt and 63.9% equity.511

The valuation literature suggests that because of the increased use of

convertible securities, assessing the debt-to-EBITDA ratio alongside capital

structure helps build a more comprehensive picture of a company’s leverage risk.512

Both experts were cognizant of the effect of Jarden’s convertible securities on its

508 Id. at ¶¶100–07, Figure 21; JX 1777 (Lillie Dep.) at 86–87. 509 JX 1816 at ¶¶98–99. 510 Id. at ¶¶104–05. 511 Id. 512 JX 2516, Koller, Valuation at 217.

119 capital structure, and Dr. Hubbard went on to consider changes in Jarden’s debt-to-

EBITDA ratio and the corresponding effect on Jarden’s future leverage risk.513

The two experts relied on one year of debt-to-equity information to calculate

their capital structure estimates. Dr. Zmijewski calculated Jarden’s capital structure

according to its median debt-to-equity ratios prior to the unaffected trading date of

December 4, 2015.514 That is where Dr. Zmijewski’s analysis ended. Dr. Hubbard

made a similar assessment of Jarden’s capital structure as it stood just prior to the

unaffected trading date, but did not end his analysis there. Instead, Dr. Hubbard

assessed Jarden’s target debt-to-EBITDA ratios, which reflected the capital structure

Jarden set as a forward-looking goal well before merger negotiations began.515

This further analysis makes sense. The cost of capital analysis should be

based on target debt-to-equity ratios instead of current ratios.516 Target capital

structure represents the ratios expected to prevail over the life of the business and

the literature stresses that relying solely on current capital structure can distort the

cost of capital analysis.517 Overly optimistic capital structure targets must be

513 JX 1816 at ¶¶100–07, Figure 21; JX 1818 at ¶63. See also Trial Tr. 161 (Zmijewski) (explaining how he accounted for convertible securities). 514 JX 1818 at ¶64. 515 JX 1816 at ¶¶103–07, Figure 21. 516 JX 1816 at ¶105; JX 2516, Koller, Valuation at 295–97. 517 JX 2516, Koller, Valuation at 295–97.

120 accounted for if they are expected to take many years to be realized.518 Jarden’s

target capital structure and debt-to-EBITDA ratio was not overly optimistic under

the circumstances. As of 2015’s third quarter, Jarden’s leverage had shifted

downward to 37.5% as its market capitalization grew,519 and Jarden planned to

continue its deleveraging strategy until it reached a debt-to-EBITDA ratio of 3.0x.520

Adjusting Jarden’s 37.5% debt as of September 30, 2015, to conform to its target

leverage ratio would lower Jarden’s debt ratio to 33.3%.521 Based on the dramatic

swings in Jarden’s capital structure in the five years prior to the Merger, a 4.2%

deleveraging was well within Jarden’s ability to achieve in the short term.

Because Dr. Hubbard’s analysis conservatively includes Jarden’s forward-

looking target capital structure in his capitalization analysis, I adopt Dr. Hubbard’s

capital structure of 63.9% equity and 36.1% debt.522 Accordingly, I adopt Hubbard’s

estimated equity and debt values for Jarden at $10,596,000,000 and $5,043,000,000,

respectively.523

518 Id. at 295; JX 1816. 519 JX 1816. 520 Id. at ¶¶100–07, Figure 21; JX 1777 (Lillie Dep.) at 86–87. 521 JX 1816 at ¶¶103–07, Figure 21. 522 Id. at ¶105. 523 Id., Ex. 11A.

121 ii. Jarden’s Cost of Debt

A company’s cost of debt reflects “the current cost to the firm of borrowing

funds to finance projects.”524 Generally, it is derived from three variables: (1) the

riskless rate, (2) the default risk (and associated default spread) of the company and

(3) the tax advantage associated with debt.525

Dr. Zmijewski estimated Jarden’s after-tax Cost of Debt at 2.8%.526 He

arrived at this figure by calculating a Debt Beta of 0.36 based on Moody’s Long-

Term Corporate Family Rating of Ba3 for Jarden as of December 4, 2015, and the

Duff & Phelps debt beta estimate for Ba debt as of March 2016.527

Dr. Hubbard estimated Jarden’s Cost of Debt based on a tax adjusted yield to

maturity rate of 5.30%.528 This yielded a Cost of Debt of 3.2%.529

524 JX 2515, Damodaran, Investment Valuation at 211. See also JX 1816 at ¶106; JX 1818 at ¶63. 525 Id. 526 JX 1818, Ex. VI-5. 527 Id. at ¶64. 528 JX 1816 at ¶¶108–09. Trial Tr. 1218:11–13 (Hubbard) (Q. “You measured Jarden’s cost of debt by using yield to maturity. Correct? A. I did.”). 529 Id.

122 I agree with Dr. Zmijewski that calculating the cost of below-investment-

grade debt by using yield to maturity sets the cost of debt too high.530 I adopt his

Cost of Debt of 2.8%

iii. Jarden’s Tax Rate

Jarden’s tax rate is 35%, which is the top marginal corporate tax rate for U.S.

companies at the time of the Merger.531

iv. Jarden’s Cost of Equity

Establishing an accurate Cost of Equity is an essential subcomponent of

Jarden’s WACC. Both experts used the Capital Asset Pricing Model (“CAPM”) to

calculate Jarden’s cost of equity capital.532 This approach calculates Jarden’s risk

separately from systematic risk to produce a reliable estimate of Jarden’s Cost of

Equity.533 CAPM has four components: the risk-free rate, equity beta, equity risk

530 JX 1828 at ¶20; JX 2032, Berk & DeMarzo, Corporate Finance at 412 (“When the firm’s debt is risky, however, the debt yield will overestimate the debt cost of capital, with the magnitude of the error increasing with the riskiness of the debt.”). 531 Trial Tr. 1213:16–18 (Hubbard). 532 JX 1818 at ¶64; JX 1816 at ¶110. 533 Id.

123 premium, and if necessary, a size premium.534 Following CAPM, a company’s cost

of equity is calculated as follows:535

where: rno-risk = risk-free rate of return  = beta coefficient of the subject company ERP = equity risk premium SS = size premium

 The Risk-Free Rate

The only point of agreement between the experts in the WACC analysis is the

risk-free rate of return. Both experts set their analyses’ risk-free rate at the 20-year

constant maturity U.S. Treasury Bonds return as of the Merger.536 That rate was

2.14%.537 Relying on 20-year U.S. Treasury Bonds for the risk-free rate is

universally accepted practice in corporate valuation.538

534 JX 1816 at ¶110; JX 2516, Koller, Valuation at 278–87; JX 2032, Berk & DeMarzo, Corporate Finance at 385–92. 535 JX 1818 at ¶64; JX 2516, Koller, Valuation at 279; JX 2515, Damodaran, Investment Valuation at 208; JX 2032, Berk & DeMarzo, Corporate Finance at 387. 536 JX 1816 at ¶111; JX 1818 at ¶64. 537 Id. 538 JX 2515, Damodaran, Investment Valuation at 155; JX 2516, Koller, Valuation at 275– 76; JX 2032, Berk & DeMarzo, Corporate Finance at 411–12.

124  Beta

Beta, in short, is a measurement of the systemic risk that a particular security

adds to a market portfolio.539 The consensus from the corporate finance literature in

the record is that the conventional approach for estimating equity beta for a publicly

traded company, like Jarden, is through a regression analysis of the historical returns

of its stock against the returns of a market index.540 In other words, equity beta is

derived by assessing a stock’s sensitivity to and correlation with changes in the

aggregate market. A beta regression analysis requires three parameter-setting

choices. First, the time period for measuring returns must be established. 541 Second,

the return interval at which measurements will be taken over the duration of the

designated time period must be specified.542 Third, an appropriate market index

must be identified that will represent the cumulative market over time as a control

to measure the target company’s market price.543

539 JX 1818 at ¶58; JX 1816 at ¶112; JX 2516, Koller, Valuation at 279; JX 1345, Duff & Phelps, Valuation Handbook at 2–14; JX 2515, Damodaran, Investment Valuation at 183; JX 2032, Berk & DeMarzo, Corporate Finance at 413. See Trial Tr. 187:10–13 (Zmijewski) (“beta is a measure of risk of a company or an asset that you––that you can measure statistically using a statistical model.”). 540 JX 2515, Damodaran, Investment Valuation at 183. See also JX 1816 at ¶¶113–20. 541 Id. 542 Id. 543 Id.

125 The experts disagreed on the relevant time periods and return intervals to use

in their regression analyses. From the evidence, it appears the most appropriate

(and commonly used) parameters are two- or five-year time periods and weekly or

monthly return intervals.544

The control market index should be one developed from the exchange where

the target company’s stock trades.545 For companies traded on the NYSE, like

Jarden, it is reasonable to use either the NYSE Composite or the S&P 500 Index.546

The experts agreed that the S&P 500 is an appropriate market index and both used

the S&P 500 as their control to measure Jarden.547

In addition, both experts relied on Jarden’s historical market returns data and

estimated Jarden-specific betas. Yet, they disputed whether it was necessary to

balance Jarden’s beta with betas estimated from historical returns of comparable

companies.

In his report, Dr. Zmijewski calculated two equity betas to use in his Jarden-

Specific DCF and Composite DCF analyses. To estimate Jarden’s beta as of the

Merger Date, Dr. Zmijewski measured the equity beta for Jarden and for each of a

544 JX 2516, Koller, Valuation at 283–84. See JX 1816 at ¶114. 545 JX 2515, Damodaran, Investment Valuation at 188. 546 Id.; JX 2032, Berk & DeMarzo, Corporate Finance at 413. See JX 1816 at ¶115. 547 JX 1816 at ¶¶111–20; JX 1818 at ¶¶58–61.

126 list of comparable companies based on five years of weekly returns ending on the

Merger Date.548 He then performed a regression analysis for each company against

the S&P 500 for the same period that showed Jarden’s unlevered beta was 1.04 and

that the unlevered beta for his comparable companies (plus Jarden) was 0.86.549

Finally, he made adjustments to account for Jarden’s cash and other financial assets

and relevered each beta to produce a Jarden-specific equity beta of 1.24 (the “Jarden-

Specific Beta”) and a combined equity beta for his comparable companies

(plus Jarden) of 1.01 (the “Composite Beta”).550

Dr. Hubbard’s regression analysis yielded an equity beta of 1.18 (the

“Hubbard Beta”) that was based on Jarden’s daily returns for one year ending on

December 4, 2015.551 Unlike Dr. Zmijewski, Dr. Hubbard did not balance his

Jarden-specific beta regression analysis with beta estimates of comparable

companies. Instead, he regressed Jarden’s single year daily returns against the

S&P 500 during the one-year period and calculated an unlevered beta of 0.771.552

548 JX 1818 at ¶¶58–61. 549 Id. at ¶¶60–61, Ex. VI-4. 550 Id. at ¶¶59–61, Ex. VI-5; JX 1828 at ¶16. Dr. Zmijewski explained that the Jarden- Specific Beta was higher due to a “lack of precision relative to the precision [of] using a set of comparable companies” and because of Jarden’s higher long-term growth relative to that of his comparable companies. JX 1818 at ¶¶60–61. 551 JX 1816 at ¶¶114–16. 552 Id. at ¶¶117–20.

127 Like Dr. Zmijewski, he then adjusted for cash and financial assets and re-levered the

beta to produce a Jarden equity beta of 1.18.553 Dr. Hubbard also calculated Jarden-

specific betas from two years of weekly returns and five years of monthly returns,

but ultimately decided to use the single year daily returns beta to mitigate the

potential confounding effects of several large acquisitions Jarden completed in the

five years prior to the Merger.554 Dr. Hubbard explained that he chose the year

ending on December 4, 2015, in order to avoid contaminating his regression analysis

with news of the possible merger.555

The literature in the record supports the use of comparable companies in a

beta regression because companies in the same industry face similar “operating

risks” and therefore should have similar operating betas.556 This, of course, assumes

that “truly” comparable peers exist that can meaningfully be compared to the target

company.557 Here again, Dr. Zmijewski failed convincingly to demonstrate that his

553 Id. 554 Id. at ¶¶114–16. Dr. Hubbard noted that the single year daily beta of 1.18 was “not substantially different” from his two-year weekly beta of 1.22. Id. at ¶¶117–20. 555 Id. at ¶¶114–16. 556 JX 2516, Koller, Valuation at 286. 557 Id. at 283–85; JX 242, Holthausen & Zmijewski, Corporate Valuation at 306 (“. . . if we have a set of truly comparable companies, we feel we can gain precision in our estimate of the cost of capital by using multiple companies.”) (emphasis supplied).

128 comparable companies shared similar risk profiles with Jarden.558 As Dr. Hubbard

persuasively testified, Dr. Zmijewski provided no analysis or discussion to support

this assumption.559 Without a thorough explanation and corroborating evidence of

how Dr. Zmijewski’s comparable companies had risk profiles comparable to

Jarden’s “complex”560 and “unique”561 structure and business model, I am

disinclined to consider on Dr. Zmijewski’s Composite Beta.

Jarden’s stock consistently traded in the upper quartile of market volume on

the NYSE from 2011 to 2015.562 And its share price had a positive correlation with

the market, as defined by the S&P 500, throughout the same time period.563 With

this in mind, I am persuaded that Dr. Hubbard’s decision to use daily interval

measurements is reasonable, and his opinion that Jarden’s market returns data

558 JX 1828 at ¶¶12–16. 559 Trial Tr. 1068:13–1069:15 (Hubbard); JX 1826 at ¶¶72–75. 560 JX 1818 at ¶29 (“More specifically, I discuss . . . complexity of Jarden’s information and holding company (or platform) business model strategy”). 561 Trial Tr. 104:7–105:18 (Lillie), 262:19–263:23 (Zmijewski) (“None of those companies is an apple-to-apple comparison to Jarden or each other. Comparable Companies––there just isn’t any such thing as a twin company. It doesn’t exist.”). 562 JX 1816 at ¶¶45–50. In addition, both experts’ beta estimates are positive, which indicates a parallel correlation with changes in the overall market. 563 JX 1816 at ¶¶112–20.

129 provide a reliable measurement of Jarden’s beta is supported by the literature in the

record.564

Dr. Hubbard corroborated his calculated beta with a second regression using

two-year weekly returns that yielded a Jarden-specific beta of 1.22.565

Dr. Zmijewski’s beta estimates were derived from a five-year period of weekly

returns, and his Jarden-specific analysis produced a beta of 1.24 for Jarden alone.566

The spread between Dr. Hubbard’s beta and Dr. Zmijewski’s Jarden-specific beta is

0.06, which, according to the literature, suggests that the Jarden-specific beta

estimates have a low error rate across different time and interval measurements.567

A narrow error rate between firm-specific beta estimates of different intervals and

time periods indicates the estimates are converging on the company’s true beta.568

Moreover, it is important to note that, when estimating beta, the goal is to

evaluate Jarden’s future beta, and by extension, the sensitivity of Jarden’s share price

564 Id.; JX 2516, Koller, Valuation at 284; JX 2515, Damodaran, Investment Valuation 183, 187–95. 565 Id. 566 JX 1818 at ¶¶58–61. 567 JX 2515, Damodaran, Investment Valuation at 192–95; JX 1816, Ex. 22F; JX 1818 at ¶¶60–61. 568 JX 2516, Koller, Valuation at 286; JX 2515, Damodaran, Investment Valuation at 192– 93.

130 to future market risk as predicted by its historical performance.569 Because betas

generally converge on the general market beta (1.0) over time,570 and Jarden, by all

indicators, was a mature, highly traded company, I am satisfied that Dr. Hubbard’s

beta (1.18) is a reasonable estimate of Jarden’s share price sensitivity to future

market risk.

 Equity Risk Premium

Equity Risk Premium (“ERP”) “captures the compensation per unit of risk

that investors demand in order to hold risky investments rather than riskless

investments.”571 The experts’ disagreement over the proper methodology for

estimating Jarden’s ERP reflects the lack of consensus regarding this issue within

the valuation community at large.572 One aspect of the broader debate that has

played out here is whether to approach ERP as Long-Term Historical ERP, Supply-

Side ERP, or an adjusted hybrid ERP derived from the available data. As explained

by Dr. Hubbard, when appraisers estimate ERP from Long-Term Historical ERP,

they consult historical data regarding stock premiums, in his case from 1926 through

569 JX 2516, Koller, Valuation at 281; JX 2032, Berk & DeMarzo, Corporate Finance at 413; JX 241, Holthausen & Zmijewski, Corporate Valuation at 295. 570 JX 2515, Damodaran, Investment Valuation at 187. 571 JX 1816 at ¶121.

See Trial Tr. 1072:2–4 (Hubbard) (“So the question is, what is the equity risk premium. 572

And this is one where economists have a range of views.”).

131 2015.573 As explained by Dr. Zmijewski, Supply-Side ERP incorporates adjustments

to the Long-Term Historical ERP to account for a long-term decline in risk

premiums that upwardly bias the Long-Term Historical rate in order more

effectively to represent recent market conditions.574

Dr. Zmijewski set Jarden’s ERP at the Supply-Side ERP estimate of 6.03%.575

Dr. Hubbard determined the proper ERP to be 6.47%, which is the mid-point

between the Long-Term Historical ERP and Supply-Side ERP.576 After considering

the evidence, I am satisfied that Dr. Zmijewski’s estimate of ERP reflects a more

principled approach. First, there is strong support for the use of the forward-looking

573 JX 1816 at ¶¶122–24. See Trial Tr. 1072:5–8 (Hubbard) (“My own view in my own work and in the work I’m tendering here is that the so-called historical risk premium is the best measure of the equity risk premium.”). See also JX 2515, Damodaran, Investment Valuation at 161 (“In practice, we usually estimate the risk premium by looking at the historical premium earned by stocks over default-free securities over long time periods.”). 574 JX 1828 at ¶18. See Trial Tr. 1072:8–15 (Hubbard) (“There is an alternative view . . . a so-called supply-side risk premium. I’m not quite sure why that word, because it’s not about supply and demand, it’s really about whether you include price earnings multiples expansion. That number is lower.”) See also JX 1345, Duff & Phelps, Valuation Handbook at 11. 575 JX 1828 at ¶17. 576 JX 1816 at ¶126. Dr. Hubbard took the mid-point of the Long-Term Historical ERP at 6.9% and Supply-Side ERP at 6.03% to produce his 6.47% ERP estimate for Jarden. Trial Tr. 1072:16–19 (Hubbard) (“I prefer the historical risk premium. I’m cognizant of the fact Delaware courts have also paid attention to the supply-side risk premium. So I picked the midpoint of the two.”).

132 Supply-Side ERP in the valuation literature.577 Second, as Dr. Zmijewski

persuasively observes, Dr. Hubbard’s “mid-point” ERP estimate is unexplained and

appears to lack any methodological foundation.578

 Size Premium

Dr. Zmijewski opined that a size premium must be incorporated in the

calculation of Jarden’s equity cost of capital given that, according to the Duff &

Phelps classification, Jarden is within the second decile of public companies, which

justifies a size premium of 0.57%.579 Dr. Hubbard implied that a Size Premium was

not necessary but provided no credible explanation for that position.580

The valuation texts in the record make the point that beta captures some, but not all

of a company’s size premium and that a size premium is an empirically observed

577 JX 1345, Duff & Phelps, Valuation Handbook at 5. 578 JX 1828 at ¶18. The lower Supply-Side ERP is supported by Duff & Phelps’ later recommended estimates of adjusted Long-Term ERP of 5.0% as of March 31, 2018. See Trial Tr. 1073:1–4 (Hubbard) (“But if one’s view is your interest in supply side is governed by Duff & Phelps' recommendation, Duff & Phelps has, indeed, changed its recommended approach.”). 579 JX 1818 at ¶64. 580 JX 1826 at ¶78; Trial Tr. at 1078:4–9 (Hubbard) (“I don’t have a size premium. He does. My quibble is more the way he’s estimated it, given the data source he has. But, again, for the Court’s consideration in the interest of the Court’s time, I don’t think these are super important.”).

133 correction to the CAPM.581 I agree with Dr. Zmijewski and the literature that the

CAPM should include a size premium when appropriate, as here, and adopt his size

premium of 0.57% for Jarden.

Dr. Zmijewski calculated a Composite Cost of Equity, but for reasons

previously stated, I have disregarded estimates based on Jarden’s so-called

comparable companies. Dr. Zmijewski calculated a Jarden-specific Cost of Equity

at 10.21%.582 Dr. Hubbard calculated Jarden’s Cost of Equity at 9.74%.583 In my

view, for reasons stated, neither view lines up entirely with the credible evidence.

Accordingly, I have calculated Jarden’s Cost of Equity with the following CAPM

inputs that reflect what I deem proven by a preponderance of the evidence:

Dr. Hubbard’s Beta of 1.18, Dr. Zmijewski’s Equity-Risk Premium of 6.03%,

Dr. Zmijewski’s Size Premium of 0.57% and both experts’ risk-free rate of 2.14%.

With these inputs, I have calculated Jarden’s Cost of Equity to be 9.83%.

581 JX 242, Holthausen & Zmijewski, Corporate Valuation at 320–21 (discussing the “empirical evidence that the CAPM overstates the returns to large firms and understates the returns to small firms”). 582 JX 1818, Ex. VI-5. 583 JX 1816 at ¶127.

134 Jarden’s Calculated WACC: Dr. Zmijewski calculated a Jarden-Specific

WACC of 7.88%.584 Dr. Hubbard calculated a WACC of 7.38%.585 Once again, for

reasons stated, I have found that neither experts’ calculated WACC is supported

entirely by the credible evidence. Instead, I calculate WACC with the following

inputs: a 9.83% Cost of Equity, a 2.8% Cost of Debt, a 35% marginal tax rate and a

capital structure of 63.9% equity and 36.1% debt. These inputs yield a WACC of

6.94% for Jarden.586 Thus, I adopt a Discount Rate of 6.94%.587

3. The Final Calculation of Terminal Value

Based on the credible evidence, I calculate Jarden’s terminal value to be

$17.7 billion, using the following equation:588

584 JX 1818 at ¶66. 585 JX 1816 at ¶11. 586 I note that this WACC is within the range calculated by Centerview but below the WACC calculated by Goldman Sachs, Deutsche Bank, RBC and Barclays. 587 JX 2516, Koller, Valuation at 295–97. 588 JX 1816 at ¶95; JX 2515, Damodaran, Investment Valuation at 313.

135 𝑔∞ 𝑁𝑂𝑃𝐿𝐴𝑇𝑃𝐴𝑇+1 (1 − ) 𝑇𝑉𝑡 = 𝑅𝑂𝐼𝐶 𝑊𝐴𝐶𝐶 − 𝑔∞

where:

𝑇𝑉𝑡 = terminal value (at time T) 𝑁𝑂𝑃𝐿𝐴𝑇𝑃𝐴 𝑇+1 = unlevered free cash flow (at time T + 1). 𝑅𝑂𝐼𝐶 = incremental return on new invested capital 𝑔∞ = terminal growth rate 𝑊𝐴𝐶𝐶 = Weighted Average Cost of Capital

In order to arrive at the unlevered free cash flow for year 2021, I subtracted the

predicted revenue for 2021 from the predicted capital expenditures for 2021.589 The

predicted revenue for 2021 is $12.9 billion, 4.964% higher than the 2020 revenue.590

The predicted capital expenditure for 2021 is $334 million, 2.6% higher than the

2020 capital expenditure.591

4. The DCF Calculation of Fair Value

Using 6.94% as the Discount Rate, I calculate Jarden’s enterprise value using

the following formula:592

589 See JX 1818 at ¶51. 590 I took the average of the revenue growth rates for the provided fiscal years of 2017–20 to determine the percentage increase. 591 I took the average of the capital expenditure growth rates for the provided fiscal years of 2017–20 to determine the percentage increase. 592 JX 2515, Damodaran, Investment Valuation at 585. See JX 1818 at ¶60.

136 𝑡=∞ 𝐹𝐶𝐹𝑡 𝐸𝑉 = ∑ (1 + 𝑊𝐴𝐶𝐶)𝑡 𝑡=1

𝐹𝐶𝐹𝑡 = unlevered cash flow in period t, terminal value in the final period 𝑊𝐴𝐶𝐶 = Weighted Average Cost of Capital

The final adjusted enterprise value is $16.6 billion.593

5. Jarden-Specific Adjustments to the DCF Valuation

In order to determine the final share price under a DCF approach, the appraiser

must account for Jarden’s excess cash and debt in its enterprise value.594

Dr. Hubbard additionally adjusts for tax effects related to future profits not captured

by tax rates, liability from net unrecognized tax benefits and pensions. 595 I do not

find any of Dr. Hubbard’s arguments for these additional adjustments persuasive

and, in any event, his proposed further adjustments have a marginal impact on the

final share value.596

593 In other words, I added the discounted cash flows from each time period in the FY16– FY21 range––$558 million, $646 million, $675 million, $687 million, $698 million, $13.3 billion respectively––to arrive at the total enterprise value. 594 JX 1818 at ¶¶69–72; JX 1816 at ¶¶130–47. 595 JX 1816 at ¶¶143–47. 596 See Trial Tr. 1079:17–21 (Hubbard) (“Maybe I should start with the bottom line. If you were to look at all of these [enterprise value adjustments], they’re a little over a dollar a share, and I think $1.06 altogether, because they go in different directions.”).

137 a. Excess Cash

Companies commonly keep liquid cash in order to conduct their operations.597

If the company holds more cash than necessary, the surplus is a source of value to

the equity holders and must be added to the DCF valuation.598 Jarden held

$799 million of cash and cash equivalents at the end of the first quarter of 2016.599

As of the Merger, Jarden required $50 million in cash for working capital

purposes.600 The excess cash balance, or the difference between the total cash and

the required cash, is $749 million, which I add to the enterprise value.

b. Nonconvertible Debt

As of March 31, 2016, Jarden’s non-convertible debt totaled $5.04 billion.601

Debt is a claim on the assets of the firm and must, therefore, be subtracted from the

DCF enterprise value.602

597 JX 1816 at ¶139. 598 Trial Tr. 1081:17–20 (Hubbard) (“[E]ssentially you want to add back excess cash that the company has. And we both agree on that, and we both agree on what the total cash was. It was $799 million.”). 599 JX 1816 at ¶140. 600 Id. 601 Id. at ¶141. 602 Id.; JX 2516, Koller, Valuation at 309; JX 2515, Damodaran, Investment Valuation at 440.

138 c. Convertible Debt

To measure the value of Jarden’s unconverted convertible notes at the Merger

Date, Dr. Hubbard uses a standard options pricing methodology to estimate the

embedded warrants value since they are economically analogous to an option on

Jarden’s common stock.603 This formula relies on various inputs for each series of

notes, including the time remaining until maturity, the conversion price, the current

value of Jarden’s stock, the risk-free rate and the expected volatility of Jarden’s stock

returns.604 Using these inputs, Dr. Hubbard estimated the equity components of the

convertible notes to be $0.71 billion in total at the Merger Date.605 He further valued

the debt component of the convertible notes by discounting the remaining coupons

and principal value of each note at Jarden’s 5.3% cost of debt. In total, the value of

the debt component of the convertible notes is $1.00 billion. The total value of

Jarden’s convertible securities is the sum of the debt and equity components. At the

Merger Date, the value of Jarden’s convertible debt totaled $1.71 billion.606

Dr. Hubbard’s approach was conservative, made sense and I adopt it here.

603 JX 1816 at ¶142. 604 Id., Ex. 18C. 605 Id., Ex. 18A. 606 Id.

139 6. Number of Shares

I calculate the shares outstanding, following Dr. Zmijewski’s calculation,607

by subtracting the Jarden stock awards issuable to executives in connection with the

merger transactions and the Jarden common stock expected to be issued upon

assumed conversion of outstanding Jarden convertible notes from the total estimated

shares of Jarden’s common stock entitled to the Merger consideration. With these

inputs, the total amount of outstanding shares and restricted stock units as of the

Merger was 219.9 million common shares.608

7. Equity Value per Share from DCF Analysis

After adding non-operating assets to the enterprise value, and subtracting non-

operating liabilities, Jarden’s equity value as of the Merger Date was $10.59 billion.

On a per share basis, the DCF valuation is $48.13.

REMAINDER OF PAGE INTENTIALLY LEFT BLANK

607 JX 1818 at ¶70. Dr. Hubbard adjusted his final share count number to align with Dr. Zmijewski’s number after double counting Jarden’s restricted stock. JX 1831. 608 JX 1565 at 242.

140 Discounted Cash Flow Analysis609 ($ in Millions, except per FY16 FY17 FY18 FY19 FY20 FY21 share value) Revenue610 $10,147 $10,640 $11,172 $11,731 $12,317 $12,928 Growth Rate – 4.9% 5.0% 5.0% 5.0% 5.0%

Unlevered Cash Flow from $869.05 $966.55 $1,062 $1,145.95 $1,235 $1,273 Operations

Capital Expenditures611 $297 $266 $279 $293 $308 $334 As % of Revenue 2.9% 2.5% 2.5% 2.5% 2.5% 2.6% Unlevered Free Cash Flow $572 $701 $783 $853 $927 $939 Terminal Value $17,688

Time Period612 0.36 1.21 2.22 3.22 4.22 4.22

Discounted Cash Flows $558 $646 $675 $687 $698 $13,326

Enterprise Value $16,591 Non-Convertible Debt ($5,043) Value of Convertible Debt ($1,712) Cash $749 Equity Value $10,585

Shares 219.9 Share Price $48.13

609 As explained above, the DCF Analysis makes the following assumptions: WACC equals 6.9%; Terminal Growth equals 3.1%; ROIC equals 11.2%; FY21 Revenue Growth equals 5%; FY21 Capital Expenditure as a percent of Revenue equals 2.6%; Fully Diluted Share Count equals 219.9 million. 610 Drs. Hubbard and Zmijewski both agree on Jarden’s Revenue numbers for FY16–FY20 reported in Standard and Poor’s Capital IQ. See JX 1816, Ex. 9; JX 1818, Ex. VI-7A. 611 Drs. Hubbard and Zmijewski both agree on Jarden’s Capital Expenditure numbers for FY16–FY20 as derived from Standard and Poor’s Capital IQ and Jarden’s FY10-15 10K. See JX 1816, Ex. 9; JX 1818, Ex. VI-1. 612 Time Period is calculated based on the mid-year convention used by Dr. Hubbard. JX 1816, Ex. 16. I note, for 2016, the mid-point uses the period from April 15, 2016 to December 31, 2016. Id.

141 8. The DCF Valuation Comports With the Market Evidence

As indicated above, I have determined that the Unaffected Market Price,

$48.31, is a reliable indicator of Jarden’s fair value as of the Merger Date. While

I have questioned the reliability of the Merger price less synergies approach,

I recognize that the most reliable estimate of fair value under that approach is

approximately $46.21. My DCF valuation yields a fair value of $48.13. What stands

out here, of course, is that Petitioners’ proffered estimate of fair value for Jarden of

$71.35 is, to put it mildly, an outlier.

Based on the preponderance of evidence, I am satisfied that the Unaffected

Market Price is the best evidence of Jarden’s fair value on the Merger Date. Insofar

as I am obliged to articulate a principled, evidence-based explanation for the delta

between the Unaffected Market Price and the DCF valuation (here, $0.18 per share),

I am satisfied the difference reflects the subjective imperfections of the DCF

methodology. The DCF valuation corroborates the most persuasive market evidence

and provides comfort that I have appraised Jarden as best as the credible evidence

allows.

III. CONCLUSION For the foregoing reasons, I have found the fair value of Jarden shares as of

the Merger was $48.31 per share. The legal rate of interest, compounded quarterly,

142 shall accrue from the date of closing to the date of payment. The parties shall confer

and submit an implementing order and final judgment within ten days.